

4-18-0/JC17 Rec'd PCT/PTO 17 APR 2001

FORM PTO-1390
(REV. 11-2000)

U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE

ATTORNEY'S DOCKET NUMBER

TRANSMITTAL LETTER TO THE UNITED STATES
DESIGNATED/ELECTED OFFICE (DO/EO/US)
CONCERNING A FILING UNDER 35 U.S.C. 371

00148-03

U.S. APPLICATION NO. (If known, see 37 CFR 1.5)

09/807757

INTERNATIONAL APPLICATION NO.

PCT/US99/24972

INTERNATIONAL FILING DATE

22 October 1999 (22.10.99)

PRIORITY DATE CLAIMED

23 October 1998 (23.10.98)

TITLE OF INVENTION COMPOSITIONS AND METHODS FOR MODULATING EXPRESSION WITHIN
SMOOTH MUSCLE CELLS

APPLICANT(S) FOR DO/EO/US OWENS, et al.

Applicant herewith submits to the United States Designated/Elected Office (DO/EO/US) the following items and other information:

1. ☒ This is a **FIRST** submission of items concerning a filing under 35 U.S.C. 371.
2. ☐ This is a **SECOND or SUBSEQUENT** submission of items concerning a filing under 35 U.S.C. 371.
3. ☒ This is an express request to begin national examination procedures (35 U.S.C. 371(f)). The submission must include items (5), (6), (9) and (21) indicated below.
4. ☒ The US has been elected by the expiration of 19 months from the priority date (Article 31).
5. ☒ A copy of the International Application as filed (35 U.S.C. 371(c)(2))
 - a. ☐ is attached hereto (required only if not communicated by the International Bureau).
 - b. ☐ has been communicated by the International Bureau.
 - c. ☒ is not required, as the application was filed in the United States Receiving Office (RO/US).
6. ☐ An English language translation of the International Application as filed (35 U.S.C. 371(c)(2)).
 - a. ☐ is attached hereto.
 - b. ☐ has been previously submitted under 35 U.S.C. 154(d)(4).
7. ☒ Amendments to the claims of the International Application under PCT Article 19 (35 U.S.C. 371(c)(3))
 - a. ☐ are attached hereto (required only if not communicated by the International Bureau).
 - b. ☐ have been communicated by the International Bureau.
 - c. ☐ have not been made; however, the time limit for making such amendments has NOT expired.
 - d. ☒ have not been made and will not be made.
8. ☐ An English language translation of the amendments to the claims under PCT Article 19 (35 U.S.C. 371 (c)(3)).
9. ☒ An oath or declaration of the inventor(s) (35 U.S.C. 371(c)(4)).
10. ☐ An English language translation of the annexes of the International Preliminary Examination Report under PCT Article 36 (35 U.S.C. 371(c)(5)).

Items 11 to 20 below concern document(s) or information included:

11. ☐ An Information Disclosure Statement under 37 CFR 1.97 and 1.98.
12. ☒ An assignment document for recording. A separate cover sheet in compliance with 37 CFR 3.28 and 3.31 is included.
13. ☒ A FIRST preliminary amendment.
14. ☐ A SECOND or SUBSEQUENT preliminary amendment.
15. ☐ A substitute specification.
16. ☐ A change of power of attorney and/or address letter.
17. ☒ A computer-readable form of the sequence listing in accordance with PCT Rule 13ter.2 and 35 U.S.C. 1.821 - 1.825.
18. ☐ A second copy of the published international application under 35 U.S.C. 154(d)(4).
19. ☐ A second copy of the English language translation of the international application under 35 U.S.C. 154(d)(4).
20. ☒ Other items or information:

Statement Regarding Sequence Listing
Sequence Listing
Small Entity Statement
Post Card Receipt

U.S. APPLICATION NO. (if known) see 37 CFR 1.51

09/807757

INTERNATIONAL APPLICATION NO.

PCT/US99/24972

ATTORNEY'S DOCKET NUMBER

00148-03

21. ☒ The following fees are submitted:**BASIC NATIONAL FEE (37 CFR 1.492 (a) (1) - (5)):**

Neither international preliminary examination fee (37 CFR 1.482)
nor international search fee (37 CFR 1.445(a) (2)) paid to USPTO
and International Search Report not prepared by the EPO or JPO \$1000.00

International preliminary examination fee (37 CFR 1.482) not paid to
USPTO but International Search Report prepared by the EPO or JPO \$860.00

International preliminary examination fee (37 CFR 1.482) not paid to USPTO
but international search fee (37 CFR 1.445(a)(2)) paid to USPTO \$710.00

International preliminary examination fee (37 CFR 1.482) paid to USPTO
but all claims did not satisfy provisions of PCT Article 33(1)-(4) \$690.00

International preliminary examination fee (37 CFR 1.482) paid to USPTO
and all claims satisfied provisions of PCT Article 33(1)-(4) \$100.00

ENTER APPROPRIATE BASIC FEE AMOUNT =

CALCULATIONS PTO USE ONLY

\$ 690.00

Surcharge of \$130.00 for furnishing the oath or declaration later than ☐ 20 ☐ 30
months from the earliest claimed priority date (37 CFR 1.492(e)).

\$ 0.00

CLAIMS	NUMBER FILED	NUMBER EXTRA	RATE	\$
Total claims	17 -20 =	0	x \$18.00	\$ 0.00
Independent claims	4 -3 =	1	x \$80.00	\$ 80.00

MULTIPLE DEPENDENT CLAIM(S) (if applicable) + \$270.00 \$ 0.00

TOTAL OF ABOVE CALCULATIONS = \$ 770.00

☒ Applicant claims small entity status. See 37 CFR 1.27. The fees indicated above
are reduced by 1/2. + \$ 385.00

SUBTOTAL = \$ 385.00

Processing fee of \$130.00 for furnishing the English translation later than ☐ 20 ☐ 30
months from the earliest claimed priority date (37 CFR 1.492(f)).

\$ 0.00

TOTAL NATIONAL FEE = \$ 385.00

Fee for recording the enclosed assignment (37 CFR 1.21(h)). The assignment must be
accompanied by an appropriate cover sheet (37 CFR 3.28, 3.31). \$40.00 per property +

\$ 80.00

TOTAL FEES ENCLOSED = \$ 465.00Amount to be
refunded: \$


charged: \$

- a. ☐ A check in the amount of \$ _____ to cover the above fees is enclosed.
- b. ☒ Please charge my Deposit Account No. 50-0423 in the amount of \$ 465.00 to cover the above fees.
A duplicate copy of this sheet is enclosed.
- c. ☒ The Commissioner is hereby authorized to charge any additional fees which may be required, or credit any
overpayment to Deposit Account No. 50-0423. A duplicate copy of this sheet is enclosed.
- d. ☐ Fees are to be charged to a credit card. **WARNING:** Information on this form may become public. **Credit card
information should not be included on this form.** Provide credit card information and authorization on PTO-2038.

NOTE: Where an appropriate time limit under 37 CFR 1.494 or 1.495 has not been met, a petition to revive (37 CFR
1.137 (a) or (b)) must be filed and granted to restore the application to pending status.

SEND ALL CORRESPONDENCE TO:


John P. Breen
University of Virginia Patent Foundation
1224 West Main Street, Suite 1-110
Charlottesville, VA 22903
US


SIGNATURE

John P. Breen
NAME

38,833

REGISTRATION NUMBER



1224 West Main Street, Suite 1-110
Charlottesville, VA 22903
Main (804) 924-2175
Direct (804) 243-6103
Fax (804) 924-2493
Email jpb5x@virginia.edu

John P. Breen, Esq.
Patent Counsel

PATENT APPLICATION

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Attorney Docket: 00148-03


Applicant: Gary K. Owens, et al.

Invention: COMPOSITIONS AND METHODS FOR
MODULATING EXPRESSION WITHIN
SMOOTH MUSCLE CELLS

Serial No: Not Yet Assigned

International

Filing Date: October 22, 1999

}
}
} Certificate Under 37 CFR 1.10
} Date of Deposit: April 17, 2001
} I hereby certify that this correspondence is
} being deposited with the United States Postal
} Service as "Express Mail" service under 37
} CFR 1.10 on the date indicated above
} addressed to Assistant Commissioner for
} Patents, Washington, DC 20231.
}
}
} 
} Sue Ann Carr
} Express Mail No. ET390189115US

Preliminary Amendment

Assistant Commissioner
for Patents
Washington, D.C. 20231

Sir:

Preliminary to the examination of the captioned application filed as a USC § 371
application of PCT/US99/24972 applicants request entry of the following amendments.

In the claims

Please cancel claims 4, 18, 19 and 20

Please amend claims 6-11 as follows. A clean copy of all pending claims accompanies this Amendment.

6. (Amended) An isolated polynucleotide comprising the polynucleotide of Claim[s] 1 [or 2] operably associated with a heterologous coding sequence.
7. (Amended) A vector comprising the polynucleotide of Claim[s] 1[, 2, 3 or 4].
8. (Amended) An expression vector comprising the polynucleotide of Claim[s] 1[, 2, 3 or 4] operably associated with a heterologous coding sequence.
9. (Amended) A genetically engineered host cell comprising the polynucleotide of Claim[s] 1[, 2, 3 or 4].
10. (Amended) A genetically engineered host cell comprising the polynucleotide of Claim[s] 1[, 2[, 3 or 4] operably associated with a heterologous coding sequence.

00148-03

11. (Amended) A transgenic, non-human animal comprising the polynucleotide of Claim[s] 1[, 2, 3 or 4].

Remarks

Applicants have amended the claims to remove multiple dependencies and reduce the number of independent and dependent claims. The application as amended is believed to be in condition for allowance.

Applicants request examination and passage of the application to issuance. The Commissioner is hereby authorized to charge any fees due for this submission to Deposit Account No. 50-0423.

Respectfully submitted,



John P. Breen
Registration No. 38,833

Copy of Pending Claims

1. An isolated polynucleotide comprising:
 - a) the nucleotide sequence of SEQ ID NO:1, or a transcriptionally active fragment thereof;
 - b) nucleotides 1-2605, 2011-2605, 2011-5342, 3331-3656, 3421-3548 or 3495-3599 of SEQ ID NO:1; or
 - c) nucleotides 3331-3656, 3495-3599 or 3421-3548 of SEQ ID NO:1.
2. An isolated polynucleotide comprising, nucleotides 3331-3656, 3495-3599 or 3421-3548 of SEQ ID NO:1 spliced downstream of nucleotides 1-2558 of SEQ ID NO:1.
3. An isolated polynucleotide that hybridizes under highly stringent conditions to the complement of the polynucleotide of Claim 1.
5. An isolated polynucleotide that comprises the complement of the polynucleotide of Claim 1.
6. An isolated polynucleotide comprising the polynucleotide of Claim 1 operably associated with a heterologous coding sequence.

7. A vector comprising the polynucleotide of Claim 1.
8. An expression vector comprising the polynucleotide of Claim 1 operably associated with a heterologous coding sequence.
9. A genetically engineered host cell comprising the polynucleotide of Claim 1.
10. A genetically engineered host cell comprising the polynucleotide of Claim 2 operably associated with a heterologous coding sequence.
11. A transgenic, non-human animal comprising the polynucleotide of Claim 1.
12. The polynucleotide of claim 6, wherein the heterologous coding sequence is a reporter gene.
13. The polynucleotide of claim 12, wherein the reporter gene is *LacZ*.
14. A method for identifying a test compound capable of modulating SMC-specific gene expression comprising:
 - (a) measuring the level of expression of a reporter gene under the control of an SM α -A regulatory region or a transcriptionally active fragment thereof in the presence and absence of said test compound,

00148-03

such that if the level obtained in the presence of the test compound differs from that obtained in its absence, then a compound which modulates SMC-specific gene expression is identified.

15. The method of claim 14 wherein the reporter gene in *LacZ*.
16. A pharmaceutical composition comprising the test compound identified by the method in claim 14.
17. A method for delivery of a therapeutic molecule comprising, introducing into SMC of a subject a vector comprising an SM α -A regulatory region sequence, or transcriptionally active fragment thereof, operatively linked to a heterologous nucleic acid which encodes said therapeutic molecule.
21. An isolated polynucleotide having a sequence identical in sequence to 20 contiguous nucleotides of the sequence as set forth in SEQ ID NO:1.

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of: OWENS, Gary K., et al.

Application No. Not Yet Assigned

Filed: April 17, 2001

For: COMPOSITIONS AND METHODS FOR MODULATING EXPRESSION
WITHIN SMOOTH MUSCLE CELLS

Assistant Commissioner for Patents
Washington, D.C. 20231

STATEMENT CLAIMING SMALL ENTITY STATUS (37 CFR 1.9(c-f) and 1.27(b-d))

With respect to the invention described in the specification filed herewith.

I. IDENTIFICATION AND RIGHTS AS A SMALL ENTITY

I hereby state that I am an official empowered to act on behalf of the nonprofit organization identified below:

University of Virginia Patent Foundation
1224 West Main Street, Suite 1-110
Charlottesville, VA 22903

TYPE OF ORGANIZATION:

Tax Exempt Under Internal Revenue Service Code (26 USC 501(a) and 501(c)(3)) and that the nonprofit organization identified above qualifies as a nonprofit organization, as defined in 37 CFR 1.9(e), for purposes of paying reduced fees under Sections 41(a) and (b) of Title 35, United States Code.

II. OWNERSHIP OF INVENTION

I hereby state that rights under contract or law remain with and/or have been conveyed to the above identified

EXCEPT, that if the rights held are not exclusive, each individual, concern or organization having rights to the invention is listed below and no rights to the invention are held (1) by any person who could not be classified as an independent inventor under 37 CFR 1.9(c) if that person had made the invention, (2) any concern which would not qualify as a small business concern under 37 CFR 1.9(d) or (3) a nonprofit organization under 37 CFR 1.9(e).


No such person, concern, or organization exists.

III. ACKNOWLEDGEMENT OF DUTY TO NOTIFY PTO OF STATUS CHANGE

I acknowledge the duty to file, in this application or patent, notification of any change in status resulting in loss of entitlement to small entity status prior to paying, or at the time of paying, the earliest of the issue fee or any maintenance fee due after the date on which status as a small entity is no longer appropriate. (37 CFR 1.28(b))

IV. SIGNATURE

April 17, 2001


John P. Breen, In-House Counsel
In-House Patent Counsel
University of Virginia Patent Foundation

COMPOSITIONS AND METHODS FOR MODULATING EXPRESSION WITHIN SMOOTH MUSCLE CELLS

5 This application claims priority under 35 U.S.C. §119 (e) to U.S. provisional patent application no. 60/105,330 filed October 23, 1998, which is hereby incorporated by reference in its entirety.

This invention was made with government support under grant numbers HL 38854 and HL 10038, awarded by the National Institutes of Health. The government may
10 have certain rights in the invention.

1. INTRODUCTION

The present invention relates to promoters, enhancers and other regulatory elements that direct expression within smooth muscle cells ("SMC"). In particular, it
15 relates to compositions comprising nucleotide sequences from the 5' regulatory region and the first intron, and transcriptionally active fragments thereof, that control expression of a smooth muscle α -actin ("SM α -A"). Specifically provided are expression vectors, host cells and transgenic animals wherein an SM α -A regulatory region is capable of controlling expression of a heterologous gene, over-expressing an endogenous SMC gene or an
20 inhibitor of a pathological process or knocking out expression of a specific gene believed to be important for an SM-related disease in SMC. The invention also relates to methods for using said vectors, cells and animals for screening candidate molecules for agonists and antagonists of disorders involving SMC.

The present invention further relates to compositions and methods for
25 modulating expression of compounds within SMC. The invention further relates to screening compounds that modulate expression within SMC. Methods for using molecules and compounds identified by the screening assays for therapeutic treatments also are provided.

30 2. BACKGROUND OF THE INVENTION

2.1 Gene Therapy

Somatic cell gene therapy is a strategy in which a nucleic acid, typically in the form of DNA, is administered to alter the genetic repertoire of target cells for
35 therapeutic purposes. Although research in experimental gene therapy is a relatively young field, major advances have been made during the last decade. (Arai, Y., *et al.*, 1997,

Orthopaedic Research Society, 22:341). The potential of somatic cell gene therapy to treat human diseases has caught the imagination of numerous scientists, mainly because of two recent technologic advancements. Firstly, there are now numerous viral and non-viral gene therapy vectors that can efficiently transfer and express genes in experimental animals *in vivo*. Secondly, increasing support for the human genome project will allow for the identity and sequence of the estimated 80,000 genes comprising the human genome in the very near future.

Gene therapy was originally conceived of as a specific gene replacement therapy for correction of heritable defects to deliver functionally active therapeutic genes into targeted cells. Initial efforts toward somatic gene therapy relied on indirect means of introducing genes into tissues, called *ex vivo* gene therapy, *e.g.*, target cells are removed from the body, transfected or infected with vectors carrying recombinant genes and re-implanted into the body ("autologous cell transfer"). A variety of transfection techniques are currently available and used to transfer DNA *in vitro* into cells; including calcium phosphate-DNA precipitation, DEAE-Dextran transfection, electroporation, liposome mediated DNA transfer or transduction with recombinant viral vectors. Such *ex vivo* treatment protocols have been proposed to transfer DNA into a variety of different cell types including epithelial cells (U.S. Patent 4,868,116; Morgan and Mulligan WO87/00201; Morgan *et al.*, 1987, Science 237:1476-1479; Morgan and Mulligan, U.S. Patent No. 4,980,286), endothelial cells (WO89/05345), hepatocytes (WO89/07136; Wolff *et al.*, 1987, Proc. Natl. Acad. Sci. USA 84:3344-3348; Ledley *et al.*, 1987 Proc. Natl. Acad. Sci. 84:5335-5339; Wilson and Mulligan, WO89/07136; Wilson *et al.*, 1990, Proc. Natl. Acad. Sci. 87:8437-8441), fibroblasts (Palmer *et al.*, 1987, Proc. Natl. Acad. Sci. USA 84:1055-1059; Anson *et al.*, 1987, Mol. Biol. Med. 4:11-20; Rosenberg *et al.*, 1988, Science 242:1575-1578; Naughton & Naughton, U.S. Patent 4,963,489), lymphocytes (Anderson *et al.*, U.S. Patent No. 5,399,346; Blaese, R.M. *et al.*, 1995, Science 270:475-480) and hematopoietic stem cells (Lim, B. *et al.* 1989, Proc. Natl. Acad. Sci. USA 86:8892-8896; Anderson *et al.*, U.S. Patent No. 5,399,346).

Direct *in vivo* gene transfer recently has been attempted with formulations of DNA trapped in liposomes (Ledley *et al.*, 1987, J. Pediatrics 110:1), in proteoliposomes that contain viral envelope receptor proteins (Nicolau *et al.*, 1983, Proc. Natl. Acad. Sci. U.S.A. 80:1068) and DNA coupled to a polylysine-glycoprotein carrier complex. In addition, "gene guns" have been used for gene delivery into cells (Australian Patent No. 9068389). It even has been speculated that naked DNA, or DNA associated with liposomes, can be formulated in liquid carrier solutions for injection into interstitial spaces for transfer of DNA into cells (Felgner, WO90/11092).

Numerous clinical trials utilizing gene therapy techniques are underway for such diverse diseases as cystic fibrosis and cancer. The promise of this therapeutic approach for dramatically improving the practice of medicine has been supported widely, although there still are many hurdles that need to be passed before this technology can be used successfully in the clinical setting.

Perhaps, one of the greatest problems associated with currently devised gene therapies, whether *ex vivo* or *in vivo*, is the inability to control expression of a target gene and to limit expression of the target gene to the cell type or types needed to achieve a beneficial therapeutic effect.

2.2 Tissue Specific Expression within Smooth Muscle Cells

Smooth muscle cells, often termed the most primitive type of muscle cell because they most resemble non-muscle cells, are called "smooth" because they contain no striations, unlike skeletal and cardiac muscle cells. Smooth muscle cells aggregate to form smooth muscle ("SM") which constitutes the contractile portion of the stomach, intestine and uterus, the walls of arteries, the ducts of secretory glands and many other regions in which slow and sustained contractions are needed.

Abnormal gene expression in SMC plays a major role in numerous diseases including, but not limited to, atherosclerosis, coronary artery disease, hypertension, stroke, asthma and multiple gastrointestinal, urogenital and reproductive disorders. These diseases are the leading causes of morbidity and mortality in Western Societies, and account for billions of dollars in health care costs in the United States alone each year.

In recent years, the understanding of muscle differentiation has been enhanced greatly with the identification of several key *cis*-elements and *trans*-factors that regulate expression of muscle-specific genes. Firulli A.B. *et al.*, 1997, *Trends in Genetics*, 13:364-369; Sartorelli V. *et al.*, 1993, *Circ. Res.*, 72:925-931. However, the elucidation of transcriptional pathways that govern muscle differentiation has been restricted primarily to skeletal and cardiac muscle. Currently, no transcription factors have yet been identified that direct SM-specific gene expression, or SMC myogenesis. Owens G.K., 1995, *Physiol. Rev.*, 75:487-517. Unlike skeletal and cardiac myocytes, SMC do not undergo terminal differentiation. Furthermore, they exhibit a high degree of phenotypic plasticity, both in culture and *in vivo*. Owens G.K., 1995, *Physiol. Rev.*, 75:487-517; Schwartz S.M. *et al.*, 1990, *Physiol. Rev.*, 70:1177-1209. Phenotypic plasticity is particularly striking when SMC located in the media of normal vessels are compared to SMC located in intimal lesions resulting from vascular injury or atherosclerotic disease. Schwartz S.M., 1990, *Physiol. Rev.*, 70:1177-1209; Ross R., 1993, *Nature*, 362:801-809; Kocher O. *et al.*, 1991, *Lab.*

Invest., 65:459-470; Kocher O. *et al.*, 1986, *Hum. Pathol.*, 17:875-880. Major modifications include decreased expression of SM isoforms of contractile proteins, altered growth regulatory properties, increased matrix production, abnormal lipid metabolism and decreased contractility. Owens G.K., 1995, *Physiol. Rev.*, 75:487-517. The process by which SMC undergo such changes is referred to as "phenotypic modulation". Chamley-Campbell J.H. *et al.*, 1981, *Atherosclerosis*, 40:347-357. Importantly, these alterations in expression patterns of SMC protein cannot simply be viewed as a consequence of vascular disease, but rather, are likely to contribute to progression of the disease.

A key to understanding SMC differentiation is to identify transcriptional mechanisms that control expression of genes that are selective or specific for differentiated SMC and that are required for its principal differentiated function, contraction. Currently, studies are ongoing in which the expression of the contractile proteins SM α -A (Shimizu R.T. *et al.*, 1995, *J. Biol. Chem.*, 270:7631-7643; Blank R.S. *et al.*, 1992, *J. Biol. Chem.*, 267:984-989) and SM myosin heavy chain (SM-MHC) (White S.L. *et al.*, 1996, *J. Biol. Chem.*, 271:15008-15017; Katoh Y. *et al.*, 1994, *J. Biol. Chem.*, 269:30538-30545; Wantanabe M. *et al.*, 1996, *Circ. Res.*, 78 :978-989; Kallmeier R.C. *et al.*, 1995, *J. Biol. Chem.*, 270:30949-30957; Madsen C.S. *et al.*, 1997, *J. Biol. Chem.*, 272:6332-6340; Madsen C.S. *et al.*, 1997, *J. Biol. Chem.*, 272:29842-29851), as well as a variety of proteins implicated in control of contraction including SM22 α (Li L. *et al.*, 1996, *J. Cell. Biol.*, 132:849-859; Kim S. *et al.*, 1997, *Mol. Cell. Biol.*, 17:2266-2278), h₁-calponin (Miano J.M. *et al.*, 1996, *J. Biol. Chem.*, 271:7095-7103), h-caldesmon (Yano H. *et al.*, 1994, *Biochem. Biophys. Res. Commun.*, 201 :618-626), telokin (Herring B.P. *et al.*, 1996, *Am. J. Physiol.*, 270:C1656-C1665) and desmin (Bolmont C. *et al.*, 1990, *J. Submicrosc. Cytol. Pathol.*, 22: 117-122) are being examined.

Recently, several *cis* elements and trans acting factors have been described that regulate muscle-specific gene expression in skeletal and cardiac muscle and are required for the terminal differentiation of these muscle cell types. In contrast, the mechanisms regulating SMC differentiation are only poorly understood, and to date, no transcription factors have been identified that direct SMC-specific gene expression. Because SMC maturation and differentiation are required for the full development of arteries and veins during angiogenesis and vasculogenesis, the identification of the molecular mechanisms that control SMC differentiation are important for an understanding of these processes that occur not only during development, but also under pathologic conditions. Furthermore, it may lead to a better understanding of SMC phenotypic modulation that has been shown to contribute to atherosclerosis and restenosis following

balloon angioplasty (Ross R, et al., *N. Engl J Med.* 1976;295:369-377; Schwartz SM, et al.; *Prog Cardiovasc Dis.* 1984;26:355-372).

One example of a protein which is required for contractile functions of SMC is SM α -actin, which makes up 40% of total SMC protein. Not only is it clearly required for the contractile function of SMC, but it also is the first SMC differentiation marker to appear during development (Duband JL, et al.; *Differentiation*; 1993;55:1-11). Although SM α -A is transiently expressed in the myocardium and skeletal muscle in the developing embryo, and in myofibroblasts during wound healing, SM α -A expression in adult animals is highly restricted to SMC or SM-like cells (Darby I, et al.; *Lab Invest.*; 1990;63:21-29; Woodcock-Mitchell J, et al.; *Differentiation*; 1988;39:161-166).

Transcriptional regulation of various SMC genes has been analyzed extensively in cultured SMC and several functional *cis*-elements have been identified. White S.L. et al., 1996, *J. Biol. Chem.*, 271:15008-15017; Katoh Y. et al., 1994, *J. Biol. Chem.*, 269:30538-30545; Wantanabe M. et al., 1996, *Circ. Res.*, 78 :978-989; Kallmeier R.C. et al., 1995, *J. Biol. Chem.*, 270:30949-30957; Madsen C.S. et al., 1997, *J. Biol. Chem.*, 272:6332-6340; Madsen C.S. et al., 1997, *J. Biol. Chem.*, 272:29842-29851. However, because differentiation of SMC is known to be dependent on many local environmental cues that cannot be completely reproduced *in vitro*, cultured SMC are known to be phenotypically modified as compared to their *in vivo* counterparts (Owens G.K., 1995, *Physiol. Rev.*, 75:487-517; Chamley-Campbell J.H. et al., 1981, *Atherosclerosis*, 40:347-357). As such, certain limitations exist regarding the usefulness of cultured SMC in defining transcriptional programs that occur during normal SMC differentiation and maturation within the animal.

One example of a transcriptional regulatory element that has been implicated in the transcriptional control of various SMC genes is the CArG element. The CArG element was first described as the core sequence of the serum response element (SRE) within early response genes such as *c-fos*, but also has been shown to be required for the activity of many muscle-specific gene promoters (Gustafson TA, et al., *Mol. Cell Biol.*; 1988;8:4110-4119; Chow K, et al., *Mol. Cell Biol.*, 1990;10:528-538; Papadopoulos N, et al., *Mol. Cell Biol.*, 1993;13:6907-6918; Mohun TJ, et al., *EMBO J.*, 1989;8:1153-1161; Lee, T, et al., *Mol. Cell Biol.*, 1991;11:5090-5100). Of interest, nearly all of the SMC differentiation marker genes characterized to date, including SM myosin heavy chain (SM MHC), caldesmon and telokin, contain two or more CArG elements that are required for maximal expression in cultured SMC (Shimizu RT, et al., *J. Biol Chem.*, 1995;270:7631-7643; Madsen CS, et al., *J. Biol Chem.*, 1997;272:6332-6340; Li L, et al., *J. Cell Biol.*, 1996;132:849-859; Herring BP, et al., *Am. J. Physiol.*, 1997;272:C1394-C1404; White SL,

et al., *J. Biol. Chem.*, 1996;271:15008-15017; Zilberman A, et al., *Circ. Res.*, 1998;82:566-575). In addition, it previously has been reported that a conserved CArG element in the SM-22 promoter is required for the arterial expression of a Lac Z transgene in the mouse (Kim S, et al., *Mol. Cell Biol.*, 1997;17:2266-2278; Li L, et al., *Dev. Biol.*, 1997;187:311-321). Electrophoretic mobility supershift studies demonstrated that the SM α -A CArG elements, like the SRE, bind serum response factor (Shimizu RT, et al., *J. Biol. Chem.*, 1995;270:7631-7643). Although recent evidence suggests that muscle derived tissues express higher levels of SRF than nonmuscle tissues (Li L, et al., *Dev. Biol.*, 1997;187:311-321), SRF is thought to be ubiquitously expressed, and a critical yet presently unresolved question remains as to the mechanism of CArG-dependent regulation of SMC-specific gene expression.

It is now well established that SMC differentiation is dependent upon a large number of local environmental cues including extracellular matrix interactions, local production of growth factors and mechanical stresses that cannot be accurately reproduced in culture (Owens G.K., *Physiol. Rev.*, 1995;75:487-517; Chamley-Champbell JH, et al., *Atherosclerosis.*, 1981;40:347-357). Moreover, recent studies have provided clear evidence that gene regulation in SMC culture systems does not always represent regulation *in vivo*. Li L, et al., *Dev. Biol.* 1997;187:311-321; Madsen CS, et al., *Circ. Res.*, 1998;82:908-917. As such, when studying SMC differentiation, it is critical that regulatory pathways initially identified in cultured SMC are tested *in vivo* through the use of transgenic animals. For example, analysis of SM-22 and SM MHC gene expression in transgenic mice has demonstrated that expression of SMC-marker genes is complex and may involve "regulatory cassettes" that drive expression within some, but not all, SM tissues (Li L, et al., *J. Cell Biol.*, 1996;132:849-859; Kim S, et al., *Mol. Cell Biol.*, 1997;17:2266-2278). As such, transgenic studies also are critical for detecting possible heterogeneity in SMC gene regulation.

Currently, no studies have reported the complete characterization of regulatory regions required for driving *in vivo* expression of SM α -A during development and maturation. Although Wang *et al.* (Wang J, et al., *J. Clin Invest.*, 1997;100:1425-1439) recently reported that an SM α -A promoter containing 1,100 bp of 5' promoter and the entire first intron could drive expression of an IGF-1 transgene in many SM tissues, there studies were restricted to analysis in adult animals and focused on examination of the effects of IGF-1 overexpression in SMC and not on the characterization of the promoter regions required for SMC-specific expression. This deficiency of Wang *et al.* is critical since the SM α -A gene is known to be expressed by all three muscle types during development. Moreover, it is highly likely that over-expression of the biologically active

substance IGF-1 in the studies by Wang *et al.* resulted in feedback alterations in the activity of the SM α -A promoter since there is extensive evidence that IGF-1 alters SMC function (Clemmons *et al.*, J Cell Physiol, 145:129-135, 1990). As such, it is unclear whether the expression patterns reported by Wang *et al.* are truly representative of the inherent activity of the SM α -A promoter, as opposed to being artifactually influenced by over-expression of IGF-1.

The current invention provides the major advance of identifying molecular elements that confer SMC-specific transcription *in vivo* during normal development and during various disease states involving SMC-specific gene expression. More specifically, the instant invention provides, for the first time, *inter alia*, the identification of sufficient regions of the SM α -A gene to direct SMC-specific expression, both *in vitro* in cultured SMC, and *in vivo* in transgenic animals.

3. SUMMARY OF THE INVENTION

The invention disclosed herein provides a model for SMC-specific gene transcription. The invention is based in part on the functional characterization described herein of an SM α -A regulatory region, which is the first SMC-specific regulatory region found to be active only in SMC.

The present invention provides compositions and methods for screening compounds that modulate expression within SMC. In particular, it provides compositions comprising nucleotides from the rat SM α -A promoter and first intron, and transcriptionally active fragments thereof, as well as nucleic acids that hybridize under highly stringent conditions to such nucleotides, that control the expression of an SMC-specific gene. Specifically provided are expression vectors comprising the SM α -A regulatory region, and transcriptionally active fragments thereof, operably associated to a heterologous reporter gene, *e.g.*, LacZ, and host cells and transgenic animals containing such vectors. The invention also provides methods for using such vectors, cells and animals for screening candidate molecules for agonists and antagonists of SMC-related disorders. Methods for using molecules and compounds identified by the screening assays for therapeutic treatments also are provided.

For example, and not by way of limitation, a composition comprising a reporter gene is operatively linked to an SMC-specific regulatory sequence, herein called the SM α -A regulatory region. The SM α -A driven reporter gene is expressed as a transgene in animals. The transgenic animal, and cells derived from the SMC of such transgenic animal, can be used to screen compounds for candidates useful for modulating SMC-related disorders. Without being bound by any particular theory, such compounds are

likely to interfere with the function of trans-acting factors, such as transcription factors, cis-acting elements, such as promoters and enhancers, as well as any class of post-transcriptional, translational or post-translational compounds involved in SMC-related disorders. As such, they are powerful candidates for treatment of such disorders, including, but not limited to, coronary artery disease, hypertension, stroke, asthma and multiple gastrointestinal, urogenital and reproductive disorders.

In one embodiment, the invention provides methods for high throughput screening of compounds that modulate specific expression of genes within SMC. In this aspect of the invention, cells from SM-tissues are removed from the transgenic animal and cultured *in vitro*. The expression of the reporter gene is used to monitor SMC-specific gene activity. In a specific embodiment, LacZ is the reporter gene. Compounds identified by this method can be tested further for their effect on SMC-related disorders in normal animals.

In another embodiment, the transgenic animal models of the invention can be used for *in vivo* screening to test the mechanism of action of candidate drugs for their effect on SMC-related disorders. Specifically, the effects of the drugs on SMC-related disorders including, but not limited to, coronary artery disease, hypertension, stroke, asthma and multiple gastrointestinal, urogenital and reproductive disorders, can be assayed.

In another embodiment, a gene therapy method for treating and/or preventing SMC-related disorders is provided. Smooth muscle α -A regulatory sequences are used to drive SMC-specific expression of therapeutic molecules and introduced in the SMC. The method comprises introducing an SM α -A regulatory sequence operatively associated with a nucleic acid encoding a therapeutic molecule into SMC. In one embodiment, the invention provides a preventative gene therapy method comprising introducing an SM α -A regulatory sequence operatively associated with a nucleic acid encoding a therapeutic molecule into SMC to delay and/or prevent an SMC-related disorder. In a specific embodiment, the invention provides a gene therapy method for treatment of cancer or other proliferative disorder involving SMC. The SM α -A regulatory sequence is used to direct the expression of one or more proteins specifically in the SM-tumor cells of a patient.

The invention further provides methods for screening for novel transcription factors that modulate the SM α -A regulatory sequence. Such novel transcription factors identified by this method can be used as targets for treating SMC-related disorders.

4. BRIEF DESCRIPTION OF THE FIGURES

FIGS. 1(A-C). Linear diagrams of Lac Z promoter constructs used to generate transgenic mice. Deletion fragments from a rat genomic clone were subcloned into the previously described pUC/AUG β -galactosidase vector (See Section 6.1. Materials and Methods for more details). FIG. 1A, Fragment from -547 to + 47 (p547/Lac Z). FIG. 1B, Fragment from -547 to +2,784 (p547Int/Lac Z). FIG. 1C, Fragment from -2,600 to +2,784 (p2600Int/Lac Z). CArG A at -71 to -62, CArG B at -112 to -121, the intronic CArG at +1,001 to 1010 and the 5'-untranslated first exon are indicated. Not I/Eco RI digestion was used to remove the pUC plasmid backbone before transgenic injections.

FIGS. 2(A-C). Examination of transgene expression at E13.5. The SM α -A promoter/Lac Z deletion constructs shown in FIG. 1 were used to generate transgenic mice using standard transgenic procedures. Transgenic embryos at E13.5 were stained for Lac Z expression and a representative embryo from each group is shown ($n > 4$ independent founders per group). At this embryonic stage SM α -actin is expressed in skeletal, heart, and SM. FIG. 2A, The p547/Lac Z construct was highly expressed in the heart and skeletal muscle, but not in SMC. FIG. 2B, Inclusion of the entire first intron (p547Int/Lac Z) which contains a highly conserved CArG element resulted in additional, but very limited expression in the abdominal aorta and umbilical arteries. FIG. 2C, Promoter sequences from -2,600 through the first intron (p2,600Int/Lac Z) were sufficient to drive expression of the Lac Z transgene that closely mimicked expression of endogenous SM α -A with staining in heart and skeletal muscle and vascular, GI, and airway SM.

FIGS. 3(A-C). Histological examination of p2600Int/Lac Z expression at E16.5. After Lac Z staining, embryos were fixed overnight, embedded in paraffin, sectioned at 6-10 μ m and counterstained with eosin. FIGS. 3A-C, Transverse sections were taken at multiple locations to obtain a representative sample of most SM tissues. Lac Z expression was seen in skeletal and cardiac muscle and in nearly all SM tissues including esophagus, bronchi, aorta, bladder, intestine, stomach, and most vascular beds. Note that staining in SM-containing tissues is highly restricted to SMC.

FIGS. 4(A-F). Expression of the p2600Int/Lac Z transgene in adult mice. Four to six week old mice were perfusion fixed and tissues were, excised, and stained over night for Lac Z expression. Expression was seen in nearly all SMC-containing tissues examined. FIG. 4A, Portion of the intestines showing uniform Lac Z staining. FIG. 4B,

Anterior view of the heart showing Lac Z expression in most, if not all, of the coronary vasculature and out flow tracts. FIG. 4C, View of the stomach which has been opened sagittally to show staining of the stomach wall and the gastric artery. Lac Z expression in the esophagus was limited to longitudinal SMC. FIG. 4D, Mesenteric vasculature removed en bloc showing SMC-specific staining of both the mesenteric arteries and veins. FIG. 4E, Bladder showing very intense and uniform Lac Z expression. FIG. 4F, Splayed view of the kidney after it was cut sagittally to reveal Lac Z staining of the renal vasculature and ureter. RCA indicates right coronary artery; LCA indicates left coronary artery; Ao indicates aorta; PA indicates pulmonary artery.

10

FIGS. 5(A-C). Histological examination of p2600Int/Lac Z expression in various adult SM-containing tissues. Four to six week old mice were perfusion fixed and tissues were, excised, and stained over night for Lac Z expression. After Lac Z staining, tissues were further fixed over night, embedded in paraffin, sectioned at 6-10 μ m, and counterstained with eosin. FIG. 5A, Section of thigh muscle skeletal muscle showing Lac Z expression in a femoral artery and vein. Note that in adult animals, the p2600Int/Lac Z transgene was not expressed in skeletal muscle. FIG. 5B, Cross section of the aorta showing nearly uniform Lac Z expression in multiple SMC layers. FIG. 5C, Transverse section of the kidney showing SMC-specific staining in the large renal arteries as well as smaller renal arterioles.

FIG. 6. The effects of CArG mutations on p2600Int/Lac Z activity in cultured SMC. Cultured rat SMC were transfected with equimolar amounts of the indicated deletion or site-directed mutant constructs. After 48 hr cells were lysed and galactosidase activity was measured spectrophotometrically. Gal activity (\pm S.D.) is expressed relative to the baseline Gal activity of a promoterless Gal construct set to 1. The first intron had significant transcriptional activity in the -547 and -2,600 context, and mutation of either CArG A, B, or the intronic CArG greatly decreased p2600Int/LacZ activity. Mutated CARG sequences were as follows: CARG A, 5'-AATTGTTTAA (SEQ ID NO:11); CARG B, 5'-CCCTATATCA (SEQ ID NO:12); and intronic CARG, 5'-AATAATTAAA (SEQ ID NO:13).

FIGS. 7(A-C). The effects of mutations to CArGs B and the intronic CArG on the expression of the p2600Int/LacZ transgene at E13.5. Site-directed CArG mutations that have previously been shown to abolish SRF binding *in vitro* were made to

CARG B and the intronic CARG in the p2600Int/Lac Z transgene construct. Transgenic mice were generated as described previously and stained for Lac Z expression at E13.5. LacZ expression in wild-type (Wt) embryos was indicative of endogenous SM α -A expression (FIG. 7A). Mutation of CARG B (B mut) completely abolished LacZ expression in all muscle cell types (FIG. 7B). Mutation of the intronic CARG (Int mut) had no effect on skeletal muscle expression but did eliminate expression in all SM (FIG. 7C). UA indicates umbilical artery. The mutated CARG sequences were as described above in FIG. 6.

FIGS. 8(A-C). Effects of mutations to CARGs A, B, and the intronic CARG on the expression of the p2600Int/LacZ transgene in adult mice. Adult lung (FIG. 8A), aorta (FIG. 8B), and skeletal muscle (FIG. 8C), from wild-type (Wt) and CARG mutant mice were processed as previously described and results of staining for LacZ expression are shown. The CARG B mutation (B mut) and the intronic CARG mutation (Int mut) abolished expression in SMC from all tissues and vascular beds. In contrast, mutation of CARG A (A mut) eliminated expression in SM organs and large vessels such as the aorta, but only partially inhibited expression in smaller blood vessels.

FIG. 9. The conserved 330 base pair intronic region contains both positive and negative regulatory elements. The ~100 bp region from +937 to +1,041 that contains the intronic CARG had significant positive activity when spliced onto the 5' promoter (compare PPInt100 with pProm) while an adjacent fragment from +863 to +990 (PPInt#2) significantly inhibited pProm activity. In addition, the full length, 330 base pair conserved intron region also resulted in significant positive activity when spliced onto the 5' promoter (compare PPInt300 with pProm). PPI (short for pProm and Intron) represents the activity of the large fragment from -2,558 bp through +2,784 bp.

FIGS. 10(A-B). Conserved *cis* Regulatory Elements in the SM α -actin 5' (FIG. 10A) and First Intron (FIG. 10B) Promoter Regions. Several important protein binding regions that have significant homology to known *cis* regulatory elements that bind AP1 and the GATA family of transcription factors were identified by DNase footprinting. This Figure also shows the mutated sequences for AP1-like, GATA and CARGs A, B and the intronic CARG which were prepared. The Figure further shows the homology that exists for the above sequences in humans, rats, mice and chickens.

FIG. 11. The GATA and AP1-like Elements within the Conserved Intronic Region are Positive Regulators of Promoter Activity. Mutation of the highly conserved AP1-like or GATA elements (see FIG. 10) in the context of the PPInt transgene caused a 35% and 65% reduction in promoter activity, respectively. pProm represents about -2,600 through about +20 of the promoter; PPI represents the large fragment from -2,558 bp through +2,784 bp; mPPI gata represents PPI with the potential GATA site near +1,152 mutated (see FIG. 10B for the sequence); mPPI AP1 represents PPI with the potential AP1 site near +823 mutated (see FIG. 10B for the sequence).

FIGS. 12(A-C). Alignment of Human, Rat, Mouse and Chicken 5' Promoter Region from about -1,100 base pairs to the Start of Transcription. CARGs A and B are marked and boxed.

FIGS. 13(A-G). Alignment of Human, Rat, Mouse and Chicken First Intron Sequence from about +47 through about +2775. The intronic CARG is marked and boxed.

5. DETAILED DESCRIPTION OF THE INVENTION

The present invention provides promoters, enhancers and other regulatory elements that direct expression within SMC, comprising nucleotide sequences from the 5' regulatory region and the first intron, and transcriptionally active fragments thereof, that control expression of an SM α -A. Specifically provided are expression vectors, host cells and transgenic animals wherein an SM α -A regulatory region is capable of controlling expression of a heterologous gene, over-expressing an endogenous SMC gene or an inhibitor of a pathological process or knocking out expression of a specific gene believed to be important for a SM-related disease in SMC. Examples of such SMC include, but are not limited to, cells which form the contractile portion of the stomach, intestine and uterus, the walls of arteries, the ducts of secretory glands and many other regions in which slow and sustained contractions are needed. The invention also provides methods for using said vectors, cells and animals for screening candidate molecules for agonists and antagonists of disorders involving SMC. In an alternated embodiment, the invention provides compositions and methods for modulating expression of compounds within SMC, and to screening compounds that modulate expression within SMC. Methods for using the molecules and compounds identified by the screening assays for therapeutic treatments also are provided.

Described in detail below, in Sections 5.1 and 5.2, are nucleotide sequences of the SM α -A regulatory region, and expression vectors, host cells and transgenic animals wherein the expression of a heterologous gene is controlled by the SM α -A regulatory region. In Section 5.3, methods for using such polynucleotides (*i.e.*, regulatory regions of the SM α -A gene) and fusion protein products, for screening compounds that interact with the regulatory region of the SM α -A gene are described. This Section describes both *in vivo* and *in vitro* assays to screen small molecules, compounds, recombinant proteins, peptides, nucleic acids, antibodies, *etc.* which bind to or modulate the activity of the SM α -A regulatory region. Section 5.4 describes methods for the use of identified agonists and antagonists for drug delivery or gene therapy. Finally, in Section 5.5, pharmaceutical compositions are described for using such agonists and antagonists to modulate SMC related disorders. Methods and compositions are provided for treating various SMC-related disorders, including, but not limited to, coronary artery disease, hypertension, stroke, asthma and multiple gastrointestinal, urogenital and reproductive disorders.

5.1 Polynucleotides and Nucleic Acids of the Invention

The present invention encompasses polynucleotide sequences comprising the 5' regulatory region and the first intron, and transcriptionally active fragments thereof, of the SM α -A gene. In particular, the present invention provides a polynucleotide comprising a 5342 bp sequence (SEQ ID NO:1) that is located within a SM α -A gene. Specifically, the polynucleotide comprises -2558 bp through +2784 bp of a SM α -A 5' promoter and first intron sequence. A 325 bp fragment (SEQ ID NO:2) of this promoter, from +773 bp to +1098 bp relative to the start of transcription is highly conserved and contains *cis* elements required to direct SMC-specific transcription *in vivo*.

In specific embodiments, SM α -A regulatory nucleic acids comprise the genomic DNA sequences of SEQ ID NO:1, or transcriptionally active fragments thereof. The regulatory sequences of the SM α -A gene comprise the polynucleotide sequences located between the nucleotide in position 1 and the nucleotide in position 5342 of the nucleotide sequence of SEQ ID NO:1, more preferably between positions 1 bp to 2605 bp, 2011 bp to 2605 bp and 2011 bp to 5342 bp of SEQ ID NO:1. Additional regulatory regions of the SM α -A gene comprise the polynucleotide sequences located between the nucleotide in position 3495 bp to 3599 bp, 3421 bp to 3548 bp of SEQ ID NO:1, most preferably between 3331 to 3656 of SEQ ID NO:1. Thus, in various embodiments of the invention, the regulatory region is a 325 bp intronic fragment from 3331 to 3656 of SEQ ID NO:1 (SEQ ID NO:2), a 104 bp fragment from 3495 bp to 3599 bp of SEQ ID NO:1 or a 127 bp fragment from 3421 bp to 3548 bp of SEQ ID NO:1 spliced downstream of the 5'

promoter sequence of SEQ ID NO:1 (from 1-2558 of SEQ ID NO:1). In various embodiments, the polynucleotide may be 5000, 4000, 3000, 2000, 1000, preferably approximately 500 and more preferably approximately 325 bp in length.

The invention further provides probes, primers and fragments of the SM α -A regulatory region. In one embodiment, purified nucleic acids consisting of at least 8 nucleotides (*i.e.*, a hybridizable portion) of an SM α -A gene sequence are provided; in other embodiments, the nucleic acids consist of at least 20 (contiguous) nucleotides, 25 nucleotides, 50 nucleotides, 100 nucleotides, 200 nucleotides, 500, 1000, 2000, 3000, 4000 or 5000 nucleotides of an SM α -A sequence. For example, the nucleic acids consist of any 20 contiguous nucleotides of the nucleic acid set forth in SEQ ID NO:1 (*e.g.*, 1-20, 5-24, 21-40, *etc.*). Methods which are well known to those skilled in the art can be used to construct these sequences, either in isolated form or contained in expression vectors. These methods include, for example, *in vitro* recombinant DNA techniques, synthetic techniques and *in vivo* genetic recombination. See, *e.g.*, the techniques described in Sambrook *et al.*, 1989, *supra*, and Ausabel *et al.*, 1989, *supra*; also see the techniques described in "Oligonucleotide Synthesis", 1984, Gait M.J. ed., IRL Press, Oxford, which is incorporated herein by reference in its entirety.

In another embodiment, the nucleic acids are smaller than 20, 25, 35, 200 or 500 nucleotides in length. Nucleic acids can be single or double stranded. The invention also encompasses nucleic acids hybridizable to or complementary to the foregoing sequences. In specific aspects, nucleic acids are provided which comprise a sequence complementary to at least 10, 20, 25, 50, 100, 200, 500 nucleotides or the entire regulatory region of an SM α -A gene.

The probes, primers and fragments of the SM α -A regulatory region provided by the present invention can be used by the research community for various purposes. They can be used as molecular weight markers on Southern gels; as chromosome markers or tags (when labeled) to identify chromosomes or to map related gene positions; to compare with endogenous DNA sequences in patients to identify potential genetic disorders; as probes to hybridize and thus discover novel, related DNA sequences; as a source of information to derive PCR primers for genetic fingerprinting; and as a probe to "subtract-out" known sequences in the process of discovering other novel polynucleotides. Methods for performing the uses listed above are well known to those skilled in the art. References disclosing such methods include, without limitation, "Molecular Cloning: A Laboratory Manual", 2d ed., Cold Spring Harbor Laboratory Press, Sambrook, J., E. F. Fritsch and T. Maniatis eds., 1989, and "Methods in Enzymology: Guide to Molecular Cloning Techniques", Academic Press, Berger, S. L. and A. R. Kimmel eds., 1987.

The nucleotide sequences of the invention also include nucleotide sequences that have at least 65%, 70%, 75%, 80%, 85%, 90%, 95%, 98% or more nucleotide sequence identity to the nucleotide sequence depicted in SEQ ID NO:1, and/or transcriptionally active fragments thereof.

5 To determine the percent identity of two amino acid sequences or of two nucleic acids, the sequences are aligned for optimal comparison purposes (*e.g.*, gaps can be introduced in the sequence of a first amino acid or nucleic acid sequence for optimal alignment with a second amino or nucleic acid sequence). The amino acid residues or nucleotides at corresponding amino acid positions or nucleotide positions are then
10 compared. When a position in the first sequence is occupied by the same amino acid residue or nucleotide as the corresponding position in the second sequence, then the molecules are identical at that position. The percent identity between the two sequences is a function of the number of identical positions shared by the sequences (*i.e.*, % identity = # of identical overlapping positions/total # of positions x 100). In one embodiment, the two
15 sequences are the same length.

The determination of percent identity between two sequences also can be accomplished using a mathematical algorithm. A preferred, non-limiting example of a mathematical algorithm utilized for the comparison of two sequences is the algorithm of Karlin and Altschul (1990) *Proc. Natl. Acad. Sci. USA* 87:2264-2268, modified as in Karlin
20 and Altschul (1993) *Proc. Natl. Acad. Sci. USA* 90:5873-5877. Such an algorithm is incorporated into the NBLAST and XBLAST programs of Altschul, *et al.* (1990) *J. Mol. Biol.* 215:403-410. BLAST nucleotide searches can be performed with the NBLAST program, score = 100, wordlength = 12 to obtain nucleotide sequences homologous to a nucleic acid molecules of the invention. BLAST protein searches can be performed with
25 the XBLAST program, score = 50, wordlength = 3 to obtain amino acid sequences homologous to a protein molecules of the invention. To obtain gapped alignments for comparison purposes, Gapped BLAST can be utilized as described in Altschul *et al.* (1997) *Nucleic Acids Res.* 25:3389-3402. Alternatively, PSI-Blast can be used to perform an iterated search which detects distant relationships between molecules (*Id.*). When utilizing
30 BLAST, Gapped BLAST and PSI-Blast programs, the default parameters of the respective programs (*e.g.*, XBLAST and NBLAST) can be used (see <http://www.ncbi.nlm.nih.gov>). Another preferred, non-limiting example of a mathematical algorithm utilized for the comparison of sequences is the algorithm of Myers and Miller, (1988) *CABIOS* 4:11-17. Such an algorithm is incorporated into the ALIGN program (version 2.0) which is part of
35 the GCG sequence alignment software package. When utilizing the ALIGN program for comparing amino acid sequences, a PAM120 weight residue table, a gap length penalty of

12 and a gap penalty of 4 can be used. In an alternate embodiment, alignments can be obtained using the NA_MULTIPLE_ALIGNMENT 1.0 program, using a GapWeight of 5 and a GapLengthWeight of 1.

The percent identity between two sequences can be determined using techniques similar to those described above, with or without allowing gaps. In calculating percent identity, typically only exact matches are counted.

The invention also encompasses:

- (a) DNA vectors that contain any of the foregoing SM α -A regulatory sequences and/or their complements (*i.e.*, antisense);
- (b) DNA expression vectors that contain any of the foregoing SM α -A regulatory element sequences operatively associated with a heterologous gene, such as a reporter gene; and
- (c) genetically engineered host cells that contain any of the foregoing SM α -A regulatory element sequences operatively associated with a heterologous gene such that the SM α -A regulatory element directs the expression of the heterologous gene in the host cell.

Also encompassed within the scope of the invention are various transcriptionally active fragments of this regulatory region. A "transcriptionally active" or "transcriptionally functional" fragment of SEQ ID NO:1 according to the present invention refers to a polynucleotide comprising a fragment of said polynucleotide which is functional as a regulatory region for expressing a recombinant polypeptide or a recombinant polynucleotide in a recombinant cell host. For the purpose of the invention, a nucleic acid or polynucleotide is "transcriptionally active" as a regulatory region for expressing a recombinant polypeptide or a recombinant polynucleotide if said regulatory polynucleotide contains nucleotide sequences which contain transcriptional information, and such sequences are operably associated to nucleotide sequences which encode the desired polypeptide or the desired polynucleotide.

In particular, the transcriptionally active fragments of the SM α -A regulatory region of the present invention encompass those fragments that are of sufficient length to promote transcription of a heterologous gene, such as a reporter gene, when operatively linked to the SM α -A regulatory sequence and transfected into an SM cell line. Typically, the regulatory region is placed immediately 5' to, and is operatively associated with the coding sequence. As used herein, the term "operatively associated" refers to the placement of the regulatory sequence immediately 5' (upstream) of the reporter gene, such that trans-acting factors required for initiation of transcription, such as transcription factors,

polymerase subunits and accessory proteins, can assemble at this region to allow RNA polymerase dependent transcription initiation of the reporter gene.

In one embodiment, the polynucleotide sequence chosen may further comprise other nucleotide sequences, either from the SM α -A gene, or from a heterologous gene. In another embodiment, multiple copies of a promoter sequence, or a fragment thereof, may be linked to each other. For example, the promoter sequence, or a fragment thereof, may be linked to another copy of the promoter sequence, or another fragment thereof, in a head to tail, head to head, or tail to tail orientation. In another embodiment, an SMC-specific enhancer may be operatively linked to the SM α -A regulatory sequence, or fragment thereof, and used to enhance transcription from the construct containing the SM α -A regulatory sequence.

Also encompassed within the scope of the invention are modifications of this nucleotide sequence without substantially affecting its transcriptional activities. Such modifications include additions, deletions and substitutions. In addition, any nucleotide sequence that selectively hybridizes to the complement of the sequence of SEQ ID NO: 1 under stringent conditions, and is capable of activating the expression of a coding sequence is encompassed by the invention. Exemplary moderately stringent hybridization conditions are as follows: prehybridization of filters containing DNA is carried out for 8 hours to overnight at 65°C in buffer composed of 6X SSC, 50 mM Tris-HCl (pH 7.5), 1 mM EDTA, 0.02% PVP, 0.02% Ficoll, 0.02% BSA, and 500 μ g/ml denatured salmon sperm DNA. Filters are hybridized for 48 hours at 65°C in prehybridization mixture containing 100 μ g/ml denatured salmon sperm DNA and 5-20 $\times 10^6$ cpm of 32 P-labeled probe. Washing of filters is done at 37°C for 1 hour in a solution containing 2X SSC, 0.01% PVP, 0.01% Ficoll, and 0.01% BSA. This is followed by a wash in 0.1X SSC at 50°C for 45 min before autoradiography. Alternatively, exemplary conditions of high stringency are as follows: e.g., hybridization to filter-bound DNA in 0.5 M NaHPO₄, 7% sodium dodecyl sulfate (SDS), 1 mM EDTA at 65°C, and washing in 0.1XSSC/0.1% SDS at 68°C (Ausubel F.M. et al., eds., 1989, Current Protocols in Molecular Biology, Vol. I, Green Publishing Associates, Inc., and John Wiley & sons, Inc., New York, at p. 2.10.3). Other conditions of high stringency which may be used are well known in the art. In general, for probes between 14 and 70 nucleotides in length the melting temperature (T_m) is calculated using the formula: $T_m(^{\circ}\text{C}) = 81.5 + 16.6(\log[\text{monovalent cations (molar)}]) + 0.41 (\% \text{ G+C}) - (500/N)$ where N is the length of the probe. If the hybridization is carried out in a solution containing formamide, the melting temperature is calculated using the equation $T_m(^{\circ}\text{C}) = 81.5 + 16.6(\log[\text{monovalent cations (molar)}]) + 0.41(\% \text{ G+C}) - (0.61\% \text{ formamide}) - (500/N)$ where N is the length of the probe. In general, hybridization is carried out at about

20-25 degrees below T_m (for DNA-DNA hybrids) or 10-15 degrees below T_m (for RNA-DNA hybrids).

The SM α -A regulatory region, or transcriptionally functional fragments thereof, is preferably derived from a mammalian organism. Screening procedures which
 5 rely on nucleic acid hybridization make it possible to isolate gene sequences from various organisms. The isolated polynucleotide sequence disclosed herein, or fragments thereof, may be labeled and used to screen a cDNA library constructed from mRNA obtained from appropriate cells or tissues (*e.g.*, muscle tissue) derived from the organism of interest. The hybridization conditions used should be of a lower stringency when the cDNA library is
 10 derived from an organism different from the type of organism from which the labeled sequence was derived. Low stringency conditions are well known to those of skill in the art, and will vary depending on the specific organisms from which the library and the labeled sequence are derived. For guidance regarding such conditions see, for example, Sambrook *et al.*, 1989, *Molecular Cloning, A Laboratory Manual*, Second Edition, Cold Spring Harbor
 15 Press, N.Y., and Ausabel *et al.*, 1989, *Current Protocols in Molecular Biology*, Green Publishing Associates and Wiley Interscience, N.Y., each of which is incorporated herein by reference in its entirety. Further, mammalian SM α -A regulatory region homologues may be isolated from, for example, bovine or other non-human nucleic acid, by performing polymerase chain reaction (PCR) amplification using two primer pools designed on the
 20 basis of the nucleotide sequence of the SM α -A regulatory region disclosed herein. The template for the reaction may be cDNA obtained by reverse transcription of the mRNA prepared from, for example, bovine or other non-human cell lines, or tissue known to express the SM α -A gene. For guidance regarding such conditions, see, *e.g.*, Innis *et al.* (Eds.) 1995, *PCR Strategies*, Academic Press Inc., San Diego; and Erlich (ed) 1992, *PCR*
 25 *Technology*, Oxford University Press, New York, each of which is incorporated herein by reference in its entirety.

Regions of the human, rat, mouse and chicken SM α -A gene sequences were compared and aligned in FIGS. 12 and 13. Specifically, FIG. 12 shows an alignment for the human (SEQ ID NO:3), rat (SEQ ID NO:4), mouse (SEQ ID NO:5) and chicken (SEQ ID
 30 NO:6) sequences from about -1,100 base pairs up to the start of transcription. FIG. 13 shows an alignment for the human (SEQ ID NO:7), rat (SEQ ID NO:8), mouse (SEQ ID NO:9) and chicken (SEQ ID NO:10) sequences from about +47 through about +2775 relative to the start of transcription. Both of the figures were created using the NA_MULTIPLE_ALIGNMENT 1.0 program, using a GapWeight of 5 and a
 35 GapLengthWeight of 1. As noted in the figures, each of the CArG elements (A, B and the intronic CArG) are absolutely conserved.

Promoter sequences within the 5' non-coding regions of the SM α -A gene may be further defined by constructing nested 5' and/or 3' deletions using conventional techniques such as exonuclease III or appropriate restriction endonuclease digestion. The resulting deletion fragments can be inserted into the promoter reporter vector to determine whether the deletion has reduced or obliterated promoter activity, such as described, for example, by Coles *et al.* (Hum. Mol. Genet., 7:791-800, 1998). In this way, the boundaries of the promoters may be defined. If desired, potential individual regulatory sites within the promoter may be identified using site directed mutagenesis or linker scanning to obliterate potential transcription factor binding sites within the promoter individually or in combination. The effects of these mutations on transcription levels may be determined by inserting the mutations into cloning sites in promoter reporter vectors. These types of assays are well known to those skilled in the art (WO 97/17359, US 5,374,544, EP 582 796, US 5,698,389, US 5,643,746, US 5,502,176, and US 5,266,488).

The SM α -A regulatory regions and transcriptionally functional fragments thereof, and the fragments and probes described herein which serve to identify SM α -A regulatory regions and fragments thereof, may be produced by recombinant DNA technology using techniques well known in the art. Methods which are well known to those skilled in the art can be used to construct these sequences, either in isolated form or contained in expression vectors. These methods include, for example, *in vitro* recombinant DNA techniques, synthetic techniques and *in vivo* genetic recombination. See, *e.g.*, the techniques described in Sambrook *et al.*, 1989, *supra*, and Ausubel *et al.*, 1989, *supra*; also see the techniques described in "Oligonucleotide Synthesis", 1984, Gait M.J. ed., IRL Press, Oxford, which is incorporated herein by reference in its entirety.

Alterations in the regulatory sequences can be generated using a variety of chemical and enzymatic methods which are well known to those skilled in the art. For example, regions of the sequences defined by restriction sites can be deleted. Oligonucleotide-directed mutagenesis can be employed to alter the sequence in a defined way and/or to introduce restriction sites in specific regions within the sequence. Additionally, deletion mutants can be generated using DNA nucleases such as Bal31, ExoIII, or S1 nuclease. Progressively larger deletions in the regulatory sequences are generated by incubating the DNA with nucleases for increased periods of time (see, *e.g.*, Ausubel *et al.*, 1989, *supra*).

The altered sequences are evaluated for their ability to direct expression of heterologous coding sequences in appropriate host cells. It is within the scope of the present invention that any altered regulatory sequences which retain their ability to direct

expression of a coding sequence be incorporated into recombinant expression vectors for further use.

5.2 Analysis of SMC-Specific Promoter Activity

5 The rat SM α -A gene regulatory region shows selective tissue and cell-type specificity; *i.e.*, it induces gene expression in SMC. Thus, the regulatory region, and transcriptionally active fragments thereof, of the present invention may be used to induce expression of a heterologous coding sequence in SMC. The present invention provides for the use of the SM α -A gene regulatory region to achieve tissue specific expression of a target gene. The activity and the specificity of the SM α -A regulatory region can further be assessed by monitoring the expression level of a detectable polynucleotide operably associated with the SM α -A promoter in different types of cells and tissues. As discussed hereinbelow, the detectable polynucleotide may be either a polynucleotide that specifically hybridizes with a predefined oligonucleotide probe, or a polynucleotide encoding a detectable protein.

5.2.1 SM α -A Promoter Driven Reporter Constructs

The regulatory polynucleotides according to the invention may be advantageously part of a recombinant expression vector that may be used to express a coding sequence, or reporter gene, in a desired host cell or host organism. The SM α -A regulatory region of the present invention, and transcriptionally active fragments thereof, may be used to direct the expression of a heterologous coding sequence. In particular, the present invention encompasses mammalian, such as murine, SM α -A regulatory regions. In accordance with the present invention, transcriptionally active fragments of the SM α -A regulatory region encompass those fragments of the region which are of sufficient length to promote transcription of a reporter coding sequence to which the fragment is operatively linked.

A variety of reporter gene sequences well known to those of skill in the art can be utilized, including, but not limited to, genes encoding fluorescent proteins such as green fluorescent protein (GFP), enzymes (*e.g.* CAT, beta-galactosidase, luciferase) or antigenic markers. For convenience, enzymatic reporters and light-emitting reporters analyzed by colorimetric or fluorometric assays are preferred for the screening assays of the invention.

In one embodiment, for example, a bioluminescent, chemiluminescent or fluorescent protein can be used as a light-emitting reporter in the invention. Types of light-

emitting reporters, which do not require substrates or cofactors, include, but are not limited to the wild-type green fluorescent protein (GFP) of *Victoria aequoria* (Chalfie *et al.*, 1994, Science 263:802-805), and modified GFPs (Heim *et al.*, 1995, Nature 373:663-4; PCT publication WO 96/23810). Transcription and translation of this type of reporter gene leads to the accumulation of the fluorescent protein in test cells, which can be measured by a fluorimeter, or a flow cytometer, for example, by methods that are well known in the art (see, *e.g.*, Lackowicz, 1983, Principles of Fluorescence Spectroscopy, Plenum Press, New York).

Another type of reporter gene that may be used are enzymes that require cofactor(s) to emit light, including but not limited to, Renilla luciferase. Other sources of luciferase also are well known in the art, including, but not limited to, the bacterial luciferase (*luxAB* gene product) of *Vibrio harveyi* (Karp, 1989, Biochim. Biophys. Acta 1007:84-90; Stewart *et al.* 1992, J. Gen. Microbiol, 138:1289-1300), and the luciferase from firefly, *Photinus pyralis* (De Wet *et al.* 1987, Mol. Cell. Biol. 7:725-737), which can be assayed by light production (Miyamoto *et al.*, 1987, J. Bacteriol. 169:247-253; Loessner *et al.* 1996, Environ. Microbiol. 62:1133-1140; and Schultz & Yarus, 1990, J. Bacteriol. 172:595-602).

Reporter genes that can be analyzed using colorimetric analysis include, but are not limited to, β -galactosidase (Nolan *et al.* 1988, Proc. Natl. Acad. Sci. USA 85:2603-07), β -glucuronidase (Roberts *et al.* 1989, Curr. Genet. 15:177-180), luciferase (Miyamoto *et al.*, 1987, J. Bacteriol. 169:247-253), or β -lactamase. In one embodiment, the reporter gene sequence comprises a nucleotide sequence which encodes a *LacZ* gene product, β -galactosidase. The enzyme is very stable and has a broad specificity so as to allow the use of different histochemical, chromogenic or fluorogenic substrates, such as, but not limited to, 5-bromo-4-chloro-3-indoyl- β -D-galactoside (X-gal), lactose 2,3,5-triphenyl-2H-tetrazolium (lactose-tetrazolium) and fluorescein galactopyranoside (see Nolan *et al.*, 1988, *supra*).

In another embodiment, the product of the *E. coli* β -glucuronidase gene (GUS) can be used as a reporter gene (Roberts *et al.* 1989, Curr. Genet. 15:177-180). GUS activity can be detected by various histochemical and fluorogenic substrates, such as X-glucuronide (Xgluc) and 4-methylumbelliferyl glucuronide.

In addition to reporter gene sequences such as those described above, which provide convenient colorimetric responses, other reporter gene sequences, such as, for example, selectable reporter gene sequences, can routinely be employed. For example, the coding sequence for chloramphenicol acetyl transferase (CAT) can be utilized, leading to SM α -A regulatory region-dependent expression of chloramphenicol resistant cell growth.

The use of CAT and the advantages of a selectable reporter gene are well known to those skilled in the art (Eikmanns *et al.* 1991, *Gene* 102:93-98). Other selectable reporter gene sequences also can be utilized and include, but are not limited to, gene sequences encoding polypeptides which confer zeocin (Hegedus *et al.* 1998, *Gene* 207:241-249) or kanamycin resistance (Friedrich & Soriano, 1991, *Genes. Dev.* 5:1513-1523).

Other reporter genes, such as toxic gene products, potentially toxic gene products, and antiproliferation or cytostatic gene products, also can be used. In another embodiment, the detectable reporter polynucleotide may be either a polynucleotide that specifically hybridizes with a predefined oligonucleotide probe, or a polynucleotide encoding a detectable protein, including an SM α -A polypeptide or a fragment or a variant thereof. This type of assay is well known to those skilled in the art (US 5,502,176 and US 5,266,488).

SM α -A driven reporter constructs can be constructed according to standard recombinant DNA techniques (see, *e.g.*, *Methods in Enzymology*, 1987, volume 154, Academic Press; Sambrook *et al.* 1989, *Molecular Cloning - A Laboratory Manual*, 2nd Edition, Cold Spring Harbor Press, New York; and Ausubel *et al.* *Current Protocols in Molecular Biology*, Greene Publishing Associates and Wiley Interscience, New York, each of which is incorporated herein by reference in its entirety).

Methods for assaying promoter activity are well-known to those skilled in the art (see, *e.g.*, Sambrook *et al.*, *Molecular Cloning A Laboratory Manual*, Cold Spring Harbor Laboratory, Cold Spring Harbor, NY, 1989). An example of a typical method that can be used involves a recombinant vector carrying a reporter gene and genomic sequences from the SM α -A genomic sequence of SEQ ID NO:1. Briefly, the expression of the reporter gene (for example, green fluorescent protein, luciferase, β -galactosidase or chloramphenicol acetyl transferase) is detected when placed under the control of a biologically active polynucleotide fragment. Genomic sequences located upstream of the first exon of the gene may be cloned into any suitable promoter reporter vector. For example, a number of commercially available vectors can be engineered to insert the SM α -A regulatory region of the invention for expression in mammalian host cells. Non-limiting examples of such vectors are pSEAPBasic, pSEAP-Enhancer, p β gal-Basic, p β gal-Enhancer, or pEGFP-1 Promoter Reporter vectors (Clontech, Palo Alto, CA) or pGL2-basic or pGL3-basic promoterless luciferase reporter gene vector (Promega, Madison, WI). Each of these promoter reporter vectors include multiple cloning sites positioned upstream of a reporter gene encoding a readily assayable protein such as secreted alkaline phosphatase, green fluorescent protein, luciferase or β -galactosidase. The regulatory sequences of the SM α -A gene are inserted into the cloning sites upstream of the reporter gene in both

orientations and introduced into an appropriate host cell. The level of reporter protein is assayed and compared to the level obtained with a vector lacking an insert in the cloning site. The presence of an elevated expression level in the vector containing the insert with respect the control vector indicates the presence of a promoter in the insert.

- 5 Expression vectors that comprise an SM α -A gene regulatory region may further contain a gene encoding a selectable marker. A number of selection systems may be used, including but not limited to, the herpes simplex virus thymidine kinase (Wigler *et al.*, 1977, Cell 11:223), hypoxanthine-guanine phosphoribosyltransferase (Szybalska & Szybalski, 1962, Proc. Natl. Acad. Sci. USA 48:2026) and adenine
- 10 phosphoribosyltransferase (Lowy *et al.*, 1980, Cell 22:817) genes, which can be employed in tk⁻, hgp^rt⁻ or ap^rt⁻ cells, respectively. Also, antimetabolite resistance can be used as the basis of selection for *dhfr*, which confers resistance to methotrexate (Wigler *et al.*, 1980, Proc. Natl. Acad. Sci. USA 77:3567; O'Hare *et al.*, 1981, Proc. Natl. Acad. Sci. USA 78:1527); *gpt*, which confers resistance to mycophenolic acid (Mulligan & Berg, 1981,
- 15 Proc. Natl. Acad. Sci. USA 78:2072); *neo*, which confers resistance to the aminoglycoside G-418 (Colberre-Garapin *et al.*, 1981, J. Mol. Biol. 150:1); and *hygro*, which confers resistance to hygromycin (Santerre *et al.*, 1984, Gene 30:147) genes. Additional selectable genes include *trpB*, which allows cells to utilize indole in place of tryptophan; *hisD*, which allows cells to utilize histinol in place of histidine (Hartman & Mulligan, 1988, Proc. Natl.
- 20 Acad. Sci. USA 85:8047); *ODC* (ornithine decarboxylase) which confers resistance to the ornithine decarboxylase inhibitor, 2-(difluoromethyl)-DL-ornithine, DFMO (McConlogue L., 1987, In: Current Communications in Molecular Biology, Cold Spring Harbor Laboratory ed.) and glutamine synthetase (Bebbington *et al.*, 1992, Biotech 10:169).

25 5.2.2 Characterization of Transcriptionally Active Regulatory Fragments

- A fusion construct comprising an SM α -A regulatory region, or a fragment thereof, can be assayed for transcriptional activity. As a first step in promoter analysis, the transcriptional start point (+1 site) of the SMC-specific gene under study has to be
- 30 determined using primer extension assay and/or RNAase protection assay, following standard methods (Sambrook *et al.*, 1989, Molecular Cloning: A Laboratory Manual, Cold Spring Harbor, Cold Spring Harbor Press). The DNA sequence upstream of the +1 site is generally considered as the promoter region responsible for gene regulation. However, downstream sequences, including sequences within introns, also may be involved in gene
- 35 regulation. To begin testing for promoter activity, a -3 kb to +3 kb region (where +1 is the transcriptional start point) may be cloned upstream of the reporter gene coding region. Two

or more additional reporter gene constructs also may be made which contain 5' and/or 3' truncated versions of the regulatory region to aid in identification of the region responsible for SMC-specific expression. The choice of the type of reporter gene is made based on the application.

5 In a preferred embodiment, a GFP reporter gene construct is used. The application of green fluorescent protein (GFP) as a reporter is particularly useful in the study of SMC-specific gene promoters. A major advantage of using GFP as a reporter lies in the fact that GFP can be detected in freshly isolated SMC without the need for substrates.

In another embodiment of the invention, a *Lac Z* reporter construct is used.

10 The *Lac Z* gene product, β -galactosidase, is extremely stable and has a broad specificity so as to allow the use of different histochemical, chromogenic or fluorogenic substrates, such as, but not limited to, 5-bromo-4-chloro-3-indoyl- β -D-galactoside (X-gal), lactose 2,3,5-triphenyl-2H-tetrazolium (lactose-tetrazolium) and fluorescein galactopyranoside (see Nolan *et al.*, 1988, *supra*).

15 For promoter analysis in transgenic mice, GFP that has been optimized for expression in mammalian cells is preferred. The promoterless cloning vector pEGFP1 (Clontech, Palo Alto, CA) encodes a red shifted variant of the wild-type GFP which has been optimized for brighter fluorescence and higher expression in mammalian cells (Cormack *et al.*, 1996, Gene 173:33; Haas *et al.*, 1996, Curr. Biol. 6: 315). Moreover,
20 since the maximal excitation peak of this enhanced GFP (EGFP) is at 488 nm, commonly used filter sets such as fluorescein isothiocyanate (FITC) optics which illuminate at 450-500 nm can be used to visualize GFP fluorescence. pEGFP1 proved to be useful as a reporter vector for promoter analysis in transgenic mice (Okabe *et al.*, 1997, FEBS Lett. 407: 313). In an alternate embodiment, transgenic mice containing transgenes with a SM α -A
25 regulatory region upstream of the *Lac Z* reporter gene are utilized.

Putative promoter fragments can be prepared (usually from a parent phage clone containing 8-10 kb genomic DNA including the promoter region) for cloning using methods known in the art. In one embodiment, for example, promoter fragments are cloned into the multiple cloning site of a *Lac Z* reporter vector. In one embodiment,
30 restriction endonucleases are used to excise the regulatory region fragments to be inserted into the reporter vector. For example, if NotI and EcoRI sites were present at -2.5 kb and +2.7 kb positions of the regulatory fragment, then the -2.5 kb to +2.7 kb fragment can be generated by digestion with NotI and Eco RI. However, the feasibility of this method depends on the availability of proper restriction endonuclease sites in the regulatory
35 fragment. In a preferred embodiment, the required promoter fragment is amplified by polymerase chain reaction (PCR; Saiki *et al.*, 1988, Science 239:487) using

oligonucleotide primers bearing the appropriate sites for restriction endonuclease cleavage. The sequence necessary for restriction cleavage is included at the 5' end of the forward and reverse primers which flank the regulatory fragment to be amplified. After PCR amplification, the appropriate ends are generated by restriction digestion of the PCR product. The promoter fragments, generated by either method, are then ligated into the multiple cloning site of the reporter vector following standard cloning procedures (Sambrook *et al.*, 1989, *supra*). It is recommended that the DNA sequence of the PCR generated promoter fragments in the constructs be verified prior to generation of transgenic animals. The resulting reporter gene construct will contain the putative promoter fragment located upstream of the reporter gene open reading frame, *e.g.*, GFP or *Lac Z* cDNA.

In the preferred embodiment, the following protocol is used. Fifty to 100 pg of the reporter gene construct is digested using appropriate restriction endonucleases to release the transgene fragment. The restriction endonuclease cleaved products are resolved in a 1% (w/v) agarose gel containing 0.5 ug/ml ethidium bromide and TAE buffer (IX: 0.04 M Tri-acetate, 0.001 M EDTA, pH 8.0) at 5-6 V/cm. The transgene band is located by size using a UV transilluminator, preferably using long-wavelength UV lamp to reduce nicking of DNA, and the gel piece containing the required band carefully excised. The gel slice and 1 ml of 0.5 X TAE buffer is added to a dialysis bag, which has been boiled in 1 mM EDTA, pH 8.0 for 10 minutes (Sambrook *et al.*, 1989, *supra*) and the ends are fastened. The dialysis bag containing the gel piece is submerged in a horizontal gel electrophoresis chamber containing 0.5 X TAE buffer, and electrophoresed at 5-6 V/cm for 45 minutes. The current flow in the electrophoresis chamber is reversed for one minute before stopping the run to release the DNA which may be attached to the wall of the dialysis tube. The TAE buffer containing the electroeluted DNA from the dialysis bag is collected in a fresh eppendorf tube. The gel piece may be observed on the UV transilluminator to ascertain that the electroelution of the DNA is complete.

The electroeluted DNA sample is further purified by passing through Elutip D columns. The matrix of the column is prewashed with 1-2 ml of High salt buffer (1.0 M NaCl, 20mM Tris. Cl, 1.0 mM EDTA, pH 7.5), followed by a wash with 5 ml of Low salt buffer (0.2 M NaCl, 20 mM Tris. Cl, 1.0 mM EDTA, pH 7.5). A 5 ml syringe is used to apply solutions to the Elutip D column, avoiding reverse flow. The solution containing the electroeluted DNA is loaded slowly. The column is washed with 2-3 ml of Low salt buffer and the DNA is eluted in 0.4 ml of High salt buffer. Two volumes of cold 95% ethanol is added to precipitate DNA. The DNA is collected by centrifugation in a microcentrifuge at 14,000 g for 10 minutes, carefully removing the alcohol without disrupting the DNA pellet. The pellet is washed at least twice with 70% (v/v) ethanol, and dried. The washing and

drying steps are important, as residual salt and ethanol are lethal to the developing embryos. The DNA is resuspend in the injection buffer (10mM TM, 0.1 mM EDTA, pH 7.5 prepared with Milli-Q quality water). The concentration of the purified transgene DNA fragment is determined by measuring the optical density at A_{260} ($A_{260} = 1$ for 50 μ g/ml DNA) using a spectrophotometer. DNA prepared in this manner is suitable for microinjection into fertilized mouse eggs.

5.2.3 SMC-Specific Promoter Analysis Using Transgenic Mice

The mammalian SM α -A regulatory region can be used to direct expression of, *inter alia*, a reporter coding sequence, a homologous gene or a heterologous gene in transgenic animals. Animals of any species, including, but not limited to, mice, rats, rabbits, guinea pigs, pigs, micro-pigs, goats, sheep, and non-human primates, *e.g.*, baboons, monkeys and chimpanzees may be used to generate transgenic animals. The term "transgenic," as used herein, refers to non-human animals expressing SM α -A gene sequences from a different species (*e.g.*, mice expressing SM α -A sequences), as well as animals that have been genetically engineered to over-express endogenous (*i.e.*, same species) SM α -A sequences or animals that have been genetically engineered to knock-out specific sequences.

In one embodiment, the present invention provides for transgenic animals that carry a transgene such as a reporter gene under the control of the SM α -A regulatory region or transcriptionally active fragments thereof in all their cells, as well as animals that carry the transgene in some, but not all their cells, *i.e.*, mosaic animals. The transgene may be integrated as a single transgene or in concatamers, *e.g.*, head-to-head tandems or head-to-tail tandems. The transgene may also be selectively introduced into and activated in a particular cell type by following, for example, the teaching of Lasko *et al.* (1992, Proc. Natl. Acad. Sci. USA 89:6232-6236). When it is desired that the transgene be integrated into the chromosomal site of the endogenous corresponding gene, gene targeting is preferred. Briefly, when such a technique is to be utilized, vectors containing some nucleotide sequences homologous to the endogenous gene are designed for the purpose of integrating, via homologous recombination with chromosomal sequences, into and disrupting the function of the nucleotide sequence of the endogenous gene.

Any technique known in the art may be used to introduce a transgene under the control of the SM α -A regulatory region into animals to produce the founder lines of transgenic animals. Such techniques include, but are not limited to, pronuclear microinjection (Hoppe & Wagner, 1989, U.S. Patent No. 4,873,191); nuclear transfer into enucleated oocytes of nuclei from cultured embryonic, fetal or adult cells induced to

quiescence (Campbell *et al.*, 1996, Nature 380:64-66; Wilmut *et al.*, Nature 385:810-813); retrovirus gene transfer into germ lines (Van der Putten *et al.*, 1985, Proc. Natl. Acad. Sci., USA 82:6148-6152); gene targeting in embryonic stem cells (Thompson *et al.*, 1989, Cell 65:313-321); electroporation of embryos (Lo, 1983, Mol. Cell. Biol. 31:1803-1814); and
5 sperm-mediated gene transfer (Lavitrano *et al.*, 1989, Cell 57:717-723; see, Gordon, 1989, Transgenic Animals, Intl. Rev. Cytol. 115:171-229).

For example, for microinjection of fertilized eggs, a linear DNA fragment (the transgene) containing the regulatory region, the reporter gene and the polyadenylation signals, is excised from the reporter gene construct. The transgene may be gel purified by
10 methods known in the art, for example, by the electroelution method. Following electroelution of gel fragments, any traces of impurities are further removed by passing through Elutip D column (Schleicher & Schuell, Dassel, Germany).

In a preferred embodiment, the purified transgene fragment is microinjected into the male pronuclei of fertilized eggs obtained from B6 CBA females by standard
15 methods (Hogan, 1986, Manipulating the Mouse Embryo, A Laboratory Manual. Cold Spring Harbor Laboratory Press, Cold Spring Harbor, NY). Mice are analyzed transiently at several embryonic stages or by establishing founder lines that allow more detailed analysis of transgene expression throughout development and in adult animals. Transgene presence is analyzed by PCR using genomic DNA purified from placentas (transients) or tail clips
20 (founders) according to the method of Vemet *et al.*, *Methods Enzymol.* 1993;225:434-451 using the following primers:

5' primer: 5'-GCATCGAGCTGGGTAATAAGCGTTGGCAAT-3' (SEQ ID NO:17)

3' primer: 5'-GACACCAGACCAACTGGTAATGGTAGCGAC-3' (SEQ ID NO:18)

25 which are complementary to the Lac Z gene from E. coli (Acc. No. V00296) and produce an 800 bp fragment. Preferably, the PCR reaction is carried out in a volume of 100 μ l containing 1 μ g of genomic DNA, in 1X reaction buffer supplemented with 0.2 mM dNTPs, 2 mM $MgCl_2$, 600 μ M each of primer, and 2.5 units of *Taq* polymerase (Promega, Madison,
30 WI). Each of the 30 PCR cycles consists of denaturation at 94°C for 1 min, annealing at 54°C for 1 min, and extension at 72°C for 1 min. The founder mice may be identified by the presence of the 800 bp PCR product. The founder mice are then mated with C57B1 partners to generate transgenic F₁ lines of mice.

5.3 Screening Assays

Compounds that interfere with the abnormal function and/or growth of SMC can provide therapies targeting defects in SMC-related disorders including, but not limited to, atherosclerosis, coronary artery disease, hypertension, stroke, asthma and multiple
5 gastrointestinal, urogenital and reproductive disorders. Such compounds may be used to interfere with the onset or the progression of SMC-related disorders. Compounds that stimulate or inhibit promoter activity may be used to ameliorate symptoms of SMC-related disorders.

Transgenic animals or SMC containing an SM α -A regulatory region, or
10 fragment thereof, operably linked to a reporter gene, can be used as systems for the screening of agents that modulate SM α -A transcriptional activity. In addition, SM α -A containing transgenic mice provide an experimental model both *in vivo* and *in vitro* to develop new methods of treating SMC-related disorders by targeting drugs to cause arrest in the progression of such disorders.

15 The present invention encompasses screening assays designed to identify compounds that modulate activity of the SM α -A regulatory region. The present invention encompasses *in vitro* and cell-based assays, as well as *in vivo* assays in transgenic animals. As described hereinbelow, compounds to be tested may include, but are not limited to, oligonucleotides, peptides, proteins, small organic or inorganic compounds, antibodies, *etc.*

20 Examples of compounds may include, but are not limited to, peptides, such as, for example, soluble peptides, including, but not limited to, Ig-tailed fusion peptides, and members of random peptide libraries; (see, *e.g.*, Lam, *et al.*, 1991, *Nature* 354:82-84; Houghten, *et al.*, 1991, *Nature* 354:84-86), and combinatorial chemistry-derived molecular library made of D- and/or L- configuration amino acids, phosphopeptides (including, but not
25 limited to members of random or partially degenerate, directed phosphopeptide libraries; see, *e.g.*, Songyang, *et al.*, 1993, *Cell* 72:767-778), antibodies (including, but not limited to, polyclonal, monoclonal, humanized, anti-idiotypic, chimeric or single chain antibodies, and FAb, F(ab')₂ and FAb expression library fragments, and epitope-binding fragments thereof), and small organic or inorganic molecules.

30 Such compounds may further comprise compounds, in particular drugs or members of classes or families of drugs, known to ameliorate the symptoms of an SMC-related disorder.

Such compounds include, but are not limited to, families of antidepressants such as lithium salts, carbamazepine, valproic acid, lysergic acid diethylamide (LSD), *p*-
35 chlorophenylalanine, *p*-propyldopacetamide dithiocarbamate derivatives *e.g.*, FLA 63; anti-anxiety drugs, *e.g.*, diazepam; monoamine oxidase (MAO) inhibitors, *e.g.*, iproniazid,

clorgyline, phenelzine and isocarboxazid; biogenic amine uptake blockers, *e.g.*, tricyclic antidepressants such as desipramine, imipramine and amitriptyline; serotonin reuptake inhibitors *e.g.*, fluoxetine; antipsychotic drugs such as phenothiazine derivatives (*e.g.*, chlorpromazine (thorazine) and trifluopromazine)), butyrophenones (*e.g.*, haloperidol (Haldol)), thioxanthene derivatives (*e.g.*, chlorprothixene), and dibenzodiazepines (*e.g.*, clozapine); benzodiazepines; dopaminergic agonists and antagonists *e.g.*, L-DOPA, cocaine, amphetamine, α -methyl-tyrosine, reserpine, tetrabenazine, benzotropine, pargyline; noradrenergic agonists and antagonists *e.g.*, clonidine, phenoxybenzamine, phentolamine, tropolone; nitrovasodilators (*e.g.*, nitroglycerine, nitroprusside as well as NO synthase enzymes); and growth factors (*e.g.*, VEGF, FGF, angiopoietins and endostatin).

In one preferred embodiment, primary cultures of germ cells containing a mammalian SM α -A regulatory region operatively linked to a heterologous gene are used to develop assay systems to screen for compounds which can inhibit sequence-specific DNA-protein interactions. Such methods comprise contacting a compound to a cell that expresses a gene under the control of an SM α -A regulatory region, or a transcriptionally active fragment thereof, measuring the level of the gene expression or gene product activity and comparing this level to the level of gene expression or gene product activity produced by the cell in the absence of the compound, such that if the level obtained in the presence of the compound differs from that obtained in its absence, a compound capable of modulating the expression of the mammalian SM α -A regulatory region has been identified. Alterations in gene expression levels may be by any number of methods known to those of skill in the art *e.g.*, by assaying for reporter gene activity, assaying cell lysates for mRNA transcripts, *e.g.* by Northern analysis or using other methods known in the art for assaying for gene products expressed by the cell.

In another embodiment, microdissection and transillumination can be used. These techniques offer a rapid assay for monitoring effects of putative drugs on SMC in transgenic animals containing an SM α -A regulatory region-driven reporter gene. In this embodiment, a test agent is delivered to the transgenic animal by any of a variety of methods. Methods of introducing a test agent may include oral, intradermal, intramuscular, intraperitoneal, intravenous, subcutaneous, intranasal and via scarification (scratching through the top layers of skin, *e.g.*, using a bifurcated needle) or any other standard routes of drug delivery. The effect of such test compounds on the SMC can be analyzed by the microdissection and transillumination of the SMC. If the level of reporter gene expression observed or measured in the presence of the compound differs from that obtained in its absence, a compound capable of modulating the expression of the mammalian SM α -A regulatory region has been identified.

In various embodiments of the invention, compounds that may be used in screens for modulators of SMC-related disorders include peptides, small molecules, both naturally occurring and/or synthetic (e.g., libraries of small molecules or peptides), cell-bound or soluble molecules, organic, non-protein molecules and recombinant molecules that
5 may have SM α -A regulatory region binding capacity and, therefore, may be candidates for pharmaceutical agents.

Alternatively, the proteins and compounds include endogenous cellular components which interact with SM α -A regulatory region sequences *in vivo*. Cell lysates or tissue homogenates may be screened for proteins or other compounds which bind to the
10 SM α -A regulatory region, or fragment thereof. Such endogenous components may provide new targets for pharmaceutical and therapeutic interventions.

In one embodiment, libraries can be screened. Many libraries are known in the art that can be used, e.g., peptide libraries, chemically synthesized libraries, recombinant (e.g., phage display libraries), and *in vitro* translation-based libraries. In one embodiment
15 of the present invention, peptide libraries may be used to screen for agonists or antagonists of SM α -A-linked reporter expression. Diversity libraries, such as random or combinatorial peptide or non-peptide libraries can be screened for molecules that specifically modulate SM α -A regulatory region activity. Random peptide libraries consisting of all possible combinations of amino acids attached to a solid phase support may be used to identify
20 peptides that are able to activate or inhibit SM α -A regulatory region activities (Lam, K.S. *et al.*, 1991, Nature 354: 82-84). The screening of peptide libraries may have therapeutic value in the discovery of pharmaceutical agents that stimulate or inhibit the expression of SM α -A by interaction with the promoter region.

Examples of chemically synthesized libraries are described in Fodor *et al.*,
25 1991, Science 251:767-773; Houghten *et al.*, 1991, Nature 354:84-86; Lam *et al.*, 1991, Nature 354:82-84; Medynski, 1994, BioTechnology 12:709-710; Gallop *et al.*, 1994, J. Medicinal Chemistry 37(9):1233-1251; Ohlmeyer *et al.*, 1993, Proc. Natl. Acad. Sci. USA 90:10922-10926; Erb *et al.*, 1994, Proc. Natl. Acad. Sci. USA 91:11422-11426; Houghten *et al.*, 1992, Biotechniques 13:412; Jayawickreme *et al.*, 1994, Proc. Natl. Acad. Sci. USA
30 91:1614-1618; Salmon *et al.*, 1993, Proc. Natl. Acad. Sci. USA 90:11708-11712; PCT Publication No. WO 93/20242; and Brenner and Lerner, 1992, Proc. Natl. Acad. Sci. USA 89:5381-5383.

Examples of phage display libraries are described in Scott and Smith, 1990, Science 249:386-390; Devlin *et al.*, 1990, Science, 249:404-406; Christian, *et al.*, 1992, J.
35 Mol. Biol. 227:711-718; Lenstra, 1992, J. Immunol. Meth. 152:149-157; Kay *et al.*, 1993, Gene 128:59-65; and PCT Publication No. WO 94/18318 dated August 18, 1994.

By way of example of non-peptide libraries, a benzodiazepine library (see e.g., Bunin *et al.*, 1994, Proc. Natl. Acad. Sci. USA 91:4708-4712) can be adapted for use. Peptoid libraries (Simon *et al.*, 1992, Proc. Natl. Acad. Sci. USA 89:9367-9371) also can be used. Another example of a library that can be used, in which the amide functionalities in peptides have been permethylated to generate a chemically transformed combinatorial library, is described by Ostresh *et al.* (1994, Proc. Natl. Acad. Sci. USA 91:11138-11142).

A specific embodiment of such an *in vitro* screening assay is described below. The SM α -A regulatory region-reporter vector is used to generate transgenic mice from which primary cultures of SM α -A regulatory region-reporter vector germ cells are established. About 10,000 cells per well are plated in 96-well plates in total volume of 100 μ l, using medium appropriate for the cell line. Candidate inhibitors of SM α -A gene expression are added to the cells. The effect of the inhibitors of SM α -A gene activation can be determined by measuring the response of the reporter gene driven by the SM α -A regulatory region. This assay could easily be set up in a high-throughput screening mode for evaluation of compound libraries in a 96-well format that reduce (or increase) reporter gene activity, but which are not cytotoxic. After 6 hours of incubation, 100 μ l DMEM medium + 2.5% fetal bovine serum (FBS) to 1.25% final serum concentration is added to the cells, which are incubated for a total of 24 hours (18 hours more). At 24 hours, the plates are washed with PBS, blot dried, and frozen at -80°C . The plates are thawed the next day and analyzed for the presence of reporter activity.

In a preferred example of an *in vivo* screening assay, SMC derived from transgenic mice can be transplanted into mice with a normal or other desired phenotype (Brinster *et al.*, 1994, Proc. Natl. Acad. Sci. USA 91: 11298-302; Ogawa *et al.*, 1997, Int. J. Dev. Biol. 41:111-12). Such mice can then be used to test the effect of compounds and other various factors on SMC-related disorders. In addition to the compounds and agents listed above, such mice can be used to assay factors or conditions that can be difficult to test using other methods, such as dietary effects, internal pH, temperature, *etc.*

Once a compound has been identified that inhibits or enhances SM α -A regulatory region activity, it may then be tested in an animal-based assay to determine if the compound exhibits the ability to act as a drug to ameliorate and/or prevent symptoms of a SMC-related disorder, including, but not limited to, atherosclerosis, coronary artery disease, hypertension, stroke, asthma and multiple gastrointestinal, urogenital and reproductive disorders.

The assays of the present invention may be first optimized on a small scale (*i.e.*, in test tubes), and then scaled up for high-throughput assays. The screening assays of the present invention may be performed *in vitro*, *i.e.*, in test tubes, using purified

components or cell lysates. The screening assays of the present invention may also be carried out in intact cells in culture and in animal models. In accordance with the present invention, test compounds which are shown to modulate the activity of the SM α -A regulatory region *in vitro*, as described herein, will further be assayed *in vivo* in cultured
5 cells and animal models to determine if the test compound has the similar effects *in vivo* and to determine the effects of the test compound on SMC-related disorders.

5.4 Compositions and Methods for Therapeutic Use of SM α -A Nucleotides

SM α -A polynucleotides, or transcriptionally active fragments thereof, can
10 be used to treat and/or prevent diseases, conditions or disorders that can be ameliorated by modifying the level or the expression of SM α -A, or a heterologous gene linked to an SM α -A regulatory region, in an SMC-specific manner. Described herein are methods for such therapeutic treatments.

The SM α -A regulatory region may be used to achieve tissue specific
15 expression in gene therapy protocols. In cases where such cells are tumor cells, the induction of a cytotoxic product by the SM α -A regulatory region may be used in the form of cancer gene therapy specifically targeted to SMC tumor cells which contain trans-acting factors required for SM α -A expression. In this way, the SM α -A regulatory region may serve as a delivery route for a gene therapy approach to cancers involving SMC.
20 Additionally, antisense, antigenic or aptameric oligonucleotides may be delivered to cells using the presently described expression constructs. Ribozymes or single-stranded RNA also can be expressed in a cell to inhibit the expression of a target gene of interest. The target genes for these antisense or ribozyme molecules should be those encoding gene products that are essential for cell maintenance.

25 The SM α -A regulatory region, and transcriptionally active fragments thereof, of the present invention may be used for a wide variety of purposes, *e.g.*, to down regulate SM α -A gene expression, or, alternatively, to achieve SMC-specific stage-specific expression of heterologous genes.

In one embodiment, for example, the endogenous SM α -A regulatory region
30 may be targeted to specifically down-regulate expression of the SM α -A gene. For example, oligonucleotides complementary to the regulatory region may be designed and delivered to the cells. Such oligonucleotides may anneal to the regulatory sequence and prevent transcription activation. Alternatively, the regulatory sequence, or portions thereof, may be delivered to cells in saturating concentrations to compete for transcription factor
35 binding. For general reviews of the methods of gene therapy, see Goldspiel *et al.*, 1993, Clinical Pharmacy 12:488-505; Wu and Wu, 1991, Biotherapy 3:87-95; Tolstoshev, 1993,

Ann. Rev. Pharmacol. Toxicol. 32:573-596; Mulligan, 1993, Science 260:926-932; and Morgan and Anderson, 1993, Ann. Rev. Biochem. 62:191-217; May, 1993, TIBTECH 11:155-215. Methods commonly known in the art of recombinant DNA technology which can be used are described in Ausubel *et al.* (eds.), 1993, Current Protocols in Molecular Biology, John Wiley & Sons, NY; and Kriegler, 1990, Gene Transfer and Expression, A Laboratory Manual, Stockton Press, NY.

In another embodiment, a gene therapy method for ameliorating SMC-related disorders is provided. SM α -A regulatory region sequences are introduced in the SMC and used to drive SMC-specific expression of drugs or toxins. The method comprises introducing an SM α -A regulatory region sequence operatively associated with a drug or toxin gene into the SMC.

In yet another embodiment, the invention provides a gene therapy method for treatment of cancer or other proliferative disorders. The SM α -A regulatory region is used to direct the expression of one or more proteins specifically in SM tumor cells of a patient. Such proteins may be, for example, tumor suppressor genes, thymidine kinase (used in combination with acyclovir), toxins or proteins involved in cell killing, such as proteins involved in the apoptosis pathway

In still another embodiment, the invention provides a preventative gene therapy method for preventing and/or delaying the onset of SMC-related disorders. The SM α -A regulatory region is introduced in the SMC and used to drive SMC-specific expression of therapeutic compounds. The method comprises introducing an SM α -A regulatory region sequence operatively associated with a nucleic acid encoding a therapeutic compound into the SMC to prevent and/or delay the onset of SMC-related disorders. For example, the SM α -A regulatory region sequence operatively associated with a nucleic acid encoding a therapeutic compound (*e.g.*, NO synthase or lipid trafficking agents) can be used to overexpress the therapeutic compound specifically within SMC to inhibit atherosclerotic lesion formation in coronary arteries, and/or promote stabilization of atherosclerotic plaques. Since new NMR and ultrasound methods are capable of being able to non-invasively detect plaques that are at risk, the present invention can be used to overexpress factors that could stabilize a plaque and, thus, prevent heart attacks.

Methods for introducing genes for expression in mammalian cells are well known in the field. Generally, for such gene therapy methods, the nucleic acid is directly administered *in vivo* into a target cell or a transgenic mouse that expresses a SM α -A regulatory region operably linked to a reporter gene. This can be accomplished by any method known in the art, *e.g.*, by constructing it as part of an appropriate nucleic acid expression vector and administering it so that it becomes intracellular, *e.g.*, by infection

using a defective or attenuated retroviral or other viral vector (see U.S. Patent No. 4,980,286), by direct injection of naked DNA, by use of microparticle bombardment (e.g., a gene gun; Biolistic, Dupont), by coating with lipids or cell-surface receptors or transfecting agents, by encapsulation in liposomes, microparticles, or microcapsules, by administering it in linkage to a peptide which is known to enter the nucleus or by administering it in linkage to a ligand subject to receptor-mediated endocytosis (see e.g., Wu and Wu, 1987, J. Biol. Chem. 262:4429-4432), which can be used to target cell types specifically expressing the receptors. In another embodiment, a nucleic acid-ligand complex can be formed in which the ligand comprises a fusogenic viral peptide to disrupt endosomes, allowing the nucleic acid to avoid lysosomal degradation. In yet another embodiment, the nucleic acid can be targeted *in vivo* for cell specific uptake and expression, by targeting a specific receptor (see, e.g., PCT Publications WO 92/06180 dated April 16, 1992; WO 92/22635 dated December 23, 1992; WO92/20316 dated November 26, 1992; WO93/14188 dated July 22, 1993; WO 93/20221 dated October 14, 1993). Alternatively, the nucleic acid can be introduced intracellularly and incorporated within host cell DNA for expression, by homologous recombination (Koller and Smithies, 1989, Proc. Natl. Acad. Sci. USA 86:8932-8935; Zijlstra *et al.*, 1989, Nature 342:435-438).

The oligonucleotide may comprise at least one modified base moiety which is selected from the group including, but not limited to: 5-fluorouracil, 5-bromouracil, 5-chlorouracil, 5-iodouracil, hypoxanthine, xanthine, 4-acetylcytosine, 5-(carboxyhydroxymethyl) uracil, 5-carboxymethylaminomethyl-2-thiouridine, 5-carboxymethylaminomethyluracil, dihydrouracil, beta-D-galactosylqueosine, inosine, N6-isopentenyladenine, 1-methylguanine, 1-methylinosine, 2,2-dimethylguanine, 2-methyladenine, 2-methylguanine, 3-methylcytosine, 5-methylcytosine, N6-adenine, 7-methylguanine, 5-methylaminomethyluracil, 5-methoxyaminomethyl-2-thiouracil, beta-D-mannosylqueosine, 5'-methoxycarboxymethyluracil, 5-methoxyuracil, 2-methylthio-N6-isopentenyladenine, uracil-5-oxyacetic acid (v), wybutoxosine, pseudouracil, queosine, 2-thiocytosine, 5-methyl-2-thiouracil, 2-thiouracil, 4-thiouracil, 5-methyluracil, uracil-5-oxyacetic acid methylester, uracil-5-oxyacetic acid (v), 5-methyl-2-thiouracil, 3-(3-amino-3-N-2-carboxypropyl) uracil, (acp3)w, and 2,6-diaminopurine.

Endogenous target gene expression also can be reduced by inactivating or "knocking out" the SM α -A regulatory region using targeted homologous recombination (e.g., see Smithies *et al.*, 1985, Nature 317:230-234; Thomas and Capecchi, 1987, Cell 51:503-512; Thompson *et al.*, 1989, Cell 5:313-321; each of which is incorporated by reference herein in its entirety). For example, a mutant, non-functional target gene (or a completely unrelated DNA sequence) flanked by DNA homologous to the regulatory region

of the SM α -A gene can be used, with or without a selectable marker and/or a negative selectable marker, to transfect cells that express the target gene *in vivo*. Insertion of the DNA construct, via targeted homologous recombination, results in inactivation of the SM α -A regulatory region. This approach can be adapted for use in humans provided the recombinant DNA constructs are directly administered or targeted to the required site *in vivo* using appropriate vectors.

In an alternative embodiment, endogenous target gene expression can be reduced by targeting deoxyribonucleotide sequences complementary to the SM α -A regulatory region to form triple helical structures that prevent transcription of the target gene in target cells in the body. (See generally, Helene, 1991, *Anticancer Drug Des.*, 6(6):569-584; Helene *et al.*, 1992, *Ann. N.Y. Acad. Sci.*, 660:27-36; and Maher, 1992, *Bioassays* 14(12):807-815).

Nucleic acid molecules to be used in triple helix formation for the inhibition of transcription should be single stranded and composed of deoxynucleotides. The base composition of these oligonucleotides must be designed to promote triple helix formation via Hoogsteen base pairing rules, which generally require sizeable stretches of either purines or pyrimidines to be present on one strand of a duplex. Nucleotide sequences may be pyrimidine-based, which will result in TAT and CGC triplets across the three associated strands of the resulting triple helix. The pyrimidine-rich molecules provide base complementarity to a purine-rich region of a single strand of the duplex in a parallel orientation to that strand. In addition, nucleic acid molecules may be chosen that are purine-rich, for example, contain a stretch of G residues. These molecules will form a triple helix with a DNA duplex that is rich in GC pairs, in which the majority of the purine residues are located on a single strand of the targeted duplex, resulting in GGC triplets across the three strands in the triplex.

In a specific embodiment, single-stranded deoxynucleotides are designed to target the 10 bp intronic CARG element located at +1001 bp relative to the start of transcription of the SM α -A regulatory region of SEQ ID NO:1. Alternatively, the potential sequences that can be targeted for triple helix formation may be increased by creating a so called "switchback" nucleic acid molecule. Switchback molecules are synthesized in an alternating 5'-3', 3'-5' manner, such that they base pair with first one strand of a duplex and then the other, eliminating the necessity for a sizeable stretch of either purines or pyrimidines to be present on one strand of a duplex.

The anti-sense RNA and DNA molecules and triple helix molecules of the invention may be prepared by any method known in the art for the synthesis of nucleic acid molecules. These include techniques for chemically synthesizing oligodeoxyri-

bonucleotides well known in the art such as for example solid phase phosphoramidite chemical synthesis. Alternatively, RNA molecules may be generated by *in vitro* and *in vivo* transcription of DNA sequences encoding the RNA molecule. Such DNA sequences may be incorporated into a wide variety of vectors which contain suitable RNA polymerase promoters such as the T7 or SP6 polymerase promoters. Alternatively, antisense cDNA constructs that synthesize antisense RNA constitutively or inducibly, depending on the promoter used, can be introduced stably into cell lines.

Various modifications to the DNA molecules may be introduced as a means of increasing intracellular stability and half-life. Possible modifications include, but are not limited to, the addition of flanking sequences of ribo- or deoxy- nucleotides to the 5' and/or 3' ends of the molecule or the use of phosphorothioate or 2' O-methyl rather than phosphodiesterase linkages within the oligodeoxyribonucleotide backbone.

The SM α -A regulatory region, and transcriptionally active fragments thereof, of the present invention can be used to express the SM α -A gene in an altered manner as compared to expression in a normal cell. The SM α -A regulatory region, and transcriptionally active fragments thereof, of the present invention also can be used to achieve tissue specific expression of a target gene. Thus, it is possible to design appropriate therapeutic and diagnostic techniques directed to this regulatory sequence in order to modulate the expression of a target gene. In accordance with the present invention, the term "modulate" encompasses the suppression or augmentation of expression of a target gene and also encompasses the tissue specific suppression or expression of a target gene. When a cell proliferative disorder is associated with underexpression or overexpression of an SM α -A gene product, oligonucleotide based compounds such as those described herein, including antisense oligonucleotides, may be used to modulate expression of the SM α -A gene. For example, where the associated disorder is cancer, the induction of a cytotoxic gene product utilizing the SM α -A regulatory region may be used as a cancer therapy. One of skill in the art can determine if a particular therapeutic course of treatment is successful by several methods known to those of skill in the art, including muscle fiber analysis or biopsy.

5.4.1 Inhibitory, Antisense, Ribozyme and Triple Helix Approaches

In another embodiment, symptoms of disorders involving SMC may be ameliorated by decreasing the level of SM α -A regulatory region activity by using well-known antisense, gene "knock-out," ribozyme and/or triple helix methods to decrease the level of SM α -A regulatory region expression. Among the compounds that exhibit the ability to modulate the activity, expression or synthesis of the SM α -A regulatory region,

including the ability to ameliorate the symptoms of a SMC-related disorder are antisense, ribozyme and triple helix molecules. Such molecules may be designed to reduce or inhibit either unimpaired, or if appropriate, mutant SM α -A regulatory region activity. Techniques for the production and use of such molecules are well known to those of skill in the art.

5 Antisense RNA and DNA molecules act to directly block the translation of mRNA by hybridizing to targeted mRNA and preventing protein translation. Antisense approaches involve the design of oligonucleotides that are complementary to a target gene mRNA. The antisense oligonucleotides will bind to the complementary target gene mRNA transcripts and prevent translation. Absolute complementarity, although preferred, is not
10 required.

A sequence "complementary" to a portion of an RNA, as referred to herein, means a sequence having sufficient complementarity to be able to hybridize with the RNA, forming a stable duplex; in the case of double-stranded antisense nucleic acids, a single strand of the duplex DNA may thus be tested, or triplex formation may be assayed. The
15 ability to hybridize will depend on both the degree of complementarity and the length of the antisense nucleic acid. Generally, the longer the hybridizing nucleic acid, the more base mismatches with an RNA it may contain and still form a stable duplex (or triplex, as the case may be). One skilled in the art can ascertain a tolerable degree of mismatch by use of standard procedures to determine the melting point of the hybridized complex.

20 In one embodiment, oligonucleotides complementary to non-coding regions of the gene of interest could be used in an antisense approach to inhibit translation of endogenous mRNA. Antisense nucleic acids should be at least six nucleotides in length, and are preferably oligonucleotides ranging from 6 to about 50 nucleotides in length. In specific aspects, the oligonucleotide is at least 10 nucleotides, at least 17 nucleotides, at
25 least 25 nucleotides or at least 50 nucleotides.

Regardless of the choice of target sequence, it is preferred that *in vitro* studies are first performed to quantitate the ability of the antisense oligonucleotide to inhibit target gene expression. It is preferred that these studies utilize controls that distinguish between antisense gene inhibition and nonspecific biological effects of oligonucleotides. It
30 is also preferred that these studies compare levels of the target RNA or protein with that of an internal control RNA or protein. Additionally, it is envisioned that results obtained using the antisense oligonucleotide are compared with those obtained using a control oligonucleotide. It is preferred that the control oligonucleotide is of approximately the same length as the test oligonucleotide and that the nucleotide sequence of the oligonucleotide
35 differs from the antisense sequence no more than is necessary to prevent specific hybridization to the target sequence.

The oligonucleotides can be DNA or RNA or chimeric mixtures or derivatives or modified versions thereof, single-stranded or double-stranded. The oligonucleotide can be modified at the base moiety, sugar moiety, or phosphate backbone, for example, to improve stability of the molecule, hybridization, etc. The oligonucleotide may include other appended groups such as peptides (*e.g.*, for targeting host cell receptors *in vivo*), or agents facilitating transport across the cell membrane (see, *e.g.*, Letsinger, *et al.*, 1989, *Proc. Natl. Acad. Sci. U.S.A.* 86:6553-6556; Lemaitre, *et al.*, 1987, *Proc. Natl. Acad. Sci. U.S.A.* 84:648-652; PCT Publication No. WO88/09810, published December 15, 1988) or the blood-brain barrier (see, *e.g.*, PCT Publication No. WO89/10134, published April 25, 1988), hybridization-triggered cleavage agents (see, *e.g.*, Krol *et al.*, 1988, *BioTechniques* 6:958-976) or intercalating agents (see, *e.g.*, Zon, 1988, *Pharm. Res.* 5:539-549). To this end, the oligonucleotide may be conjugated to another molecule, *e.g.*, a peptide, hybridization triggered cross-linking agent, transport agent, hybridization-triggered cleavage agent, *etc.*

The antisense oligonucleotide may comprise at least one modified base moiety which is selected from the group including but not limited to 5-fluorouracil, 5-bromouracil, 5-chlorouracil, 5-iodouracil, hypoxanthine, xanthine, 4-acetylcytosine, 5-(carboxyhydroxymethyl) uracil, 5-carboxymethylaminomethyl-2-thiouridine, 5-carboxymethylaminomethyluracil, dihydrouracil, beta-D-galactosylqueosine, inosine, N6-isopentenyladenine, 1-methylguanine, 1-methylinosine, 2,2-dimethylguanine, 2-methyladenine, 2-methylguanine, 3-methylcytosine, 5-methylcytosine, N6-adenine, 7-methylguanine, 5-methylaminomethyluracil, 5-methoxyaminomethyl-2-thiouracil, beta-D-mannosylqueosine, 5'-methoxycarboxymethyluracil, 5-methoxyuracil, 2-methylthio-N6-isopentenyladenine, uracil-5-oxyacetic acid (v), wybutoxosine, pseudouracil, queosine, 2-thiocytosine, 5-methyl-2-thiouracil, 2-thiouracil, 4-thiouracil, 5-methyluracil, uracil-5-oxyacetic acid methylester, uracil-5-oxyacetic acid (v), 5-methyl-2-thiouracil, 3-(3-amino-3-N-2-carboxypropyl) uracil, (acp3)w, and 2,6-diaminopurine.

The antisense oligonucleotide may also comprise at least one modified sugar moiety selected from the group including but not limited to arabinose, 2-fluoroarabinose, xylulose, and hexose.

In yet another embodiment, the antisense oligonucleotide comprises at least one modified phosphate backbone selected from the group consisting of a phosphorothioate, a phosphorodithioate, a phosphoramidothioate, a phosphoramidate, a phosphordiamidate, a methylphosphonate, an alkyl phosphotriester, and a formacetal or analog thereof.

In yet another embodiment, the antisense oligonucleotide is an α -anomeric oligonucleotide. An α -anomeric oligonucleotide forms specific double-stranded hybrids

with complementary RNA in which, contrary to the usual β -units, the strands run parallel to each other (Gautier, *et al.*, 1987, *Nucl. Acids Res.* 15:6625-6641). The oligonucleotide is a 2'-O-methylribonucleotide (Inoue, *et al.*, 1987, *Nucl. Acids Res.* 15:6131-6148), or a chimeric RNA-DNA analogue (Inoue, *et al.*, 1987, *FEBS Lett.* 215:327-330).

5 Oligonucleotides of the invention may be synthesized by standard methods known in the art, *e.g.*, by use of an automated DNA synthesizer (such as are commercially available from Biosearch, Applied Biosystems, etc.). As examples, phosphorothioate oligonucleotides may be synthesized by the method of Stein, *et al.* (1988, *Nucl. Acids Res.* 16:3209), methylphosphonate oligonucleotides can be prepared by use of controlled pore
10 glass polymer supports (Sarin, *et al.*, 1988, *Proc. Natl. Acad. Sci. U.S.A.* 85:7448-7451), *etc.*

While antisense nucleotides complementary to the target gene coding region sequence could be used, those complementary to the transcribed, untranslated region are most preferred.

15 Antisense molecules should be delivered to cells that express the target gene *in vivo*. A number of methods have been developed for delivering antisense DNA or RNA to cells; *e.g.*, antisense molecules can be injected directly into the tissue site, or modified antisense molecules, designed to target the desired cells (*e.g.*, antisense linked to peptides or antibodies that specifically bind receptors or antigens expressed on the target cell surface)
20 can be administered systemically.

A preferred approach to achieve intracellular concentrations of the antisense sufficient to suppress translation of endogenous mRNAs utilizes a recombinant DNA construct in which the antisense oligonucleotide is placed under the control of a strong pol III or pol II promoter. The use of such a construct to transfect target cells in the patient will
25 result in the transcription of sufficient amounts of single stranded RNAs that will form complementary base pairs with the endogenous target gene transcripts and thereby prevent translation of the target gene mRNA. For example, a vector can be introduced *e.g.*, such that it is taken up by a cell and directs the transcription of an antisense RNA. Such a vector can remain episomal or become chromosomally integrated, as long as it can be transcribed
30 to produce the desired antisense RNA. Such vectors can be constructed by recombinant DNA technology methods standard in the art. Vectors can be plasmid, viral, or others known in the art, used for replication and expression in mammalian cells. Expression of the sequence encoding the antisense RNA can be by any promoter known in the art to act in mammalian, preferably human cells. Such promoters can be inducible or constitutive. Such
35 promoters include but are not limited to: the SV40 early promoter region (Bernoist and Chambon, 1981, *Nature* 290:304-310), the promoter contained in the 3' long terminal

repeat of Rous sarcoma virus (Yamamoto, *et al.*, 1980, *Cell* 22:787-797), the herpes thymidine kinase promoter (Wagner, *et al.*, 1981, *Proc. Natl. Acad. Sci. U.S.A.* 78:1441-1445), the regulatory sequences of the metallothionein gene (Brinster, *et al.*, 1982, *Nature* 296:39-42), etc. Any type of plasmid, cosmid, YAC or viral vector can be used to prepare the recombinant DNA construct which can be introduced directly into the tissue site. Alternatively, viral vectors can be used that selectively infect the desired tissue, in which case administration may be accomplished by another route (*e.g.*, systemically).

Ribozyme molecules designed to catalytically cleave target gene mRNA transcripts can also be used to prevent translation of target gene mRNA and, therefore, expression of target gene product. (See, *e.g.*, PCT International Publication WO90/11364, published October 4, 1990; Sarver, *et al.*, 1990, *Science* 247, 1222-1225).

Ribozymes are enzymatic RNA molecules capable of catalyzing the specific cleavage of RNA. (For a review, see Rossi, 1994, *Current Biology* 4:469-471). The mechanism of ribozyme action involves sequence specific hybridization of the ribozyme molecule to complementary target RNA, followed by an endonucleolytic cleavage event. The composition of ribozyme molecules must include one or more sequences complementary to the target gene mRNA, and must include the well known catalytic sequence responsible for mRNA cleavage. For this sequence, see, *e.g.*, U.S. Patent No. 5,093,246, which is incorporated herein by reference in its entirety.

While ribozymes that cleave mRNA at site specific recognition sequences can be used to destroy target gene mRNAs, the use of hammerhead ribozymes is preferred. Hammerhead ribozymes cleave mRNAs at locations dictated by flanking regions that form complementary base pairs with the target mRNA. The sole requirement is that the target mRNA have the following sequence of two bases: 5'-UG-3'. The construction and production of hammerhead ribozymes is well known in the art and is described more fully in Myers, 1995, *Molecular Biology and Biotechnology: A Comprehensive Desk Reference*, VCH Publishers, New York, (see especially FIG. 4, page 833) and in Haseloff and Gerlach, 1988, *Nature*, 334:585-591, which is incorporated herein by reference in its entirety.

Preferably the ribozyme is engineered so that the cleavage recognition site is located near the 5' end of the target gene mRNA, *i.e.*, to increase efficiency and minimize the intracellular accumulation of non-functional mRNA transcripts.

The ribozymes of the present invention also include RNA endoribonucleases (hereinafter "Cech-type ribozymes") such as the one that occurs naturally in *Tetrahymena thermophila* (known as the IVS, or L-19 IVS RNA) and that has been extensively described by Thomas Cech and collaborators (Zaug, *et al.*, 1984, *Science*, 224:574-578; Zaug and Cech, 1986, *Science*, 231:470-475; Zaug, *et al.*, 1986, *Nature*, 324:429-433; published

International patent application No. WO 88/04300 by University Patents Inc.; Been and Cech, 1986, *Cell*, 47:207-216). The Cech-type ribozymes have an eight base pair active site which hybridizes to a target RNA sequence whereafter cleavage of the target RNA takes place. The invention encompasses those Cech-type ribozymes which target eight base-pair
5 active site sequences that are present in the target gene.

As in the antisense approach, the ribozymes can be composed of modified oligonucleotides (*e.g.*, for improved stability, targeting, *etc.*) and should be delivered to cells that express the target gene *in vivo*. A preferred method of delivery involves using a DNA construct "encoding" the ribozyme under the control of a strong constitutive pol III or
10 pol II promoter, so that transfected cells will produce sufficient quantities of the ribozyme to destroy endogenous target gene messages and inhibit translation. Because ribozymes unlike antisense molecules, are catalytic, a lower intracellular concentration is required for efficiency.

Endogenous target gene expression can also be reduced by inactivating or
15 "knocking out" the target gene or its promoter using targeted homologous recombination (*e.g.*, see Smithies, *et al.*, 1985, *Nature* 317:230-234; Thomas and Capecchi, 1987, *Cell* 51:503-512; Thompson, *et al.*, 1989, *Cell* 5:313-321; each of which is incorporated by reference herein in its entirety). For example, a mutant, non-functional target gene (or a completely unrelated DNA sequence) flanked by DNA homologous to the endogenous
20 target gene (either the coding regions or regulatory regions of the target gene) can be used, with or without a selectable marker and/or a negative selectable marker, to transfect cells that express the target gene *in vivo*. Insertion of the DNA construct, via targeted homologous recombination, results in inactivation of the target gene. Such approaches are particularly suited in the agricultural field where modifications to ES (embryonic stem) cells
25 can be used to generate animal offspring with an inactive target gene (*e.g.*, see Thomas and Capecchi, 1987 and Thompson, 1989, *supra*). However this approach can be adapted for use in humans provided the recombinant DNA constructs are directly administered or targeted to the required site *in vivo* using appropriate viral vectors.

Alternatively, endogenous target gene expression can be reduced by targeting
30 deoxyribonucleotide sequences complementary to the regulatory region of the target gene (*i.e.*, the target gene promoter and/or enhancers) to form triple helical structures that prevent transcription of the target gene in target cells in the body. (See generally, Helene, 1991, *Anticancer Drug Des.*, 6(6):569-584; Helene, *et al.*, 1992, *Ann. N.Y. Acad. Sci.*, 660:27-36; and Maher, 1992, *Bioassays* 14(12):807-815).

35 Nucleic acid molecules to be used in triplex helix formation for the inhibition of transcription should be single stranded and composed of deoxynucleotides.

The base composition of these oligonucleotides must be designed to promote triple helix formation via Hoogsteen base pairing rules, which generally require sizeable stretches of either purines or pyrimidines to be present on one strand of a duplex. Nucleotide sequences may be pyrimidine-based, which will result in TAT and CGC⁺ triplets across the three
5 associated strands of the resulting triple helix. The pyrimidine-rich molecules provide base complementarity to a purine-rich region of a single strand of the duplex in a parallel orientation to that strand. In addition, nucleic acid molecules may be chosen that are purine-rich, for example, contain a stretch of G residues. These molecules will form a triple helix with a DNA duplex that is rich in GC pairs, in which the majority of the purine
10 residues are located on a single strand of the targeted duplex, resulting in GGC triplets across the three strands in the triplex.

Alternatively, the potential sequences that can be targeted for triple helix formation may be increased by creating a so called "switchback" nucleic acid molecule. Switchback molecules are synthesized in an alternating 5'-3', 3'-5' manner, such that they
15 base pair with first one strand of a duplex and then the other, eliminating the necessity for a sizeable stretch of either purines or pyrimidines to be present on one strand of a duplex.

In instances wherein the antisense, ribozyme, and/or triple helix molecules described herein are utilized to inhibit mutant gene expression, it is possible that the technique may so efficiently reduce or inhibit the transcription (triple helix) and/or
20 translation (antisense, ribozyme) of mRNA produced by normal target gene alleles that the possibility may arise wherein the concentration of normal target gene product present may be lower than is necessary for a normal phenotype. In such cases, to ensure that substantially normal levels of target gene activity are maintained, therefore, nucleic acid molecules that encode and express target gene polypeptides exhibiting normal target gene
25 activity may, be introduced into cells via gene therapy methods such as those described, below, in Section 5.4.2 that do not contain sequences susceptible to whatever antisense, ribozyme, or triple helix treatments are being utilized. Alternatively, in instances whereby the target gene encodes an extracellular protein, it may be preferable to co-administer normal target gene protein in order to maintain the requisite level of target gene activity.

30 Anti-sense RNA and DNA, ribozyme and triple helix molecules of the invention may be prepared by any method known in the art for the synthesis of DNA and RNA molecules, as discussed above. These include techniques for chemically synthesizing oligodeoxyribonucleotides and oligoribonucleotides well known in the art such as for example solid phase phosphoramidite chemical synthesis. Alternatively, RNA molecules
35 may be generated by *in vitro* and *in vivo* transcription of DNA sequences encoding the antisense RNA molecule. Such DNA sequences may be incorporated into a wide variety of

vectors that incorporate suitable RNA polymerase promoters such as the T7 or SP6 polymerase promoters. Alternatively, antisense cDNA constructs that synthesize antisense RNA constitutively or inducibly, depending on the promoter used, can be introduced stably into cell lines.

5

5.4.2 Gene Replacement Therapy

The nucleic acid sequences of the invention, described above in Section 5.1, can be utilized for transferring recombinant nucleic acid sequences to cells and expressing said sequences in recipient cells. Such techniques can be used, for example, in marking
10 cells or for the treatment of a disorder involving SMC. Such treatment can be in the form of gene replacement therapy. Specifically, one or more copies of a normal gene or a portion of the gene that directs the production of a gene product exhibiting normal gene function, may be inserted into the appropriate cells within a patient, using vectors that include, but are not limited to adenovirus, adeno-associated virus and retrovirus vectors, in addition to other
15 particles that introduce DNA into cells, such as liposomes.

In one embodiment, techniques for delivery involve direct administration, *e.g.*, by stereotactic delivery of such gene sequences to the site of the cells in which the gene sequences are to be expressed.

Additional methods that may be utilized to increase the overall level of gene
20 expression and/or gene product activity include using targeted homologous recombination methods, as discussed above, to modify the expression characteristics of an endogenous gene in a cell or microorganism by inserting a heterologous DNA regulatory element such that the inserted regulatory element is operatively linked with the endogenous gene in question. Targeted homologous recombination can thus be used to activate transcription of
25 an endogenous gene that is "transcriptionally silent", *i.e.*, is not normally expressed or is normally expressed at very low levels, or to enhance the expression of an endogenous gene that is normally expressed.

Further, the overall level of target gene expression and/or gene product activity may be increased by the introduction of appropriate target gene-expressing cells,
30 preferably autologous cells, into a patient at positions and in numbers that are sufficient to ameliorate the symptoms of a SMC-related disorder. Such cells may be either recombinant or non-recombinant.

When the cells to be administered are non-autologous cells, they can be administered using well known techniques that prevent a host immune response against the
35 introduced cells from developing. For example, the cells may be introduced in an encapsulated form which, while allowing for an exchange of components with the

immediate extracellular environment, does not allow the introduced cells to be recognized by the host immune system.

Additionally, compounds, such as those identified via techniques such as those described above that are capable of modulating activity of a SM α -A regulatory region can be administered using standard techniques that are well known to those of skill in the art.

5.5 Pharmaceutical Preparations and Methods of Administration

The compounds that are determined to modify SM α -A regulatory region activity or gene product activity can be administered to a patient at therapeutically effective doses to treat or ameliorate a SMC-related disorder. A therapeutically effective dose refers to that amount of the compound sufficient to result in amelioration of symptoms of such a disorder.

5.5.1 Effective Dose

Toxicity and therapeutic efficacy of such compounds can be determined by standard pharmaceutical procedures in cell cultures or experimental animals, *e.g.*, for determining the LD₅₀ (the dose lethal to 50% of the population) and the ED₅₀ (the dose therapeutically effective in 50% of the population). The dose ratio between toxic and therapeutic effects is the therapeutic index and it can be expressed as the ratio LD₅₀/ED₅₀. Compounds that exhibit large therapeutic indices are preferred. While compounds that exhibit toxic side effects may be used, care should be taken to design a delivery system that targets such compounds to the site of affected tissue in order to minimize potential damage to uninfected cells and, thereby, reduce side effects.

The data obtained from the cell culture assays and animal studies can be used in formulating a range of dosage for use in humans. The dosage of such compounds lies preferably within a range of circulating concentrations that include the ED₅₀ with little or no toxicity. The dosage may vary within this range depending upon the dosage form employed and the route of administration utilized. For any compound used in the method of the invention, the therapeutically effective dose can be estimated initially from cell culture assays. A dose may be formulated in animal models to achieve a circulating plasma concentration range that includes the IC₅₀ (*i.e.*, the concentration of the test compound that achieves a half-maximal inhibition of symptoms) as determined in cell culture. Such information can be used to more accurately determine useful doses in humans. Levels in plasma may be measured, for example, by high performance liquid chromatography.

5.5.2 Formulations and Use

Pharmaceutical compositions for use in accordance with the present invention may be formulated in conventional manner using one or more physiologically acceptable carriers or excipients.

5 Thus, the compounds and their physiologically acceptable salts and solvates may be formulated for administration by inhalation or insufflation (either through the mouth or the nose) or oral, buccal, parenteral or rectal administration.

For oral administration, the pharmaceutical compositions may take the form of, for example, tablets or capsules prepared by conventional means with pharmaceutically acceptable excipients such as binding agents (*e.g.*, pregelatinised maize starch, 10 polyvinylpyrrolidone or hydroxypropyl methylcellulose); fillers (*e.g.*, lactose, microcrystalline cellulose or calcium hydrogen phosphate); lubricants (*e.g.*, magnesium stearate, talc or silica); disintegrants (*e.g.*, potato starch or sodium starch glycolate); or wetting agents (*e.g.*, sodium lauryl sulphate). The tablets may be coated by methods well 15 known in the art. Liquid preparations for oral administration may take the form of, for example, solutions, syrups or suspensions, or they may be presented as a dry product for constitution with water or other suitable vehicle before use. Such liquid preparations may be prepared by conventional means with pharmaceutically acceptable additives such as suspending agents (*e.g.*, sorbitol syrup, cellulose derivatives or hydrogenated edible fats); 20 emulsifying agents (*e.g.*, lecithin or acacia); non-aqueous vehicles (*e.g.*, almond oil, oily esters, ethyl alcohol or fractionated vegetable oils); and preservatives (*e.g.*, methyl or propyl-p-hydroxybenzoates or sorbic acid). The preparations may also contain buffer salts, flavoring, coloring and sweetening agents as appropriate.

Preparations for oral administration may be suitably formulated to give 25 controlled release of the active compound.

For buccal administration the compositions may take the form of tablets or lozenges formulated in conventional manner.

For administration by inhalation, the compounds for use according to the present invention are conveniently delivered in the form of an aerosol spray presentation 30 from pressurized packs or a nebuliser, with the use of a suitable propellant, *e.g.*, dichlorodifluoromethane, trichlorofluoromethane, dichlorotetrafluoroethane, carbon dioxide or other suitable gas. In the case of a pressurized aerosol the dosage unit may be determined by providing a valve to deliver a metered amount. Capsules and cartridges of *e.g.*, gelatin for use in an inhaler or insufflator may be formulated containing a powder mix of the 35 compound and a suitable powder base such as lactose or starch.

The compounds may be formulated for parenteral administration by injection, *e.g.*, by bolus injection or continuous infusion. Formulations for injection may be presented in unit dosage form, *e.g.*, in ampoules or in multi-dose containers, with an added preservative. The compositions may take such forms as suspensions, solutions or emulsions
5 in oily or aqueous vehicles, and may contain formulatory agents such as suspending, stabilizing and/or dispersing agents. Alternatively, the active ingredient may be in powder form for constitution with a suitable vehicle, *e.g.*, sterile pyrogen-free water, before use.

The compounds may also be formulated in rectal compositions such as suppositories or retention enemas, *e.g.*, containing conventional suppository bases such as
10 cocoa butter or other glycerides.

In certain embodiments, it may be desirable to administer the pharmaceutical compositions of the invention locally to the area in need of treatment. This may be achieved by, for example, and not by way of limitation, local infusion during surgery, topical application, *e.g.*, in conjunction with a wound dressing after surgery, by injection, by
15 means of a catheter, by means of a suppository, or by means of an implant, said implant being of a porous, non-porous, or gelatinous material, including membranes, such as sialastic membranes, or fibers. In one embodiment, administration can be by direct injection at the site (or former site) of a malignant tumor or neoplastic or pre-neoplastic tissue.

20 For topical application, the compounds may be combined with a carrier so that an effective dosage is delivered, based on the desired activity.

In addition to the formulations described previously, the compounds also may be formulated as a depot preparation. Such long acting formulations may be administered by implantation (for example subcutaneously or intramuscularly) or by
25 intramuscular injection. Thus, for example, the compounds may be formulated with suitable polymeric or hydrophobic materials (for example as an emulsion in an acceptable oil) or ion exchange resins, or as sparingly soluble derivatives, for example, as a sparingly soluble salt.

The compositions may, if desired, be presented in a pack or dispenser device
30 that may contain one or more unit dosage forms containing the active ingredient. The pack may for example comprise metal or plastic foil, such as a blister pack. The pack or dispenser device may be accompanied by instructions for administration.

6. EXAMPLE: Delineation of a Regulatory Region within the 5' and First Intron of SM α -Actin Sufficient for SM-specific Expression *In Vivo*

6.1 Materials and Methods

6.1.1 Construction of Rat SM α -Actin Lac Z Reporters.

The pUC19-Lac Z plasmid used to generate reporter gene constructs was a generous gift of Dr. Eric Olsen (See also, Acc. No. V00296). Several deletion constructs were generated for analysis in transgenic mice. The p125/Lac Z, p547/Lac Z, and p2800/Lac Z reporters were made by subcloning the corresponding promoter regions from previously described CAT reporter constructs (Shimizu RT, et al., *J. Biol. Chem.* 1995;270:7631-7643) into the Lac Z vector after HindIII/Xba I restriction digestion. Constructs containing the first intron, p547Int/Lac Z and p2600Int/Lac Z, were subcloned from a larger genomic fragment isolated and described previously using PmII/Xho I and Sca I/Xho I digestion, respectively.

CARG mutations in the p2600Int/Lac Z construct were made using the PCR based Excite method (Promega) as per protocol. To avoid potential PCR-induced mutations in the Lac Z reporter, the promoter was subcloned into pBluescript, and after the mutagenesis protocol, returned to the Lac Z vector. The oligonucleotides used to make these mutations contained the following sequences, all of which have been shown to abolish SRF binding in gel shift analyses (mutated sequences are in italics); A mut, 5'-aattgtttaa-3' (SEQ ID NO:11); B mut, 5'-ccctatatca-3' (SEQ ID NO:12); Int mut, 5'-aataattaa-3' (SEQ ID NO:13).

Site directed mutants mPPI gata and mPPI AP1 were generated by the excite method (Promega) as per protocol using the PPI construct as a template (see FIG. 10B for the mutant sequences). The intron fragments #2, 100 and 300 were PCR generated and then ligated (*Kpn* I) to the pProm construct to create PPInt#2, PPInt100 and PPInt300.

Final subcloning steps and all mutations were verified by direct DNA sequencing. Before transgenic injections, all constructs were tested for Lac Z expression by transient transfection into cultured rat aortic SMC cultures to ensure functional activity of all constructs. All clones, including those containing CARG mutations, showed at least some activity in these assays.

6.1.2 Generation and Analysis of Transgenic Mice.

All constructs were prepared for transgenic injection by removal of pUC19 backbone sequences by NotI/EcoRI digestion and subsequent agarose gel purification of the linearized promoter/Lac Z fragment. Transgenic mice were generated using standard methods (Li L, et al., *J Cell Biol.* 1996;132:849-859; Gordon JW, et al., *Science*,

1981;214:1244-1246) either commercially (DNX, Princeton, NJ), or within the transgenic core facility at The University of Virginia, Charlottesville. Mice were analyzed transiently at several embryonic stages or by establishing founder lines that allowed more detailed analysis of transgene expression throughout development and in adult animals. Transgene presence was analyzed by PCR using genomic DNA purified from placentas (transients) or tail clips (founders) according to the method of Vemet (Vemet M, et al., *Methods Enzymol.* 1993;225:434-451). Mice were euthanized by IP injection of pentobarbital (100 mg/kg), and transgene expression and histological analysis were performed as previously described (Li L, et al., *J. Cell Biol.* 1996;132:849-859; Cheng TC, et al.; *Science*, 1993;261:215-218).

6.1.3 Cell Culture, Transient Transfections and Reporter Gene Assays

SMCs from rat thoracic aorta were isolated and cultured as previously described (Blank RS, et al., *J. Biol Chem.* 1992;267:984-989). SMCs were seeded into 6-well plates and transfected 24 h after plating at 70-80% confluency. Transfections were performed using 4 μ g of plasmid DNA and the transfection reagent, DOTAP (Boehringer Mannheim). Growth conditions and preparation of cell lysates for measurement of Lac Z activity were performed as previously described (Shimizu RT, et al., *J. Biol Chem.* 1995;270:7631-7643). The enzyme activity of each sample was normalized to the protein concentration of each cell lysate as measured by the DC protein assay (BioRad). In each experiment, the promoterless Lac Z construct was also transfected to serve as the base-line indicator of Lac Z activity, and the activity of each promoter construct is expressed relative to promoterless activity. All activities represent at least 3 independent experiments, with each construct tested in triplicate per experiment. Relative Lac Z activities are expressed as the mean \pm S.D. computed from the results obtained from each set of transfection experiments. Cotransfection of a viral promoter/reporter construct as a control for transfection efficiency was not performed since it has previously been shown that such constructs exhibit unknown and variable squelching effects on the SM α -actin promoter presumably due to competition for common transcription factors (Shimizu RT, et al., *J. Biol Chem.* 1995;270:7631-7643). Moreover, it has previously been shown that inclusion of such controls are unnecessary in that variations in transfection efficiency between independent experimental samples is routinely very small (<10%) (Shimizu RT, et al., *J. Biol Chem.* 1995;270:7631-7643).

6.1.4 Preparation of Nuclear Extracts, *In Vitro* Synthesis of SRF, and Electromobility Shift Assays

Nuclear extracts were prepared from confluent rat aortic SMCs using the methods of Dignam (Dignam JD, et al., *Nucleic Acids Res.* 1983;11:1475-1489). Culture conditions matched those used for transient transfection assays. Oligonucleotides used in EMSAs were purchased commercially (Operon Technologies) and include the following: CArG A, 5'-ttgtcctctgtttggaagc-3' (SEQ ID NO:14); CArG B, 5'-gaggtccctatatggtgtg-3' (SEQ ID NO:15); Intronic CArG, 5'-ttttacctaattaggaaatg-3' (SEQ ID NO:16). Probes were ³²P end labeled and annealed. All probes were purified on a 6% acrylamide gel, eluted in TE, and precipitated twice in ethanol.

EMSAs were performed with 20 µl of binding reaction that included ≈30 pg of labeled probe, 5 µg of SMC nuclear extract 0.2 to 0.6 µg of poly (dI-dC) in 1x binding buffer (10 mM TrisHCl (pH 7.5), 100 mM KCl, 50 mM NaCl, 1 mM dithiothreitol, 1 mM EDTA, and 5% glycerol). Following a 30 min incubation at room temperature, the samples were subjected to electrophoresis on a 5% polyacrylamide gel, which had been pre-run at 170V for 1 hr. Electrophoresis was performed at 170V in 0.5X TBE (45 mM Tris Borate, 1 mM EDTA). Gels were dried and exposed to film for 24-72 h at -70 °C. For supershift studies, 1 µl of SRF antibody was added after the 30 min incubation period and the reaction was incubated for an additional 15 min and then loaded onto the gel for electrophoresis.

6.1.5 Immunohistochemical Staining of SM α -actin Expression

Embryos were fixed overnight in formalin. Tissues were dehydrated, incubated in 100% xylene, and embedded in paraffin. Thin sections (6 µm) were placed on uncoated slides and dried on a slide warmer. Sections were cleared in 100% xylene and rehydrated through a graded ethanol series to a final incubation in PBS. Endogenous peroxidase activity was quenched by incubating slides in methanol containing 0.3% hydrogen peroxide for 30 min. Slides were subsequently rehydrated in PBS and blocked in a 1:50 solution of normal goat serum made up in PBS. Sections were then incubated with SM α -actin primary antibody for 1 hour and washed with three changes of PBS. Detection of primary antibody was performed using a Vectastain ABC kit (Vector Laboratories) according to the manufacturers instructions with 3,3'-diaminobenzidine (DAB) as the chromagen.

6.2 Results

6.2.1 The SM α -Actin Promoter Region from -2,600 through the First Intron Conferred *In Vivo* Expression of a LacZ Reporter in a Manner Similar to that of the Endogenous Gene

Previous results from transient transfections into rat aortic SMC cultures demonstrated that reporter constructs containing the first 547 bps of the SM α -actin 5' promoter were expressed at high levels only in SMC or other muscle cells that are known to express their endogenous SM α -actin gene (Shimizu RT, et al., *J. Biol Chem.*, 1995;270:7631-7643). Therefore, the present transgenic mouse studies were initiated using a construct that contained this promoter region (FIG. 1; construct A). FIG. 2A shows a p547/Lac Z positive embryo at E 13.5, a time point when SM α -actin is expressed in skeletal, cardiac, and smooth muscle. Results show that this promoter region was sufficient to drive transgene expression in skeletal and cardiac muscle, but not in the vasculature or in any other SMC tissue. In subsequent studies, similar results were obtained with a construct containing 2,800 bps of the 5' promoter region.

The preceding observations indicated that additional regions of the SM α -actin gene were necessary for expression of SM α -actin in SMC *in vivo*. Nakano (Nakano Y, et al., *Gene*, 1991;99:285-289) previously reported that the first intron of the human gene had significant enhancer activity in cultured SMC, an observation consistent with present observations for the rat first intron (see FIG. 4). Constructs were generated from a genomic clone that included the first intron and 547 or 2,600 bps of the 5' promoter (FIG. 1; constructs B and C). Results shown in FIG. 2B demonstrate that p547Int/Lac Z, like the p547 construct, was expressed highly in embryonic cardiac and skeletal muscle. However, in addition, all independent transgenic founder embryos (E13.5) generated with this construct (n=8) expressed high levels of Lac Z in the umbilical arteries and half showed expression in the lower portion of the abdominal aorta. These data demonstrate that the addition of the first intron to 547 bps of the 5' promoter promoted transgene expression in only a small subset of SMC.

A transgenic construct containing sequences from -2,600 through the first intron (p2600Int/Lac Z) was next tested. Results shown in FIG. 2C demonstrated that this construct was expressed at E 13.5 in a pattern that closely followed expression of the endogenous SM α -actin gene with staining in heart and skeletal muscle as well as in multiple SM tissues including the aorta, carotids, multiple small and large arteries, esophagus, stomach, intestines, bladder, ureter, and airway smooth muscle. Examination of histological sections from p2600Int/Lac Z animals at E 10.5 - 16.5 showed that Lac Z staining was highly restricted to the vasculature or the SMC layers of smooth muscle

containing organs as well as to cardiac and skeletal muscle. FIG. 3 shows representative sections at E 16.5 with panel 5D showing immunohistochemical detection of SM α -actin expression for comparison. FIG. 4 shows p2600Int/Lac Z expression in various organs taken from adult mice 4-6 weeks of age. Lac Z staining was seen in nearly all adult SM tissues examined including; the esophagus, stomach, intestines, bladder, trachea, bronchi, and most blood vessels including the coronary, mesenteric, and renal vascular beds.

Histological sections taken from adult tissues are shown in FIG. 5. Note that expression was completely restricted to SMC, and that the p2600Int/LacZ transgene which was highly expressed in skeletal and cardiac muscle during embryonic development, was no longer expressed in the adult skeletal or cardiac muscle cells. The latter observation is consistent with the absence of expression in these tissues in the adult animals and indicates that the -2,600 to +2784 promoter region tested is sufficient to confer appropriate developmental regulation of this gene in multiple cell types. Expression in most structures was found to be very homogeneous with most, if not all, SMC being stained. This is in contrast to previous observations with certain SM MHC and SM 22 promoter constructs suggesting that the p2600Int/Lac Z transgene also contains sufficient information to drive expression in SMC subtypes that have been shown to differentially express SM-22 or SM MHC transgenic constructs within a given SMC tissue.

A total of ten independent founder lines were established with the p2600Int/Lac Z construct. Of these, six showed expression patterns during embryonic development and as adults that virtually mimicked expression of the endogenous SM α -actin gene with two exceptions. Only one founder exhibited expression in uterine SMC, and most founders showed relatively low expression in small cranial arteries during development. In adult animals, however, expression was consistently detected in the basilar artery and other cerebral vessels in each of these six independent founders suggesting developmental signals may be important for expression of the p2600Int/Lac Z transgene in some SMC subtypes. Of the 4 remaining founders; two showed high expression in all vascular SMC but only limited expression in SM-containing organs, one was expressed only in cardiac and skeletal muscle during development, and one was expressed only in a small subset of skeletal muscle in the head and neck. These results indicate that the insertion site had only minor effects on expression of the p2600Int/Lac Z construct in most SMC. This provides strong evidence that the observed expression pattern was the result of sequences contained within the p2600Int/LacZ construct and not insertional locus.

6.2.2 CArG Mutations Attenuated the Activity of p2600Int/Lac Z Activity in Cultured SMCs

Previous studies have shown that CArGs A and B when contained within a construct containing either 125 or 547 bps of the 5' promoter region are absolutely required for expression in SMC cultures (Shimizu RT, et al., *J. Biol Chem.* 1995;270:7631-7643). However, the transgenic results shown above demonstrate that additional sequences, including the CArG containing first intron, are required for expression *in vivo*. Therefore, to measure the transcriptional activity of the first intron, and to test the effects of mutations to CArGs A, B, and the intronic CArG in the context of the promoter region shown to be sufficient for *in vivo* expression, cultured rat SMC were transfected with equimolar amounts of the deletion or site-directed mutant constructs shown in FIG. 6. Results demonstrated that the first intron had significant transcriptional activity in the -547 and -2600 context, and that mutation of either CArG A, B, or the intronic CArG greatly decreased p2600Int/LacZ activity in cultured SMC.

6.2.3 Serum Response Factor Bound the Intronic CArG.

EMSA supershift analysis was performed to test whether the intronic CArG, like CArGs A and B, binds SRF. Results demonstrated that SRF bound to the intronic CArG. In fact, the intronic CArG binds SRF more avidly than CArGs A and B, a result consistent with the fact that these CArGs contain a conserved G or C substitution in their internal A/T rich nucleotide region (Shimizu RT, et al., *J. Biol Chem.* 1995;270:7631-7643) and that such substitutions lower SRF binding affinity (Santoro IM, et al., *Mol. Cell Biol.* 1991;11:6296-6305).

6.2.4 CArG B was Required for Expression of the p2600Int/LacZ Transgene in Skeletal, Cardiac, and Smooth Muscle at Embryonic Day 13.5 while the Intronic CArG was required only in SMC

Results from the transgenic analyses of the SM α -actin promoter demonstrated that the first intron was required for transgene expression in SMC. Taken together with the cell culture studies described above, these results suggest that the intronic CArG, and perhaps CArGs A and B, are required for SMC expression of SM α -actin *in vivo*. CArG mutations were therefore tested to see if they affected expression of the p2600Int/LacZ transgene in developing embryos and in adult mice. At least 5 independent founder lines were generated for each CArG mutant construct. Results shown in FIG. 7 compare the effects of CArG mutations on LacZ expression in mouse embryos at E 13.5 when the endogenous SM α -actin gene and the p2600Int/LacZ transgene (Wt) is expressed

in all three muscle cell types. Mutation of CArG B (B mut) completely abolished LacZ expression in all three muscle cell types indicating that it is absolutely required for SM α -actin expression. Of major significance, mutation of the intronic CArG (Int mut) had no effect on cardiac or skeletal muscle expression, but completely abolished expression in all SM tissues indicating that it is required for expression in SMC but not in cardiac and skeletal muscle. Mutation of CArG A had no visible effect on staining in skeletal or heart muscle, but reduced or eliminated staining in some SM tissues. However, these effects varied somewhat between founders suggesting that the activity of this construct was somewhat sensitive to the site of transgene insertion.

6.2.5 Mutations to CArG B and the Intronic CArG Abolished Expression of the p2600Int/LacZ Transgene in SMC in Adult Mice

To determine whether CArG elements are also required for expression in adult mice, expression of the wild-type p2600Int/Lac Z transgene construct and respective CArG mutants in 4-6 week old mice (FIG. 8) were compared. Results demonstrated that mutation of CArG B or the intronic CArG abolished expression in SMC from all tissues including, trachea, lung, bladder, stomach and intestines and from all blood vessels including the aorta, carotids, and coronary mesenteric, renal, and skeletal muscle arteries. Interestingly, mutation of CArG A eliminated expression in smooth muscle organs and large vessels such as the aorta and carotids, but only partially inhibited expression in smaller arterioles.

6.2.6 The conserved Intronic Region Contains Positive and Negative Regulatory Activities

A series of studies on the 330 bp conserved region within the first intron (from about +770 to about +1100) were performed to identify potentially important regulatory elements. Results shown in FIGS. 9 and 11 demonstrate that this intronic fragment contains both positive and negative regulatory regions. Specifically, the ~100 bp region from +937 to +1,041 that contains the intronic CArG had significant positive activity when spliced downstream of the 5' promoter (compare PPInt100 with pProm) while an adjacent fragment from +863 to +990 (PPInt#2) significantly inhibited pProm activity (FIG. 9). Other important protein binding regions have been identified by DNase footprinting that have significant homology to known *cis* regulatory elements that bind AP1 and the GATA family of transcription factors. Mutation of the highly conserved AP1-like or GATA elements (see FIG. 10) in the context of the PPInt transgene caused a 35% and 65% reduction in promoter activity, respectively (FIG. 11). Still other regulatory elements,

including, but not limited to, MCAT elements and transforming growth factor- β control elements, have been found within the SM α -actin regulatory region (Swartz EA, *et al.*, 1998, *Am. J. Physiol.*, 275 (2 Pt 1):C608-18).

5 6.3 Discussion

Results of the present examples demonstrate that the SM α -actin first intron is required for expression of a Lac Z transgene in SMC and that the promoter regions from -2,600 through the first intron were sufficient to drive transgene expression in a pattern virtually identical to that of the endogenous gene. The present invention also provides clear
10 evidence that SM α -actin expression is CArG dependent, and that SMC-specific regulation requires unique cooperative interactions between the intronic CArG and CArGs A and B.

Results of the present transgenic analyses illustrated a number of interesting features of SM α -actin gene regulation that both confirm and extend previous observations in cultured SMC, but also point out some key differences. Previous studies demonstrated
15 that 2,800 bps of the SM α -actin 5' promoter were sufficient to drive high level expression of SM α -actin only in cultured SMC or other cell types such as L6 myotubes that are known to express their endogenous gene (Blank RS, *et al.*; *J Biol Chem.* 1992;267:984-989; Shimizu RT, *et al.*; *J Biol Chem.* 1995;270:7631-7643). In contrast, this same construct was completely inactive in a variety of cell types such as endothelial cells and AKR2B
20 fibroblasts that do not express SM α -actin (Shimizu RT, *et al.*; *J Biol Chem.* 1995;270:7631-7643). The results presented in the present example demonstrated that neither the p2800/Lac Z nor the p547/Lac Z transgenes were expressed in SMC *in vivo*. These same constructs, however, were expressed highly in embryonic skeletal and heart muscle which are known to express SM α -actin during embryonic development. These
25 results highlight the fact that regulation of expression of the SM α -actin gene is cell-type-specific, and also emphasize the critical importance of studying SMC gene regulation in transgenic animals in order to reproduce complex local environmental cues (i.e. matrix interactions, neuronal and hormonal input, mechanical stresses, etc.) that are necessary for SMC differentiation but which cannot be accurately simulated in SMC cultures.

30 More extensive promoter analyses revealed that both the first intron and sequences from -547 to -2,600 contain promoter elements that are required for transgenic expression in SMC. The fact that the p547/Lac Z and p2800/Lac Z constructs were expressed in embryonic skeletal and cardiac muscle but not in SMC indicates that SM α -actin expression in these tissues is differentially regulated depending upon muscle cell type.
35 It is possible that cardiac and skeletal muscle contain additional trans acting factors that regulate expression in these cell types, or that the sequences that are required for expression

in SMC (i.e. the first intron and from -547 to -2,600) mediate the positive activity of SMC-specific trans acting factors.

Because of the qualitative nature of Lac Z analysis in transgenic animals, the possibility of insertional variegation, and known SMC heterogeneity, considerable caution must be employed when analyzing expression patterns between different transgenic promoters and even between independent founder lines containing the same transgene. Nevertheless, it is interesting that expression of the p2600Int/Lac Z transgene was readily detected in nearly all SM tissues in 6 out of 10 independent founder lines, and expression in those lines was remarkably homogeneous both between and within SMC populations. Recently published transgenic studies using other SMC marker gene promoters resulted in considerably different patterns of SMC expression and provided evidence for significant SMC heterogeneity. For example, a transgene driven by 441 or 1110 bps of the SM-22 5' promoter, although expressed in arterial SMC, was not expressed in any other SM tissues (Kim S, et al., *Mol Cell Biol.* 1997;17:2266-2278; Li L, et al., *Dev Biol.* 1997;187:311-321). In addition, a Lac Z transgene construct under the control of the SM MHC promoter region from -4,299 through +11,600 was expressed in most SMC tissues but showed significant heterogeneity between SMC within the same tissue (Madsen CS, et al., *Circ Res.* 1998;82:908-917). Although the present data may reflect the relative strength of the SM α -actin promoter, it also indicates that SMC from nearly all lineages share at least some common transcriptional regulatory programs. Such SMC-specific high-level expression should make the SM α -actin promoter an attractive vector for use in cardiovascular gene therapy.

The present report is the first to report the activity of the SM α -actin CArG elements *in vivo* and provide several interesting findings concerning CArG-dependent regulation of SM α -actin expression. First, CArG B was absolutely required for *in vivo* expression in all three muscle cell types and may provide transcriptional activity in skeletal and cardiac muscle during embryonic development. Second, CArG A which is a much weaker CArG in that it binds SRF poorly, was required for expression in nearly all SMC tissues except for the smaller resistance vessels (see FIG. 8). This may represent previously undescribed lineage differences between large and small vessels but may also be the result of known differences in hemodynamic and/or other environmental stresses that could possibly regulate SM α -actin expression independent of CArG A. The effects of the CArG A and B mutations on *in vivo* expression of the SM α -actin transgene are somewhat analogous to the effects of mutations to the "near" (-141) and "far" (-264) CArGs described in the SM-22 promoter (Kim S, et al., *Mol Cell Biol.* 1997;17:2266-2278; Li L, et al., *Dev Biol.* 1997;187:311-321). In those studies, mutation of the "strong" near CArG abolished

expression in all cell types while mutation of the much "weaker" far CArG had only limited effects on expression. Finally, the intronic CArG functions as a SMC-specific enhancer-like element affecting expression in SMC but not in embryonic skeletal and cardiac muscle. SRF was shown to bind intronic CArG more avidly than both CArGs A and B (see FIG. 6), and it may be that in SMC, SRF binding to the SM α -actin promoter may be rate limiting making the presence of the strong intronic CArG required for *in vivo* expression. It is also possible that the intronic CArG, or other elements within the first intron that interact with the intronic CArG, recruit SMC-specific factors that are required for SM α -actin expression *in vivo*. Although such a factor was not detected in the gel shift analyses, this was not surprising since only a 20 bp intronic CArG oligo was used as shift probes.

The requirement for multiple CArGs for p2600IntLac Z expression in SMC and the fact that the CArGs have differential effects in SMC versus non-SMC indicates that these elements act interdependently *in vivo* to regulate SM α -actin expression. Recent evidence demonstrated that CArG phasing and spacing is an important determinant in the activity of a reporter construct containing the first 125 bp of the 5' promoter suggesting that CArGs A and B coordinate the formation of a transcription activation complex sufficient to drive expression at least in SMC cultures. The *in vivo* requirement for the intronic CArG suggests that this model is probably more complex. Indeed, it has been shown that the highly conserved intronic region functions only in one orientation which argues that it also has specific structural requirements important for transcription complex assembly or activation. Moreover, the results of the present examples demonstrate that numerous regulatory elements exist within the conserved 325 bp intronic region.

Taken together, the present specification is the first report to provide evidence that CArG, AP-1-like and GATA-like elements play a critical role in transcriptional regulation of the SM α -actin gene *in vivo*, and that they exhibit differential activity in SMC versus non-SMC.

The invention described and claimed herein is not to be limited in scope by the specific embodiments herein disclosed since these embodiments are intended as illustration of several aspects of the invention. Any equivalent embodiments are intended to be within the scope of this invention. Indeed, various modifications of the invention in addition to those shown and described herein will become apparent to those skilled in the art from the foregoing description. Such modifications are also intended to fall within the scope of the appended claims.

All publications, patents and patent applications mentioned in this specification are herein incorporated by reference to the same extent as if each individual

publication, patent or patent application was specifically and individually indicated to be incorporated by reference.

5

10

15

20

25

30

35

WHAT IS CLAIMED IS:

1. An isolated polynucleotide comprising:
 - a) the nucleotide sequence of SEQ ID NO:1, or a transcriptionally active
5 fragment thereof;
 - b) nucleotides 1-2605, 2011-2605, 2011-5342, 3331-3656, 3421-3548 or
3495-3599 of SEQ ID NO:1; or
 - c) nucleotides 3331-3656, 3495-3599 or 3421-3548 of SEQ ID NO:1.
- 10 2. An isolated polynucleotide comprising, nucleotides 3331-3656, 3495-3599 or
3421-3548 of SEQ ID NO:1 spliced downstream of nucleotides 1-2558 of SEQ ID NO:1.
3. An isolated polynucleotide that hybridizes under highly stringent conditions to
the complement of the polynucleotide of Claim 1.
- 15 4. An isolated polynucleotide that hybridizes under moderately stringent
conditions to the complement of the polynucleotide of Claim 1.
5. An isolated polynucleotide that comprises the complement of the
20 polynucleotide of Claim 1.
6. An isolated polynucleotide comprising the polynucleotide of Claims 1 or 2
operably associated with a heterologous coding sequence.
- 25 7. A vector comprising the polynucleotide of Claims 1, 2, 3 or 4.
8. An expression vector comprising the polynucleotide of Claims 1, 2, 3 or 4
operably associated with a heterologous coding sequence.
- 30 9. A genetically engineered host cell comprising the polynucleotide of Claims 1,
2, 3 or 4.
10. A genetically engineered host cell comprising the polynucleotide of Claims 1,
2, 3 or 4 operably associated with a heterologous coding sequence.

35

11. A transgenic, non-human animal comprising the polynucleotide of Claims 1, 2, 3 or 4.

12. The polynucleotide of claim 6, wherein the heterologous coding sequence is a
5 reporter gene.

13. The polynucleotide of claim 12, wherein the reporter gene is *LacZ*.

14. A method for identifying a test compound capable of modulating SMC-specific
10 gene expression comprising:

(a) measuring the level of expression of a reporter gene under the control of
an SM α -A regulatory region or a transcriptionally active fragment
thereof in the presence and absence of said test compound,
such that if the level obtained in the presence of the test compound differs from that
15 obtained in its absence, then a compound which modulates SMC-specific gene expression is
identified.

15. The method of claim 14 wherein the reporter gene is *LacZ*.

20 16. A pharmaceutical composition comprising the test compound identified by the
method in claim 14.

17. A method for delivery of a therapeutic molecule comprising, introducing into
SMC of a subject a vector comprising an SM α -A regulatory region sequence, or
25 transcriptionally active fragment thereof, operatively linked to a heterologous nucleic acid
which encodes said therapeutic molecule.

18. A method for inhibiting or treating SMC-related cancer or other proliferative
disorder comprising introducing into smooth muscle cells of a subject a vector comprising
30 an SM α -A regulatory region sequence, or transcriptionally active fragment thereof,
operatively linked to a heterologous nucleic acid whose gene product is capable of killing
said smooth muscle cell.

19. A method for preventing or delaying a SMC-related disorder comprising
35 introducing into smooth muscle cells of a subject a vector comprising an SM α -A regulatory
region sequence, or transcriptionally active fragment thereof, operatively linked to a

heterologous nucleic acid which encodes a therapeutic molecule which is capable of preventing or delaying said disorder.

20. The method of Claim 19, wherein said disorder is a heart attack.

5

21. An isolated polynucleotide having a sequence identical in sequence to 20 contiguous nucleotides of the sequence as set forth in SEQ ID NO:1.

10

15

20

25

30

35




FIG.1

2/27




FIG. 2C




FIG. 2B




FIG. 2A

3/27




FIG. 3A




FIG. 3B




FIG. 3C

4/27

Esoph. →




FIG. 4C




FIG. 4B



FIG. 4A

5/27




FIG. 4F



FIG. 4E




FIG. 4D

6/27




FIG.5A




FIG.5B




FIG.5C

7/27




FIG.6

Int mut




FIG. 7C

B mut




FIG. 7B

Wt




FIG. 7A

9/27




FIG. 8A




FIG. 8B

10/27




FIG.8C

11/27




FIG.9




FIG. 10A




FIG. 10B

13/27




FIG. 11

14/27

	1				50
human	-----	-----	-----	~AGAGAGCAA	GCAAGAGCAG
rat	-----	-----	~GACATGGT	AGCGTGAGTA	GACAGCTGCT
mouse	ACACCATAAA	ACAAGTGCAT	GAGCCGTGGG	AGCGTGAGTC	GACAGCTGCT
chicken	-----	-----	-----	-----	-----
	51				100
human	GGAAAAC TGC	CTTATAAAAC	CATCAGATAT	CGTGAGAACT	CACTCACTTT
rat	GGCATT CACC	CTGGGCTTTC	CCTGACATGC	CAACAGTTCA	GAGCCACT.T
mouse	GCCATT CACC	CTGGGGTTTC	CCTAACATGT	GCACAGTTCA	GAAGCACTCC
chicken	-----	-----	-----	-----	-----
	101				150
human	CATGAGAACA	GCATGGTATA	AAACGCCCCC	ATCGATCCAG	TCACCTCCCA
rat	ATGGATCCGT	CTAAAATATC	TCCATCATGA	ATTGAATCAG	AACCTTGGCT
mouse	CAGAATCCAT	CCAAAATATC	TCTATCATGA	ATGGAATCAG	AACCTTGGCT
chicken	~GAATTCATG	GGCTTTT TGA	ATTTGTAGTG	GTTTGAGATG	GAGTTTGGAG
	151				200
human	CCATGCCTTT	CTCTGGACAT	GGG...ATTA	TGGAGATTAG	AATTCGAGAC
rat	TGCAGGAGGG	AAGTAGAGAA	AGGTAAAGTC	GTTGACTGTC	CATTGAAGCC
mouse	TGCAGGAGGA	AAGTACAGAA	ATGTAAAGTC	ACTGACTGTC	CATCAAAGCC
chicken	ATGCTAATTT	CTGATCTCTA	GTAGTAGTTC	AAGGGCAATG	TATTGT TACT
	201				250
human	GAGATTTGGG	TGGGGACGTA	GAACCAAACC	ATATCACCTG	GTCTCTCTA.
rat	AAAGAGCTGA	TGATGTCTTT	GAAGAATGG.CAGG	GTCAC TTGAT
mouse	AACGATCTGA	TGCCTTTGAA	GAATGATAGG	GTCAC TTGAG	GTCAC TTGAT
chicken	GTGAAAGGGC	TGCTCATGAG	ACACAGTCTG	CCTAGAGAAC	AGCTGGCTGC
	251				300
humanCTTCCT	GTCAAGGAGG	TTAGTGGGCA	GAGAGGAGGG	CTACAGAGGC
rat	CGCTCTTTCT	GTCCAGTGGG	CTCATAAACA	CGGAGGAGGA	TGAGCAGGCT
mouse	CTCTGTTTCT	GTCCAGTGGG	CTCATAGTCA	TGGAGGAGAG	TGAGCAGGCT
chicken	AGCCAAATAA	ATCCAGTCCT	CTGA.AAATA	GCTCATACAT	TGAGAACCTT

FIG.12A

15/27

	301		350
human	TTCCTTTGAA	CAATCTCCTT	TCTTTTCCAA A.....C TACTTCTTTG
rat	TCATTTCAAC	ATTTCAAAC	TCTTTTACAAT TTTTTTATG
mouse	TCATTTCAAC	ATTTCAAAT	TCTTTTACAA AGTTTTTTTT TTTTTTATG
chicken	TGCTTTAGTT	GCTAAAAATA	TGCTCAGGGC AAAGCTAGCT AGAGGTTATG
	351		400
human	ACAGGCTGCT	GGGTAGACTC	TCTGGTCAAA GGATGGTCCC TACTTATGCT
rat	ACGGGGCAAT	GGGTCTCTC	TGTGGCCAAA AGACGGTCCT TAAGCATGAT
mouse	ACAGGGTGAC	TGGTGATCTC	TGTGGCCAAA GGATGGTCCT TAATCATGCT
chicken	AAATTCAGCA	ACTTTATTAT	GAATGTTTTG AGATAGGAGT TTACAACTTG
	401		450
human	GCTAAATTGC	TCGGTGACAA	ATTAGTAGAC AAAGCTAATG CACCAAAAAA
rat	ATCAGGGGTC	AGCGATAAAC	CAACAACATG CACGTGGACT GTACCTAGGG
mouse	GTAAAGGGTC	AGTAAAAAGC	CAGCAACATG CGGAATG...TTAAGG
chicken	TGTCCATCAG	TGGAATTGAC	ACTAGGATGA AGCTTGCCA CAGTTCCTAG
	451		500
human	ATGAATGTAG	TTATAGTAAT	GCTAACATCC AAATTCCTCT TTGTAAGACA
rat	GTAAACGCAG	TTACAGTGAT	TCTGACTTCT AAGTTCCTCT TAGGGTAACA
mouse	GTAAAGCAG	TTACAGTGAT	TCTGACTTCT AAGTACTCT TTGGGCAACA
chicken	TGCTTTGGAA	ATAAACTGAT	GGAGACAGGA TATTGATTGT CACCCATTAC
	501		550
human	TAGGCCTGTC	AACCTTGCT	CCATACTTC.A ATTCCTATTT
rat	TAGGCTGGTG	AATCCTGATT	ACATACTTCC ATATGTAATA CATACAGACT
mouse	CAGGCTGGTT	AATCCTCACT	ACATACTTC.A GTTCCTGGTT
chicken	AGGCTAGGGG	CACCATAACA	ACCTGTTAGC AGAACGTTTA CACAGCCTTC
	551		600
human	CCA.CTCACC	TCCCTCAAGA	ACTTGATTTA TAA..ACAGT GTGCCTACCA
rat	TCA.TTGATA	CTACACACAG	ACTCCA.GAC TACATACAAT GTGGCTTCCA
mouse	TCA.TTACTA	CAACACAAAG	ACACAATGTA TAAGTACAAT GTAGCTTCCA
chicken	AAAGACCCTA	CCATGAACCC	TATGCAACAG CAGGTACTTC TTTTAGTATC

FIG. 12B

16/27

601 650
human TAAAATCATC ACTCCCTCTA TGTATTTATA GACGACTGAA GGAATATCTT
rat TAAAATGATC ACT.CCTCTG CAGATTCGCA GGTGAC.CCA AGCATCT.TT
mouse TAAAAACATG ACT.CCTCTG CATATTTATG GGTGACTCGA AGCATCT.TT
chicken CCAAGTGCA GACCTTTTAA GTGAATTTGT GGCAAAATTC AGTAGCTGTT

651 700
human TCTTCTTTGC ATGCTACCGT GGTAGAAGGA TTTTAAAAGT CCATGCTAGG
rat TGTTATAGGC TACCTTTTGC AACAG.TGTT GCCTTAAAGT CCCAGCTAGT
mouse TGATCTAGGC TACCTTTTGC AACAG.TGTT GCTTAAAAAT CGCAGCTAGT
chicken TAGCTTGCCG AAAGTATTCT CATTGCTTTG GTCCAAATCT TTAACAAATG

701 750
human CAGAGGCAGC CCTTTCTGCC CCTTTCTGTT CTCAGTTTAT TAGGAAATAG
rat CAGAGACA..GGC CCTTCCTCAT CTCAAGCCCT TAGCTAATGG
mouse CAGAGACA..GGC CCTTCCTTAT C.CAAGTCCT CAGCTAATGG
chicken CAAAGTGTCT CCTTAAAAAC ACTTTCCTA TTACAAATGA CTGCTCTTTC

751 800
human CCTGAAATTC CAGCATGATA GCAA...CT.GGCATC CGTCTGTGAA
rat ACCCAAAGGC TAGCCTGACA GGAAGAGCT.GGCATC TTCTGAGGAA
mouse CCCAAAAGAC TAGCCTGACA G...GGGCT.GGCATC TTCTGAGGAA
chicken AGTTTTCACT CTGCCTCTTG GATGTTCTTG TGAAGGCCAG GGCCTCTCTC

801 850
human TGTGCAAACC ATGCCTGCAT CTGCCCATT A CCGTAGCTC AGTGTCTCTG
rat TGTGCAAACC ATGCCTGCGT CTGCTTCATG A CACTAGCCC AGTG..TCTG
mouse TGTGCAAACC GTGCCTGCGT CTGTCCCATG A CACTAGCCC AGTG..TCTG
chicken TCTTGTTTGA ACGTGTGCTC TTCCTGACAG AGGGTGTCTG TCCCAGGCAC

851 900
human GGCATTTCTG CAGTTGTTCT GAAGGCTTGG CGTGTTTATC TCCCACAGGC
rat GGCATTTGAG CAGTTGTTCT GAGGGCTCAG GATGTTTATC CCCATAAGCA
mouse GGCATTTAAG CAGTTGTTCT GAGGGCTTAG GATGTTTATC CCCATAACGA
chicken GCTTTTCTTG CTGCATTTTA GCAAGTTCTG CAGTGTTTAT CTTACACAGC

FIG.12C

17/27

	901		950
human	GGCTGAACCG CTCCCGTTTC ATGAGCAGAC CAGTGAATG CAGTGAAGA		
rat	GCTGAACTGC CTCCTGTTTC GAGAGCAGAG CAGAGGAATG CAGTGAAGA		
mouse	GCTGAGCTGC CTCCTGTTTC GGGAGCAGAA CAGAGGAATG CAGTGAAGA		
chicken	TGAAAGTCTC CTCCTGTTTC ATGAGCTCTG CGTTGAATG CAGTGAAGG		

	951		1000	CarG B
human	GACCCAGGCC TCCGGC..AC CAGATTAGAG AGTTTTGTGC TGAGGT	CCCT		
rat	GACCCAGGCC TCTGGCCACC CAGATTAGAG AGTTTTGTGC TGAGGT	CCCT		
mouse	GACCCA.GCC TCTGGCCACC CAGATTAGAG AGTTTTGTGC TGAGGT	CCCT		
chicken	GACTGAGGGC .CTGTCGACC CAGATTAGAG GTTTTTGTAA TAAGGT	CCCT		

	1001		1050	CarG A
human	ATATGGTTGT GTTAGACTGA ACGACAGGCT CAAGTCTGTC TTTGCT	CCTT		
rat	ATATGGTTGT GTTAGAGTGA ACGGCCAGCT TCAGCCTGTC TTTGCT	CCTT		
mouse	ATATGGTTGT GTTAGAGTGA ACGGCCAGCT TCAGCCCGTC TTTGCT	CCTT		
chicken	ATATGGTTT GTTAGAGACT TCGGCTCTGT CTCTCTCATC TCTGCT	CCTT		

	1051		1100
human	GTTTGGGAAG CAAGTGGGAG GAGAGCAGGC CAA.GGGCTA TATAACCCTT		
rat	GTTTGGGAAG CGAGTGGGAG GGGATCAGAC CAGGGGGCTA TATAACCCTT		
mouse	GTTTGGGAGG CGAGTGGGAG GGGATCAGAG CAAGGGGCTA TATAACCCTT		
chicken	GTTTGGGAGG CTGGTGGGAG GAGAAGAGCT GAAGGGGCTA TATAACCCTG		

	1101	1118	
human	CAGCTTTCAG CTTCCCTG		
rat	CAGCATTCAG CCTCCCC~	EXON 1	
mouse	CAGCCTTCAG CCTCCC~		
chicken	GTGCTTTTGG ATACAC~		

FIG.12D

18/27

1 50
human -GTAAGTGCG CCAGGCCAAG GATGTGACTT ATAGATTCCA GTGGCTCTTT
rat -----GTAAG GATGTGACTT AGAGTTTTCC CAGGCT.TTT
mouse GTAAGTAGCC CCAGCCCAGG GATATGACTT CGAGTTTTCC CAGGCT.CTT
chicken -----

51 100
human TAATTACCCG GTATAATAAG ACACCATCTG CAGGGATTG GCTGGGTTCA
rat TAATCATCCA GTGAACCAG ACGTTGTCTG TAGTAATCTG AATGACTCAC
mouse TTATCATCCA ATGTAGCCAG ACATTGTCTG TGGGAATCTG AATGACTCAC
chicken -----GTA AGTGGCACTG AACCAATAGT GGGATTATA GTTTTCTGGA

101 150
human TGCACTGATA TTTCTGAATG AAGA.TTGTA CTAATAAAAT GATTGTAGCT
rat ATGTTtGGAA TTTGGGAATA AAGATTTATG CTGTTAAAAT GATTGTAGCT
mouse GTGTTTTGAA TTTTGAATA AAGATTTATA CTGTTAAAAT GATTGTAGCT
chicken TGACTTTAAT TAAGTAATGT CACATGGAAG CTATTCAGGA GGATGTACTG

151 200
human .TTTG.GCTT TAATGATCTA ACGTTAAAGA CAGG..... ..GCTAATAT
rat CCTTA.GCTT GCATGATTC GTATCTAAAC GGG..... .ACTAAAAAT
mouse TTTTA.GCTT GCATGATTTT ACATCCGAAT AGGGCTGATT TACTGGAAAC
chicken CTATGCTGCA GTTTGCTTAG GCATTACTTA CTAGAACTGA ATTGGTAAAA

201 250
human GTAGTTTGGT ATGATGGAAG GGGTAGAGAA GA.ATATGAA AATTTTATTA
rat GAATCGTGGT TTA CTGGCAA AGGAGATGGA GAGGAAATTA AAGTTTGTTC
mouse AACGCTTGAT TTA CTGGAAA AGGAAATGGA TAGAAAATTA AAGTTTGTTC
chicken TACTTTCAAT GTCTACACTG AGTTGTATTI GTTTTAAAGC ACTTTTGAAT

251 300
human ATGCATGTCT TCTGTAAAA. .TGTTTCATCC TAAACAAACA GCCCAGATCT
rat ATGCGTGGCA TCTGTGAAAT CTGTTTACAC TAAACCAACT GCTCGGATCC
mouse ATGTGTGTCA TCTGCAAAAC CTGTTTACAC TAAACCAACT GCTCTGATCC
chicken GGGAAATACG TCTGATGATT TTGCCGATTC CACCAACACT CCAACGGTAA

FIG.13A

19/27

301 350

human TGCAGCACAA TACAGGTATG CAGGTTAGCT GTGTGCAGTA AGTTATAC.A
 rat CGCAGCCTAC TATAGGGGAG AAGTCCAGCC ATCTATGGTA AATTATAC.A
 mouse CGCAGCGTAC TGTAGGGGTG GAGTCTAGCT GTATGTGGTA AATTATAC.G
 chicken TATAAAGACA CAGACTGTTT AATGGCACAG CTGGAATTTA AGAGAACCTG

351 400

human TTTATTTGTA TTTAGGCACT GGAAACTCAG ATTTCTTTCT GGTTCTGATT
 rat TTTGTTTCTA CTTAGGTGTT GGACACTTGT GGATTTGTCT ATGGTTCA.G
 mouse TTTGTTTCTA TTAGG..... CAAAAGTTGG AAACTTTGG ATGTATCATG
 chicken TGTGCCCCTG TGGAGTTAGC TTTGGACAGA ACAGAGTTCC TGAATGGGTG

401 450

human TGTTGTAGGG GTTTTCTTTC ACTGGGCTGT ATTTTGGTG CAGCTTAGGT
 rat ACTTAGTGTG AGGACTTTCC ATCTGACCG.ACTA CAGCCGGGT
 mouse ATGTAGCATG AGGTATTT..AGTG CAGCTGAGGT
 chicken AATTTGCACA CTGTGTAGTG GTTTCTCAGC AGCTTTGCTT CAGTGCTCTC

451 500

human GTCTGGAAGT CGGA.TTTTG GAAGTGAACA GAAGAATAGT TGCCTAGTCT
 rat AACTGGAAGT .GGA.TGTCA GGAGTGAAGT GGCG..CGGT TGCCTGCGCT
 mouse AACTGGAAGT .GAA.TATCA GGAATGAAGT GAGG..TAGT TGCCTGCTCT
 chicken AAAATCAGCT TAAATTGACG TAAGTGTTTT GGAGTGTGAC TGCAAGAAGA

501 550

human TTGATTGTGC CTGAATTTGT GTATTCCCTT CTGGTTTCCC ..TGCTCTAA
 rat CTGGTTTtGG CTGAGTGGAC TGC GTTGCCT CTGGGTTTCC GGGGCTCTAA
 mouse CTGATGTTGG CTGAGTGGAC .GCATTGCTT CTGGGTTTCC GGGGCTCTAA
 chicken GCTGGAAGAT GCAAAATAGC AGTATCTAAT CAGATGCAAT GAGGATGCAT

551 600

human CTGGTAGTGT CTTTTGTTGG AAATGTATAT CTCTTTTTTG TTGGAAATGT
 rat CAG..... .TAG ACATGTATAT CTT.....
 mouse GAGCTGGTGT CCTATGCTGG AAATGTGTAT CTTGT..... GACT
 chicken GTGTATTCAT TGCTGTCTCG ATAGATATGA AAGCTGTGGT CTGCAAAACG

FIG.13B

20/27

601 650
human GTATGTGTGA CCTTACAAGT TTGGATCTAC ATCATTGGTC ATTTGCAGC.
ratGTGC CCTTACGA.T TCAAACCTAT GTCATTGGTC ATTTGCAGC.
mouse GTGTTGGTGC CCTTACAA.G TCAGACCTAT GCCATTGGTC ATTTGCAGC.
chicken CCCAATATTT TATTAAAGAT CACATTATAC ACAGAGTTCC TTGTGAGGCT

651 700
human AGAGCGCAGC AGGTGACCTG CTGAATTTTT CTCTGGAAAG AAAGATTTAG
rat AAAGCATA..G CTCCTCTACT CTCTGCAAAG AAA.....
mouse ATAGCATA..G CTTTTCTACT TTCTGCAAAG AAA.....
chicken GGAGTTGTTT TCCTGATAGC ATGCTGTAGA GGCTGGGGAA GTGATTGGTT

701 750
human GGAGCAGAGC CTGCATCTGA CAGCTGTGTG TCCTCCCGGC CGGATATCTG
ratTG AGGAAGTGTC TCATTCCGGGA AGGATCT...
mouseGG AGGAAGTGTC TCATCCAGGG GAGATCT...
chicken GTCTTTTCAGT GTAAAGCAGG TAGAAGTAAG AGGCTAAATA CTGTATTAAT

751 800
human GTTGCATCTC CCTCAGCTTA AAGCTCCCTT CAGCCTGGTG AGGCAAGTGT
rat GA.TTGC GTT TCTCTGCCTC AAGTGTCCCT CTGGCCCTT A.....G.
mouse GATTTGCATT TCTCTGCCTC ACGTGTCCCT CAGCCGCTTA A.....GT
chicken TGCTGGGGTG AATATGTCCT TTATTCTGCA GTGTGAGTGA CTTTGTCTGC

801 850
human GACTGTGCAG CCAGCCCTGC CAACCCAGGC TGAGTTTCAC TGCAAATCAA
ratGCAGAA TCTCTGTGGG AGCCACC...C... ..CACTCAG
mouse ATCTGTGGAA CCAGCCTTGC CACCCCA...CAT TGTAAGTCA
chicken TGGAGGATGT TACTACTGCA TGCCATGGCA GTCCTTGAGC TGTAAGTCA

851 900
human GGTTTGGCAG CTTCAGCCCA G.ACTGGAGT TTTCATGCTG AGATTTTCCT
rat GACTTGGTAa CTTCTGCAGG GAAACGGAGT TTTCTCGATA AGATTTTCCT
mouse GGCTCGGTAG CTTTCATCAGG G.AATGGAGT TTTCTCGATA AGATTTTCCT
chicken TCCTTGGAAG AGAGTGTCTT GCCTGAATGA TTTAGCTTG ATTTTATAGC.

FIG. 13C

21/27

901 950
human AGCATTTTGT GTTTCATGGA CTAAATATGG TTTGTGTTTC AAGACCAATG
rat CCCcTTTTGT GATTCAT.GA CTAAATATGG TTTGCGTTTT GAGACTCACA
mouse CCTGTTTTGT GATTCAT.GA CTAAATATGG TTTGC.ATTT GAGACTCATA
chickenTTTTTG TGCTCTATTA CTAAATATGG TTTTC.ATTA GAGTCCTCCA

951 1000
human AGCT.GGGAA CTGTACTGTT CTTTC.....C CCTCCCATCA
rat AACTGGGGAA GGTTACTGTC CTTTCCTCCT CCCTCCCCTC CCCTCTTACA
mouse AGCT.GGGAA GGGTACTGTC CTTTCCTCCC TTCCCCCCTC CCC.CCAACA
chicken AGCTAGAAA. ...TGCAGCC TTTTCAGCT CCCTCCTCTC CCCTCCCCCA

1001 1050
human ACTCATTTTT GGCACAAGAC GCACTCTAGT CAGTTGGAGC AAA..CCCCT
rat ATTCATTTTT GGCACAAGAT GAGCTCCACT GTGCTGCACC AAACCTCCCCG
mouse ATTCATTTTT GGCACCAGAT GAGCTCCACT GGGCTGCACC AAACCTCCCCG
chicken AGTGATTTTT GGCATTGCAT TCTCTGCATT G.GTTTGAGC AAACCCCTG

1051 1100
human GACCCGGGTG CAGTTCCAAA AGCAGACACT CGAGC.....GTGTTTTACC INTRONIC
rat GCCTCGGGTG CAGTTCCAAA AGCGGACGCT GGAGCCCAGT GTGTTTTACC CarG
mouse ..CCCCGGTG CAGTTCCAAA AGCAGAGGCT GGAGCCCAGT GTGTTTTACC
chicken ACCTCGAACT CTGTTCCAAA AACAGACGGT TG...GAAA GCATATTTC

1101 1150
human TAATTAGGAA ATGCT..TTG CTCCAAACCG AA.CTGCTCA TTCAGGTTAG
rat TAATTAGGAA ATGCTCCCTG CTTCAAACCTG AAGCTGCTCC TTCAGGTTAG
mouse TAATTAGGAA ATGCTCCCCG CTTCAAACCG .AGCTGCTCA TTCAGGTTAG
chicken TAATTAGGAA ATGGTTTC.. ..TCTAAACC ACTCTGTTCA TTCATGTTAG

1151 1200
human AGAGGAGCTG TAAACCACTG AGCTCGACTC TTTCCGGGGA CACAGTGACT
rat ATAAGAGTTG CAAACCACAG CGGCAGTTTC .CTCTGGAAA CACACCGACG
mouse ATAAGAGTTG CAAACCACAG CGGCTGCGTC .CTCTGGAAA CACACAGACT
chicken ATAACAATTG TACTCCATAG ACTAAATGCT TAAATATAAA GAGCCTGTTT

FIG.13D

22/27

1201 1250
human TCTTCAATGA CAGTGCTCCT TTTGGACATT ATAACATTCT TCCTAGATTT
rat TCT.....TCTC TAGTGACGAC GCTCCTTTCA AAGCTTATTA
mouse TCT.....TCTC CAGTGACAAG CCTCCTTTCA GAGCTTAATA
chicken TCCCAAAGT TTAAGAAAGT GCGAAAAATT GCAACCTACT TTCCTTTTCT

1251 1300
human TC..TTTTTC TTTTCTTTT TTTTGGGCC AAGTAAAAA CATTTTTCTG
rat AG..ACA..T ATTTCTGGA TATTTGGAT GAAGTAGAAA TACGTCTTTA
mouse AG..ACAATT TTTTCTGGA TATTTTGAT GAAATAGAAA TACATCTTTA
chicken GGTAATAATG ACTTAATATC TGGAGTACAT CAACGTGGGA TTTCCCTCTC

1301 1350
human CATTCTTGCT GATGCTGAGG GCCAGTCTCC TTTTCTGAG TATAGTCAAC
rat CTGAATTAG. .TGATTTT ACTTGCAATT TAAAAAAA CTAGGAAGCT
mouse CGGAATTTGA CAGTATTTT TCCTGCATT TTTTAAAAAC CAGGGTAGCT
chicken CATGCCTTCT CCTGGCAGCT AC.TGTATCC ATCGAGAACT GCAGCCTGAG

1351 1400
human CCCTCCTCCC AAGCCATCAC TGCCCAACAA AACAGTTATT AAAAATATCC
rat TATTTCTCTG AATATACTAA GGCACAACCT TAAGTCATCC TGCCCAAC..
mouse TATTTTCTG AATATACTAA GGCACAACCT TAAGCCATCT TGCCCAACAA
chicken AAGCAGTCCA CAGCTGCGTG CTCGTGGCTG TGAAGGGTCT GCAGTGAGAG

1401 1450
human CACATTCATG GTAACCATAC CTTC.....CCATTTTC AGAGACCATC
rat ..AGTTTATG TGGGTTATCC TTCC.....CCGTTTTC AAAGGGCATC
mouse AAAGTTTATG TGGGTTATCC TTCC.....CCATTTTC AGAGGGTATC
chicken GCGTTTGGGG GAGGCTGTCC CTCCTAGGTC CATCTATGGT GGAGGCTGAA

1451 1500
human CTAATTTGAA ATGTTTTATC CTCTTTTCAG CCCTTACTTT TGGTTTGGAA
rat CTAATTCGA GTGGTTTATC TCATTTGCAG CCCGGATGCT ATGTTTGGGA
mouse CTAATTCGAA GTGGCTTATC CCATTTGCAG CCCTGGTGCT AAGTATGGAA
chicken GCGTTGCCTC ATGCTCCCAT GCTCAATCAG CCATGGCTCT CACTGACGCG

FIG. 13E

23/27

1501 1550
human AATGCACTTA GCACATCCAT AGAGTGCCTG CTTATCCCCT GGGGCTGGCT
rat CA....GCA GGCTTCCTGT AGACTCTCTG CTGGTCCTTT GCTGCTGGCT
mouse AACAGGCTTA GTGGACACAC AGACTCTCTG CTGGTCCTTT GGTGGTTTCT
chicken CACTGCCGCT TCGACGTGCA CGCCAGCAGG CCCATGGCAG CAGGTTTTGA

1551 1600
human GCTTCTGACA GATACCCCAG GCTCTTAGGC TTCTTCCCTT TTTTCTCCTT
rat GCCTCTGCCA aTACC.... .TGGC TGCTGTGCCT CTCTGTGCTT
mouse GCCTCTGCCA GTCACC.... .TGGC TTCTGTGCCT CCTTGTGGTT
chicken TCGTTCGCGA GGAGCCAGCT GGGCTGCTGG ATGACAGCCT GTCTCGCTTT

1601 1650
human TATAGTTCTC GCCTCTTTTC TAAAGCTTCT TAATCTGCTC TGAGGGAAGC
rat TGAGACTGTC TTCTGAGTCT TTATCGTCC. .ACTGGAAAG GAAGCTAAAT
mouse TGAAACTTTC TTCTGAGTCC TTATCATCC. .ACTGGAAAG GAAGCTAAGT
chicken GGCTGTTAAC ACATTGCAAT TTGTTGACCT CTGCATGGAA GTCCAGGCTC

1651 1700
human CAAATCACAG GAATGCCAAA ATAATTCAGC ATCTGGAAAG GGAAAAGAAG
rat ATAAATTCAG TGTCTGAAAG AAGAGGCAGA GTAGAGAGAG GAAAGAGCAA
mouse ATAATT.... . CAGAGGCATA GTGGAAAGAG GAAAGAGCAA
chicken CCAGCTAGTC GAGTGATTCC CTAACACACT ATAAATTGTG GGCAAATAGT

1701 1750
human GGTGGGAAAG GAAAGGGCAA GCCATTCATG AGTCCCATGT CCATTCTTGC
rat ACCAACCAAG ATCCCATTTT TCCGTTCTTG TGAGGGGAAC CCAGGCATTG
mouse ACTGCTGAAG AAAGGGATTT TCCATTCTT GCAAGGGGA. ..ACACATTG
chicken TCTCCTCGAG TGCTGGTATT CGGGGCTTGT TTCCGTAATT GACTTTAATA

1751 1800
human AAGTGAATC CACACGTTGA TTATTTTAT TCTAAGCCTG GAGCAGTGTG
rat AA...GATTT CACTCTGATT TTGGAGGCAG GGTTTGAAAG GAAACCAAAA
mouse AA...GATTT CACTCTGATC TTGGGGACAG GG.TTGAAAG AAAACCAAGA
chicken CAAACCCTTT AAAGCATTTT TATTACCCTT GTTATCTTCC TGTTGCCTGA

FIG. 13F

24/27

	1801		1850
human	GAAAGAAAGC	AAAGGTTAGA	AACAAAGAGT TCTGG..... .ATACTGAAA
rat	TCACAAACAG	AATCTCTGGG	TAAAGACAAT AGTCA..... .CATGGTGAG
mouse	TCGCAACAG	AATCTTTGGG	TAGGGATAAT AGTTA..... .CTTGATGAT
chicken	GGAGAAAAAC	AATTTCTGTT	TTAGTGAAGC AGGGAGCCAG CATAAATTAC
	1851		1900
human	ATAATCACAC	AGTGATAGTA	ATAATAATGA TGATGAAATT AGTATTTATT
rat	ATCGACAAGC	AATGCTTGT.	ACAATGCCCT TGATGTCCCC cGAAGCTGTC
mouse	ATCCACGCGC	AATGCTTGT.	CCAACACTCT GGATGTCCTT TGAAGCTCTC
chicken	TTTGTCAATC	TACAAATGCA	GCTTATTAGC TGGTTTGAAA TGATGATGGA
	1901		1950
human	GAGAACTTAG	AGTATCTCTG	CCACTATAAA TTATTTTAAA CACTTTAAAA
rat	GAAAACACAA	GCTTAAATGT	CAATTACTTA AAATGCTATT TTA...AGCC
mouse	AAAAATCCAA	GCTTAAATGT	CAATTCCTTA AATTGTTGTT AAAACAACC
chicken	GCACACACTA	TGGACAGTTT	CAAAACACAT GCTGTCCTTG ATTGCATTTT
	1951		2000
human	AACCCAATCT	CTATAAGAAC	TCCATGAGGT ATGTCCTGAT ATCATTACTG
rat	CAAAAGAGTA	TGTGCTCAGT	TAGTCAAGGT TAGAAGAAAT ACCAGAATC
mouse	CTAAGGGGTA	TATACTCAGT	TAATCAAGCT TAGAAGAAGA TACCAGAGCT
chicken	AAAGTCAGGA	TATCATCTTT	CTACGTGCAC CAGTCTTGTC AGGATGATAG
	2001		2050
human	TTTTATAGTA	AGGAAATTGT	GGTTTAGAGA TGTAAATAA CTGAAATCAC
rat	AGGGGAGGAA	AAAATATtTA	TAAACCTGA TACTTGCCAC TTCCAAAGAA
mouse	CAGGGAAGAA	AAAAAGTCTA	CAAAAGCTGA TGCTTGCCAC TTCAAAGAA
chicken	AGGCAGGGGA	CATCATACTG	AATCTGATGC AAAGAGACCT TTGTTTTTGC
	2051		2100
human	ACAGCTTTTA	ACTGTTGGAG	.CCTGGACTC AAATCCAGGC TTTCTGACTT
rat	CCCCAGTAAA	TATTTTGGAG	AGAATAAGTA AGCTTTGGGG GTGAGGGAGT
mouse	TCTAGTAACA	...TTTGGAC	AGAATAAGTA AGCTTTGGG.TA
chicken	AGCTGTCAGT	CCAGCAGTCT	TCTTTATCTC CCACCTACGC CTCAGTGGTG

FIG.13G

25/27

2101 2150
human CAGAGTCTAA GCTCATAATC ATGTGATCTG AAATCTTCGT TGTCCCTAAAT
rat GGGGGGCAAT TCACTTTTTA TTACGGTCAT ATTAAGTTTC TTTCTGTAAC
mouse GAGGAACAAC TCACATTTTA TTAAGGTCAT A.TCTGTCTC TTTCTGTAAC
chicken GATTTCCGTG GCCGAATTTA .GATAAACAT TCGCTGTCTC AAAGCTGTAA

2151 2200
human GTATCAGTTC AAGGCTCTTG GACAAGTCAC TTCAACTCCT TAAGCCTTGG
rat TTATCAGTCT TAAG..TAAG AATAGCTATT ATCATCCTGT TGGGTTTTCA
mouse TTATCAGTCT TAAA..CAAG AATAGCTCTC AGCAACCTGT TGGGTTTTCA
chicken TGATCTGTCT TTCCATGCAG CAGGACTGGA ATAGTTCCAT GGAGTACTTT

2201 2250
human TTTCTTGTC AGCTGAAGAT AATATTACAT GCCTTGACTT TAAAATATGT
rat GCTTAGCAGT GATTTTGATT AATGAGGAAA TGTTGTAAaT CCTAAATTG
mouse GCTTAACAGT GACTTTAATA AATGAAGAAA TGTTATAACT CGTAAATTT
chicken GAATTATGTC TGGTGCATAC AGCCTTCCTG CCTATCAGTT CCTTTTATAC

2251 2300
human CATCTCAATT GCAGTTTTAT GTTCTTTGCA AAGAGTTATT TTACATGAAG
rat CAAACTCCCC CATCAAAAAT TTtCAATCCA ATATTtTTTA CTAGAGTAGg
mouse CAAAC.ACCA TATTTGAAA TTTCTATCCA AGTTTCCATA TTAGA.....
chicken CGCATTCTCT GTCTTACAGG GTGGTTCTGG TACCTCACTT TGTTGTTTTT

2301 2350
human CACTGCTAAG GAAGTTTTAG GCCTTTGGCA AGATGCAGGT TTGATTTTGT
rat ACTTGgTAGC CTTTCAACTT GTGATCtTCC TGCCTCAGCT TCCCAAGTGg
mouseCCAGC TCCTTAACTT GTGATCCTCC TGCCTCAGCC T.CCAAGTGC
chicken TTTTCAATTA TTCTTTTCTT GCTGTTTCCA TAG-----

2351 2400
human GGGAAATGTTT TGGCAGAACT CCAACTC... ..TGTAATAG CTATTTTATT
rat TAGGATCACA GGTCTACATC ACCACGCCCA GTCTTGATTG ATGTCTAATG
mouse TAGGAT.ATA GGTGTACATC ATCACACCCA GCCTTGATTG ATATTTAATA
chicken -----

FIG. 13H

26/27

	2401				2450
human	TCCCTACTTC	TCAGATGTTT	CCTTAAAAGA	ACTGCCTTTT	TTATATGGAT
rat	CCACACCAGC	ACCcAAGTCT	TCAGAGACAA	AAGATTTTTC	TTTTAAACAT
mouse	CCTCACCGGC	TCACAAGTCT	TTAGAGCCAA	AAGTTTTCTC	TTTTAAACAT
chicken	-----	-----	-----	-----	-----
	2451				2500
human	TTGGAGGTGC	AATCAGTTAA	CCCATTTAGA	AGAAGAAATT	TTCTCAATTT
rat	TTAATATGAG	CAAAcATTIT	AACATTCTCA	TATGCTGCCC	ATTATTCCAA
mouse	TTAATATGAG	TAAACATTIT	AACATTITCA	AATTCTCACA	TGCTGCCCCA.
chicken	-----	-----	-----	-----	-----
	2501				2550
human	GAAATCCTAA	TTGAGATCTC	AATGCCAGGC	AGATAACTCT	GGGTGTCCTT
rat	AATCTACCTT	TTTGGGGGAA	AATATATTTT	ACCAAAAAAA	AAAGTGACTT
mouse
chicken	-----	-----	-----	-----	-----
	2551				2600
human	CTCTTAACGG	AACATTTTGA	CCTAATTGTG	ATTAGAAAAG	TGGAAGAGGT
rat	TGGTTTGATA	TAGATAACAA	ACCTTGTTT	GATATAGATA	ACAAACCTTT
mouseTTCCT	TGAAAATCTA	CCTTTGGTGG	GGGGGGGGGG	GGGACTATAT
chicken	-----	-----	-----	-----	-----
	2601				2650
human	CTTGAACCTG	AAGCCAAGGG	GTGGCTAAAG	AGTACCT...	GATGTCTGGC
rat	CTAGATAGTT	CTTTAACATG	TGgTATCACT	ATTCCCTATA	GACCTGTGTT
mouse	ATATATA...	TGTCCCTATA	GAACTCTGCT
chicken	-----	-----	-----	-----	-----
	2651				2700
human	TGGAGCTCTC	CTCTAATGCC	CTGTGTGCCC	TTGAGCAATC	ACTTCCTGAT
rat	CTCCACTCAG	GACCTCTCAT	CTGTGCTCTG	TGGCCTGTTC	ACACACTAAT
mouse	CTCTACACTG	CATCTCTCAT	CTGTGCTCTA	TGATCTATTG	ACACACTAAT
chicken	-----	-----	-----	-----	-----

FIG. 13I

27/27

	2701				2750
human	TTTCTTATTT	G..TGAAAAT	GAGAGCATTG	GATGAAAATG	TCCTCTAATA
rat	GCTCTGCCCT	GCTTGAGAGT	GgTAAAAGAG	CCTGTGA.GC	TCCTGCTCTT
mouse	GCTCTGACCA	GCTTGAGAGT	GTTATAAGAG	CCTGTGACAC	TCCCGCTCTT
chicken	-----	-----	-----	-----	-----
	2751				2800
human	TGCCTTCAAT	TTCTCAAATT	TGTAAGTTGA	TAGGCTGCTC	CAGCCTTTCT
rat	TGTGCTGAGG	GCTTGTGGTG	CTAACCTGGA	AGTCAGGGTT	TCAGCTCATC
mouse	TGTGCTGAGG	ACTTGTGGTG	TTAACCTGGA	AGTCAGGGTT	TCGGATCATC
chicken	-----	-----	-----	-----	-----
	2801				2850
human	AATTTTATGA	AAGGATCCAA	GTATAAGATC	CAAGTATAAA	ATGG-----
rat	AAAGGCcTTA	CAGTCTGGTG	AAAGCATTTC	AAGATAAAGA	GTGTTAGTTG
mouse	AAAGGCTTTA	CAGCCTAGTG	AAAGCATTTC	AAGATAAAGG	GTGTTAGTTG
chicken	-----	-----	-----	-----	-----
	2851				2900
human	-----	-----	-----	-----	-----
rat	AGATCTGGGG	AGAGCGTCCA	GCTAAAATAA	CACAACAGGG	CCAAGAACCC
mouse	AGAACTGTGG	AGAGCCTCCA	GCTAAAATAA	CACAACAGGA	CCAAGAACCC
chicken	-----	-----	-----	-----	-----
	2901				2950
human	-----	-----	-----	-----	-----
rat	TGGTTGTGGT	TGGGAGTGAC	CGTAGGCTCC	GGCCAAACGC	-----
mouse	TGTCTGTGGG	TGGGAGTGAC	..TAGGCTCT	AGCCAAATGC	TCTGCGCTAC
chicken	-----	-----	-----	-----	-----
	2951				3000
human	-----	-----	-----	-----	-----
rat	-----	-----	-----	-----	-----
mouse	AGTAGCTTCT	CGCTCGCTGT	CTCTGCAGAA	CCCTGAGACG	CTGCTCCAGC
chicken	-----	-----	-----	-----	-----

FIG.13J

SEQUENCE LISTING

<110> OWENS, Gary K.
MACK, Christopher
BLANK, Randall

<120> Compositions and Methods for Modulating
Expression within Smooth Muscle Cells

<130> 9426-016-228

<150> US60/105,330

<151> 1998-10-23

<160> 18

<170> FastSEQ for Windows Version 4.0

<210> 1

<211> 5342

<212> DNA

<213> Rodent

<400> 1

agtactgggt	tcaagggaaa	gatcctgtct	aaaagatcct	atggagacaa	tcgagggaca	60
taaacactat	cacccctgg	ctttcgcaga	cctatatatg	cacaagcatg	tgcccttgta	120
catgtaaag	tgacacacac	gaggcatgca	cacctgacat	cataccaaag	caaagatgaa	180
atgaagtaga	aatgtcaact	ctacatat	tggtgggttaa	tagttgcatg	tgtccagtg	240
ctactgcatc	aggagtgtgt	gattctgggc	attcctgtca	ctaccagagc	taactcacca	300
ataccatgct	aagtcatctc	tggaccagag	cccagtgagg	actaaaatgg	tctccagttc	360
tcaagggctg	aactataaac	catcactaaa	tcacattg	gagacattct	gtgatgtctg	420
tggagcaata	cagctggaga	tgactcttca	gtgtgtgtct	atagcttgga	tttattttct	480
agtttccctg	aactgcaacc	aagtgaccag	atgtacgctc	cccaatcagt	ccatagctcc	540
ttgcatccat	ggctgccaac	cctggcagtt	atctaagcgc	tcagtggagc	tctgtaaaact	600
tgtacgcact	catccagtg	gcctttctct	cccagaagag	actggagctg	gatataaaat	660
ctcaaaactct	ggctggagag	atggctcagt	gtttaagagc	actgactgct	cttccagagt	720
tcaaatccca	gcaaccacat	ggtggtttac	agccatctgt	aatgatattt	gataccctct	780
tctggtgtat	ctgaagacag	ttacactgtg	ctcataataa	ataaataaat	ataagtaaat	840
aaataaataa	atatttttaa	aaaccctcaa	actcacacat	tgtgaccatt	aattacttgc	900
tcaaaaattg	agcaaatcct	ccttgggttac	ttcagattgc	tttttgaaat	tcttaaaata	960
aataaaaaca	ctgaaactta	ctttcttctt	cttgtcataa	tattctgatt	attgacaaat	1020
acaaccagta	taaacaaaaa	agttataaga	ttatcaaagc	tcttttcttg	gtttttaaag	1080
gaattagcat	cttgaaatga	ccaagacaac	actccaacac	tcatgaaaca	aaacatcagc	1140
acagatatcc	atgccaggtt	ctaaagtaaa	aaataaaaaca	agaaacaaaa	acaaaacaaa	1200
aaaaaacaaa	aaaacaaaaga	aaaacatgga	actttacttt	atatgatgcc	tatgataaaa	1260
ccggttgcat	taatcataaa	tgtcccatcc	tgcctcacaa	aatgcagtct	ctgtatttga	1320
gtgatcagac	aatgtatttc	tagttggtga	aaccagatac	agagtagaaa	actcttaagc	1380
aacacaaaaga	agccccatta	ttatttagca	accattacac	tcttctaaga	gtcaacgggtg	1440
taattctcaa	agacagctat	gcgtgcctgg	gtgcaggtgg	acaccattaa	tcaagagcat	1500
gagacatgg	agcgtgagta	gacagctg	ggcattcacc	ctgggctttc	cctgacatgc	1560
caacagttca	gagccactta	tggatccgtc	taaaatatct	ccatcatgaa	ttgaatcaga	1620
accttggtt	gcaggaggga	agtagagaaa	ggtaaagtcg	ttgactgtcc	attgaagcca	1680
aagagctgat	gatgtctttg	aagaatggca	gggtcacttg	atcgctcttt	ctgtccagtg	1740
ggctcataaa	cacggaggag	gatgagcagg	cttcatttca	acatttcaaa	cttcttttac	1800
aatttttttt	atgacggggc	aatgggtcct	ctctgtggcc	aaaagacggg	ccttaagcat	1860
gatatacagg	gtcagcgata	aaccaacaac	atgcacgtgg	actgtacctt	gggggttaacg	1920
cagttacagt	gattctgact	tctaagttcc	tcttagggta	acataggctg	gtgaatcctg	1980
attacatact	tccatagtga	atacatacag	acttcattga	tactacacac	agactccaga	2040
ctacatacaa	tgtggtctcc	ataaaatgat	cactcctctg	cagattcgca	ggtgacccaa	2100
gcattctttg	tttatggcta	ccttttgcaa	cgtgttgcc	ttaaagtccc	agctagtcag	2160
agacaggccc	ttcctcatct	caagccctta	gctaattggac	ccaaaggcta	gcctgacagg	2220

aagagctggc atcttctgag gaatgtgcaa accatgcctg cgtctgcttc atgacactag 2280
cccagtgctt gggcatttga gcagttgttc tgagggctca ggatgtttat ccccataagc 2340
agctgaactg cctcctgttt cgagagcaga gcagaggaat gcagtggaag agacccaggc 2400
ctctggccac ccagattaga gagttttgtg ctgaggtccc tatatggttg tgttagagtg 2460
aacggccagc ttcagcctgt ctttgcctct tgtttgggaa gcgagtggga ggggatcaga 2520
ccagggggct atataaccct tcagcattca gcctccccag acaccaccca cccagagtcg 2580
agaagcccag ccagtcgcca tcagggtaag gatgtgactt agagttttcc caggcttttt 2640
aatcatccag tggaaaccaga cgttgtctgt agtaatctga atgactcaca tgtttggaat 2700
ttgggaataa agatttatgc tgtaaaaatg attgtagctc cttagcttgc atgatttcgt 2760
atctaaacgg gactaaaaat gaatcgtggg ttactggcaa aggagatgga gaggaaatta 2820
aagtttgttc atgcgtggca tctgtgaaat ctgtttacac taaaccaact gctcggatcc 2880
cgcagcctac tataggggag aagtcacagc atctatggta aattatacat ttgtttctac 2940
ttaggtgttg gacacttgtg gatttgtcta tgggtcagac ttagtgtgag gactttccat 3000
ctgaccgact acagccgggt taactggaac tggatgtcag gagtgaactg gcgcgggttg 3060
ctgcgctctg gttttggctg agtggactgc tttgcctctg ggtttccggg gctctaacag 3120
tagacatgta tatcttgtgc ccttacgatt caaacctatg tcattggtca tttgcagcaa 3180
agcatagctc ctctactctc tgcaaaagaaa tgaggaagtg tctcattcgg gaaggatctg 3240
attgcgtttc tctgcctcaa gtgtccctct ggccctctag gcagaatctc tgtgggagcc 3300
acccactca ggacttgga acttctgcag ggaaacggag ttttctcgat aagattttcc 3360
tccccttttg tgattcatga ctaaatatgg tttgcgtttt gagactcaca aactggggaa 3420
ggttactgtc ttttccctct cctccctctc cctcttaca attcattttt ggcacaagat 3480
gagctccact gtgctgcacc aaactccccg gcctcgggtg cagttccaaa agcggacgct 3540
ggagcccagt gtgttttacc taattaggaa atgctccctg cttcaaaactg aagctgctcc 3600
ttcaggttag ataagagttg caaacacag cggcagtttc ctctggaaac acaccgacgt 3660
cttctctagt gacgacgctc ctttcaaagc ttattaagac atattttctg gatattttgg 3720
atgaagtaga aatacgtctt tactgaatta gtgattttta cttgcatttt aaaaaaaac 3780
taggaagctt atttctctga atatactaag gcacaacctt aagtcacct gccaacagt 3840
ttatgtgggt tatcttccc cgttttcaaa gggcatccta attccgagtg gtttatctca 3900
tttgcagccc ggatgctatg ttttggacag caggcttctt gtgactctc tgcgtgctct 4020
ttgtctgttg ctgcctctgc caatcacctg gctgctgtgc ctctctgtgc tttgagactg 4080
tctctgagtt ctttatcgtc cactggaaaag gaagctaaat ataaattcag tgtctgaaag 4140
aagaggcaga gttagagagag gaaagagcaa accaaccaag atcccathtt tccgttcttg 4200
tgaggggaac ccaggcattg aagatttcac tctgattttg gaggcagggt ttgaaaggaa 4260
accaaataca caaacagaat ctctgggtaa agacaatagt cacatggtga gatcgacaag 4320
caatgcttgt acaatgccct tgatgtcccc cgaagctgtc gaaaacacaa gcttaaatgt 4380
caattactta aaatgctatt ttaagcccaa aagagtatgt gctcagttag tcaaggttag 4440
aagaaatacc agaactcagg ggaggaaaaa atatttataa aacctgatac ttgccacttc 4500
caaagaaccc cagtaaatat tttggagaga ataagtaagc tttgggggtg agggagtggg 4560
gggcaattca ctttttatta cggtcattat aagtttcttt ctgtaactta tcagtcttaa 4620
gtaagaatag ctattatcat cctgttgggt tttcagctta gcagtgattt tgattaatga 4680
ggaaatgttg taaatcctaa aattgcaaac tccccatca aaaattttca atccaatatt 4740
ttttactaga gtaggacttg gtagcctttc aacttgtgat cctcctgcct cagcttccca 4800
agtgttagga tcacaggtct acatcaccac gccagctctt gattcatgtc taatgccaca 4860
ccagcaccga agtcttcaga gacaaaagat ttttctttta aacatttaat atgagcaaac 4920
atttttaacat tctcatatgc tgcccattat tccaaaatct accttttttg gggaaaatat 4980
atttttacaa aaaaaaaagt gactttgggt tgatatagat aacaaaacctt ggtttgatat 5040
agataacaaa cctttctaga tagttcttta acatgtggta tcactattcc ctatagacct 5100
gtgttctcca ctcaggacct ctcatctgtg ctctgtggcc tgttcacaca ctaatgctct 5160
gccctgcttg agagtggtaa aagagcctgt gagctcctgc tctttgtgct gagggcttgt 5220
ggtgctaacc tggaaagtcag ggtttcagct catcaaaggc cttacagtct ggtgaaagca 5280
tttcaagata aagagtgtta gttgagatct ggggagagcg tccagctaaa ataacacaac 5340
agggccaaga accctgggtg tggttgggag tgaccgtagg ctccggccaa acgcaacctc

ga

5342<210>

2

<211> 326

<212> DNA

<213> Rodent

<400> 2

ggaaacggag ttttctcgat aagattttcc tccccctttg tgattcatga ctaaataatgg 60
tttgcgtttt gagactcaca aactggggaa ggttactgtc ctttccctct cctccctctc 120
ccctcttaca attcattttt ggcacaagat gagctccact gtgctgcacc aaactccccg 180

gcctcgggtg	cagttccaaa	agcggacgct	ggagcccagt	gtgttttacc	taattaggaa	240
atgctccctg	cttcaaaactg	aagctgctcc	ttcagggttag	ataagagttg	caaaccacag	300
cggcagtttc	ctctggaaac	acaccg				326

<210> 3

<211> 1047

<212> DNA

<213> Homo Sapiens

<400> 3

agagagcaag	caagagcagg	gaaaactgcc	ttataaaacc	atcagatatc	gtgagaactc	60
actcactttc	atgagaacag	catggtataa	aacgccccca	tcgatccagt	cacctccac	120
catgcctttc	tctggacatg	ggattatgga	gattagaatt	cgagacgaga	tttgggtggg	180
gacgtagaac	caaaccatat	cacctgggtc	ctctacttcc	tgtcaaggag	gttagtgggc	240
agagaggagg	gctacagagg	cttcctttga	acaatctcct	ttcttttcca	aactacttct	300
ttgacaggct	gctgggtaga	ctctctggtc	aaaggatggg	ccctacttat	gctgctaaat	360
tgctcgggtg	caaattagta	gacaaagcta	atgcacccaa	aaaatgaatg	tagttatagt	420
aatgctaaca	tccaaattcc	tctttgtaag	acataggcct	gtcaaccttg	tctccatact	480
tcaattccta	tttccactca	cctccctcaa	gaacttgatt	tataaacagt	gtgcctacca	540
taaaatcatc	actccctcta	tgtatttata	gacgactgaa	ggaatatcct	tcttctttgc	600
atgctaccgt	ggtagaagga	ttttaaaagt	ccatgctagg	cagaggcagc	cctttctgcc	660
cctttctgtt	ctcagtttat	taggaaatag	cctgaaattc	cagcatgata	gcaactggca	720
tccgtctgtg	aatgtgcaaa	ccatgcctgc	atctgccccat	taccctagc	tcagtgtctc	780
tgggcatctt	tgcagttggt	ctgaaggctt	ggcgtgttta	tctcccacag	gcggctgaac	840
cgctcccgtt	tcattgagcag	accagtggaa	tgcagtggaa	gagacccagg	cctccggcac	900
cagattagag	agttttgtgc	tgaggtccct	atatggttgt	gttagactga	acgacaggct	960
caagtctgtc	tttgctcctt	gtttgggaag	caagtgggag	gagagcaggc	caagggctat	1020
ataacccttc	agctttcagc	ttccctg				1047

<210> 4

<211> 1056

<212> DNA

<213> Rodent

<400> 4

gacatggtag	cgtgagtaga	cagctgctgg	cattcacccct	gggctttccc	tgacatgcca	60
acagttcaga	gccacttatg	gatccgtcta	aaatatctcc	atcatgaatt	gaatcagaac	120
cttggttgc	aggagggaag	tagagaaagg	taaagtcggt	gactgtccat	tgaagccaaa	180
gagctgatga	tgtctttgaa	gaatggcagg	gtcacttgat	cgctctttct	gtccagtggg	240
ctcataaaca	cggaggagga	tgagcaggct	tcatttcaac	atttcaaact	tcttttacia	300
ttttttttat	gacggggcaa	tgggtcctct	ctgtggccaa	aagacgggtc	ttaagcatga	360
tatcaggggt	cagcgataaa	ccaacaacat	gcacgtggac	tgtacctagg	ggttaacgca	420
gttacagtga	ttctgacttc	taagttcctc	ttagggtaac	ataggctggg	gaatcctgat	480
tacatacttc	catatgtaat	acatacagac	ttcattgata	ctacacacag	actccagact	540
acatacaatg	tggcttccat	aaaatgatca	ctcctctgca	gattcgcagg	tgacccaagc	600
atcttttgtt	ataggctacc	ttttgcaaca	tggttgccct	aaagtcccag	ctagtcaag	660
acaggccctt	cctcatotca	agcccttagc	taatggaccc	aaaggctagc	ctgacaggaa	720
gagctggcat	cttctgagga	atgtgcaaac	catgcctgog	tctgcttcat	gacactagcc	780
cagtgtctgg	gcatttgagc	agttgttctg	agggctcagg	atgtttatcc	ccataagcag	840
ctgaactgcc	tcctgtttcg	agagcagagc	agaggaatgc	agtggaagag	acccaggcct	900
ctggccaccc	agattagaga	gttttgtgct	gaggtcccta	tatggttgtg	ttagagtga	960
cggccagctt	cagcctgtct	ttgtccttg	tttgggaagc	gagtgggagg	ggatcagacc	1020
agggggctat	ataacccttc	agcattcagc	ctcccc			1056

<210> 5

<211> 1074

<212> DNA

<213> Rodent

<400> 5

acaccataaa	acaagtgcac	gagccgtggg	agcgtgagtc	gacagctgct	gccattcacc	60
ctgggggtttc	cctaactatg	gcacagttca	gaagcactcc	cagaatccat	ccaaaatata	120
tctatcatga	atggaatcag	aaccttggct	tgcaggagga	aagtacagaa	atgtaaagtc	180

actgactgtc	catcaaagcc	aacgatctga	tgcctttgaa	gaatgatagg	gtcacttgag	240
gtcacttgat	ctctgtttct	gtccagtggg	ctcatagtca	tggaggagag	tgagcaggct	300
tcattttcaac	atttcaaatt	tcttttacaa	agtttttttt	tttttttatg	acaggggtgac	360
tggtgatctc	tgtgggcaaa	ggatggctct	taatcatgct	gttaaggggtc	agtaaaaagc	420
cagcaacatg	cggaatgtta	aggggttaaag	cagttacagt	gattctgact	tctaagttac	480
tctttgggca	acacaggctg	gttaatcctc	actacatact	tcagttcctg	gtttcattac	540
tacaacacaa	agacacaatg	tataagtaca	atgtagcttc	cataaaaaaca	tgactcctct	600
gcataatttat	gggtgactcg	aagcatcttt	tgatctaggc	taccttttgc	aacagtgttg	660
cttaaaaaatc	gcagctagtc	agagacaggc	ccttccttat	ccaagtcctc	agctaattggc	720
ccaaaagact	agcctgacag	gggctggcat	cttctgagga	atgtgcaaac	cgtgcctgcg	780
tctgtcccat	gacactagcc	cagtgtctgg	gcatttaagc	agttgttctg	agggcttagg	840
atgtttatcc	ccataacgag	ctgagctgcc	tcctgtttcg	ggagcagaac	agaggaatgc	900
agtggaagag	accagcgctc	tggccaccca	gattagagag	ttttgtgctg	aggtccttat	960
atgggttggt	tagagtgaac	ggccagcttc	agcccgctct	tgctccttgt	ttgggaggcg	1020
agtgggaggg	gatcagagca	aggggctata	taacccttca	gccttcagcc	tccc	1074

<210> 6

<211> 1013

<212> DNA

<213> Avian

<400> 6

gaattcatgg	gctttttgaa	tttgtagtgg	tttgagatgg	agttttggaga	tgctaatttc	60
tgatctctag	tagtagttca	agggcaatgt	attgttactg	tgaaagggct	gctcatgaga	120
cacagtctcg	ctagagaaca	gctggctgca	gccaaataaa	tccagtcctc	tgaaaatagc	180
tcatacattg	agaacctttg	ctttagttgc	taaaaatatg	ctcagggcaa	agctagctag	240
aggttatgaa	attcagcaac	tttattatga	atgttttgag	ataggagtgt	acaacttggt	300
tccatcagtg	gaattgacac	taggatgaag	cttgctccaca	gttcctagtg	ctttggaaat	360
aaactgatgg	agacaggata	ttgattgtca	cccattacag	gctaggggca	ccataacaac	420
ctgttagcag	aacgtttaca	cagccttcaa	agaccctacc	atgaacccta	tgcaacagca	480
ggtacttctt	ttagtatccc	caagtgcaga	ccttttaagt	gaatttgtgg	caaaattcag	540
tagctgttta	gcttgccgaa	agtattctca	ttgctttggg	ccaaatcttt	aacaaatgca	600
aagtgtctcc	ttaaaaacac	tttccctatt	acaaatgact	gctctttcag	ttttcactct	660
gcctcttgga	tgttcctgtg	aaggccaggg	cctctctctc	ttgtttgaac	gtgtgctctt	720
cctgacagag	gggtgtctgtc	ccaggcacgc	ttttcttgct	gcatttttagc	aagttctgca	780
gtgtttatct	tacacagctg	aaagtctcct	cctgtttcat	gagctctgcg	ttggaatgca	840
gtggaaggga	ctgagggcct	gtcgaccag	attagaggtt	tttgtaataa	ggccctata	900
tgggtttgtt	agagacttcg	gctctgtctc	tctcatctct	gctccttgtt	tgggaggctg	960
gtgggaggag	aagagctgaa	ggggctatat	aaccctggtg	cttttgata	cac	1013

<210> 7

<211> 2678

<212> DNA

<213> Homo Sapiens

<400> 7

gtaagtgcgc	caggccaagg	atgtgactta	tagattccag	tggctctttt	aattaccogg	60
tataataaga	caccatctgc	agggatttgg	ctgggttcat	gcactgatat	ttctgaatga	120
agattgtact	actaaaatga	ttgtagcttt	tggctttaat	gatctaactg	taaagacagg	180
gctaatatgt	agtttgggtat	gatggaaggg	gtagagaaga	atatgaaaat	tttattaatg	240
catgtcttct	gtaaaatgtt	catcctaaac	aaacagccca	gatcttgtag	cacaatacag	300
gtatgcaggt	tagctgtgtg	cagtaagtta	tacatttatt	tgtatttagg	cactggaaac	360
tcagatttct	ttctggttct	gatttgttgt	aggggttttc	tttactggg	ctgtattttt	420
ggtgcagctt	aggtgtctgg	aagtcggatt	ttggaagtga	acagaagaat	agttgcctag	480
tctttgattg	tgcctgaatt	tgtgtattcc	cttctggttt	ccctgctcta	actggtagtg	540
tctttgttg	gaaatgtata	tctctttttt	gttggaatg	tgtatgtgtg	acottacaag	600
tttggatcta	catcattggg	catttgcagc	agagcgcagc	aggtgacctg	ctgaattttt	660
ctctggaaag	aaagatttag	ggagcagagc	ctgcatctga	cagctgtgtg	tccctccggc	720
cggatatctg	gttgcattct	cctcagctta	aagctccctt	cagcctgggtg	aggcaagtgt	780
gactgtgcag	ccagccctgc	caacccaggc	tgagtttcac	tgcaaatcaa	ggtttggcag	840
cttcagccca	gactggagtt	ttcatgctga	gattttccta	gcattttgtg	tttcatggac	900
taaatatggg	tttgttttca	agaccaatga	gctgggaact	gtactgttct	ttccctccc	960
atcaactcat	ttttggcaca	agacgcactc	tagtcagttg	gagcaaacc	ctagaggagc	1020

tgtaaaccac	tgagctcgac	tctttccggg	gacacagtga	cttcttcaat	gacagtgtc	1080
cttttggaca	ttataacatt	cttcctagat	tttctttttc	ttttctttt	tttttggcc	1140
agtaaaaaac	atttttctgc	attcttctgc	atgctgaggg	ccagtctcct	ttttctgagt	1200
atagtcaacc	cctcctccca	agccatcact	gcccacaaaa	acagttatta	aaaatatccc	1260
acattcatgg	taaccatacc	ttcccatttt	cagagaccat	cctaatttga	aatgttttat	1320
cctcttttca	gccccttactt	ttgggttggga	aaatgcactt	agcacatcca	tagagtgcct	1380
gcttatcccc	tggggctggc	tgcttctgac	agatacccca	ggctcttagg	cttcttcctt	1440
tttttctcct	ttatagttct	cgctcttttt	ctaaagcttc	ttaatctgct	ctgagggaag	1500
ccaaatcaca	ggaaatgccaa	aataattcag	catctggaaa	gggaaaagaa	gggtgggaaa	1560
ggaaagggca	agccattcat	gagtcccatg	tccattcttg	caagtggaa	ccacacgttg	1620
attattttta	ttctaagcct	ggagcagtg	ggaaagaaa	caaaggtag	aaacaaagag	1680
ttctggatac	tgaaaataat	cacacagtga	tagtaataat	aatgatgat	aaattagtat	1740
ttattgagaa	cttagagtat	ctctgccact	ataaattatt	ttaaacactt	taaaaaaccc	1800
aatctctata	agaactccat	gaggtatgtc	ctgatatcat	tactgtttta	tagtaaggaa	1860
attgtggttt	agagatgtta	aataactgaa	atcacacagc	ttttaactgt	tggagcctgg	1920
actcaaatcc	aggctttctg	acttcagagt	ctaagctcat	aatcatgtga	tctgaaatct	1980
tcgttgtcct	aaatgtatca	gttcaaggct	cttggaacag	tactttcaac	tccttaagcc	2040
ttggtttctt	tgtcagctga	agataatatt	acatgccttg	actttaaaat	atgtcatctc	2100
aattgcagtt	ttatgttctt	tgcaaagagt	tattttacat	gaagcactgc	taagggaagt	2160
ttaggccttt	ggcaagatgc	aggtttgatt	ttgtgggaat	gttttggcag	aactccaact	2220
ctgtaatagc	tattttattt	cctacttctt	cagatgtttc	cttaaaagaa	ctgccttttt	2280
tatatggatt	tggaggtgca	atcagttaac	ccatttagaa	gaagaaattt	tctcaatttg	2340
aaatccta	tgagatctca	atgccaggca	gataactctg	ggtgtccttc	tcttaacgga	2400
acatttctgc	ctaattgtga	ttagaaaagt	ggaagcagtc	ttgaactgga	agccaagggg	2460
tggctaaaga	gtacctgatg	tctggctgga	gctctcctct	aatgccctgt	gtgcccttga	2520
gcaatcactt	cctgattttt	ttatttgtga	aaatgagagc	attggatgaa	aatgtcctct	2580
aatatgcctt	caatttctca	aatttgtta	ttgataggct	gctccagcct	ttctaatttt	2640
atgaaaggat	ccaagtataa	gatccaagta	taaaatgg			2678

<210> 8

<211> 2678

<212> DNA

<213> Rodent

<400> 8

gtaaggatgt	gacttagagt	tttcccaggg	tttttaatac	tccagtggaa	ccagacgttg	60
tctgtagtaa	tctgaatgac	tcacatgttt	ggaatttggg	aataaagatt	tatgctgtta	120
aaatgattgt	agctccttag	cttgcatgat	ttcgtatcta	aacgggacta	aaaatgaatc	180
gtggtttact	ggcaaaaggag	atggagagga	aattaaaagt	tgttcatgcg	tggcatctgt	240
gaaatctgtt	tacactaaac	caactgctcg	gatcccgag	cctactatag	gggagaagtc	300
cagccatcta	tggttaaatta	tacatttgtt	tctacttagg	tggtggacac	ttgtggattt	360
gtctatgggt	cagacttagt	gtgaggactt	tccatctgac	cgactacagc	cggtttaaact	420
ggaactggat	gtcaggagt	aactggcgcg	gttgccctgc	ctctggtttt	ggctgagtg	480
actgcgttgc	ctctgggttt	ccggggctct	aacagtagac	atgtatatct	tgtgccctta	540
cgattcaaac	ctatgtcatt	ggtcatttgc	agcaaagcat	agctcctcta	ctctctgcaa	600
agaaatgagg	aagtgtctca	ttcgggaagg	atctgattgc	gtttctctgc	ctcaagtgtc	660
cctctggccc	cttaggcaga	atctctgtgg	gagccacccc	actcaggact	tggttaacttc	720
tgcagggaaa	cggagttttc	togataagat	tttctcctcc	ttttgtgatt	catgactaaa	780
tatggtttgc	gttttgagac	tcacaaactg	gggaagggtta	ctgtcctttc	ctcctccctc	840
ccctcccttc	ttacaattca	tttttggcac	aagatgagct	ccactgtgct	gcaccaaact	900
ccccggcctc	gggtgcagtt	ccaaaagcgg	acgctggagc	ccagtgtggt	ttacctaat	960
aggaaatgct	cctgcttca	aactgaagct	gctccttcag	gttagataag	agttgcaaac	1020
cacagcggca	gtttcctctg	gaaacacacc	gacgtcttct	ctagtacga	cgctcctttc	1080
aaagcttatt	aagacataat	ttctggatat	tttggatgaa	gtagaaatac	gtctttactg	1140
aattagtgat	ttttacttgc	attttaaaaa	aaaactagga	agcttatttc	tctgaatata	1200
ctaaggcaca	accttaagtc	atcctgcccc	acagtttatg	tgggttatcc	ttccccgttt	1260
tcaaagggca	tcctaattcc	gagtggttta	tctcatttgc	agcccgatg	ctatgttttg	1320
gacagcaggc	ttcctgtaga	ctctctgctg	gtccttttgc	gctggctgcc	tctgccaatc	1380
acctggctgc	tgtgctcttc	tgtgctttga	gactgtcttc	tgagtcttta	tctgccaactg	1440
gaaaggaagc	taaaataaaa	ttcagtgctc	gaaagaagag	gcagagtaga	gagaggaaa	1500
agcaaaccaa	ccaagatccc	atttttccgt	tcttgtgagg	ggaacccagg	cattgaagat	1560
ttcactctga	ttttggaggc	aggggttgaa	acgaacacaa	aatcacaaac	agaatctctg	1620
ggtaaagaca	atagtcacat	ggtgagatcg	acaagcaatg	cttgtacaat	gcccttgatg	1680

tccccogaag	ctgtcgaaaa	cacaagctta	aatgtcaatt	acttaaaatg	ctatttttaag	1740
cccaaaaagag	tatgtgctca	gttagtcaag	gttagaagaa	ataccagaac	tcaggggagg	1800
aaaaaatatt	ttaaaacctg	atacttgcca	cttccaaaga	acccagtaaa	atatttttga	1860
gagaataagt	aagctttggg	ggtagaggag	tggggggcaa	ttcacttttt	attacgggtca	1920
tattaagttt	ctttctgtaa	cttatcagtc	ttaagtaaga	atagctatta	tcactcctgtt	1980
gggtttttcac	aaactccccc	atcaaaaatt	ttcaatccaa	tatttttttac	tagagtagga	2040
cttggtagcc	tttcaacttg	tgatcctcct	gcctcagctt	cccaagtggg	aggatcacag	2100
gtctacatca	ccacgcccag	tcttgattca	tgtctaattg	cacaccagca	cccaagtctt	2160
cagagacaaa	agatttttct	tttaaacatt	taatatgagc	aaacattttta	acatttctcat	2220
atgctgcccc	ttattccaaa	atctaccttt	ttgggggaaa	atatattttta	ccaaaaaaaa	2280
aagtgacttt	ggtttgatat	agataacaaa	ccttggtttg	atatagataa	caaacctttc	2340
tagatagttc	tttaacatgt	ggtatcacta	ttccctatag	acctgtgttc	tcactcagg	2400
acctctcatc	tgtgctctgt	ggcctgttca	cacactaattg	ctctgccctg	cttgagagtg	2460
gtaaaagagc	ctgtgagctc	ctgctctttg	tgctgagggc	ttgtgggtgct	aacctggaa	2520
tcaggggttc	agctcatcaa	aggccttaca	gtctgggtgaa	agcatttcaa	gataaagagt	2580
gttagttgag	atctggggag	agcgtccagc	taaaataaca	caacaggggc	aagaaccctg	2640
gttggtggtg	ggagtgaaccg	taggctcccg	ccaaacgc			2678

<210> 9

<211> 2719

<212> DNA

<213> Rodent

<400> 9

gtaagtagcc	ccagcccagg	gatatgactt	cgagttttcc	caggctcttt	tatcatccaa	60
tgtagccaga	cattgtctgt	gggaatctga	atgactcacg	tgttttgaat	ttttgaataa	120
agattttatac	tggtaaaatg	attgtagctt	tttagcttgc	atgattttac	atccgaatag	180
ggctgatttta	ctggaaacaa	cgcttgattt	actggaaaag	gaaatggata	gaaaattaaa	240
gtttgttcat	gtgtgtcatc	tgcaaaacct	gtttacacta	aaccaactgc	tctgatcccc	300
cagcgtactg	taggggtgga	gtctagctgt	atgtggtaaa	ttatacgttt	gtttctatta	360
ggcaaaaagtt	ggaaaactttt	ggatgtatca	tgatgtagca	tgaggatattt	agtgcagctg	420
aggtaactgg	aagtgaatat	caggaatgaa	ctgaggtagt	tgctgtctct	ctgatgttgg	480
ctgagtgagc	gcattgcttc	tgggtttccg	gggctctaag	agctgggtgc	ctatgctgga	540
aatgtgtatc	ttgtgactgt	gttgggtgcc	ttacaagtca	gacctatgcc	attgggtcatt	600
tgcagcatag	catagctttt	ctactttctg	caaagaaaag	aggaagtgtc	tcattccagg	660
gagatctgat	ttgcatttct	ctgcctcacg	tgccccctag	cgccttaagt	atctgtggaa	720
ccagccttgc	cacccccacat	tgtaactcag	ggctcggtag	cttcatcagg	gaatggagtt	780
ttctcgataa	gatttttctc	ctgttttctg	attcatgact	aaatatgggt	tgcatattgag	840
actcataagc	tgggaagggt	actgtccttt	cctcccttcc	ccccctcccc	caacaattca	900
tttttggcac	cagatgagct	ccactgggct	gcaccaaact	ccccgccccg	gtgcagttcc	960
aaaagcagag	ctctggagccc	agtgtgtttt	acctaatagg	gaaatgctcc	cgccttcaaa	1020
ccgagctgct	gattcagggt	agataagagt	tgcaaaaccac	agcggctgcg	tcctctggaa	1080
acacacagac	ttcttctcca	gtgacaagcc	tcctttcaga	gcttaataag	acaatttttt	1140
cctggatatt	tttgatgaaa	tagaaataca	tcctttacgga	atttgacagt	attttttcct	1200
gcattttttt	aaaaaccagg	gtagcttatt	tttctgaata	tactaaggca	caaccttaag	1260
ccatcttgcc	caacaaaaag	tttatgtggg	ttatccttcc	ccattttcag	agggtatcct	1320
aattccaagt	ggcttatccc	atttgagccc	ctgggtgctaa	gtatggaaaa	caggcttagt	1380
ggacacacag	actctctgct	ggctccttgg	tgggtttctgc	ctctgccagt	cacctggcct	1440
ctgtgcctcc	ttgtgggtttg	aaactttctt	ctgagtcctt	atcatccact	ggaaagggaag	1500
ctaagtataa	ttcagaggca	tagtggaaaag	aggaaagagc	aaactgctga	agaaagggat	1560
tttcccatc	ttgcaagggg	aacacattga	agatttcact	ctgatcttgg	ggacaggggt	1620
gaaagaaaaac	caagatcgca	aacagaaact	ttgggtaggg	ataatagtta	cttgatgata	1680
tcacgcgcga	atgcttgtcc	aacactctgg	atgtcctttg	aagctctcaa	aaatccaagc	1740
ttaaatgtca	attccttaaa	ttgttggtta	aaacaaccct	aaggggtata	tactcagtta	1800
atcaagctta	gaagaagata	ccagagctca	gggaagaaaa	aaagtctaca	aaagctgatg	1860
cttgccactt	caaaaagaatc	tagtaacatt	tggacagaat	aagtaagctt	tgggttagagg	1920
aacaactcac	atttttattaa	ggcatatct	gtctctttct	gtaacttatc	agtcttaaac	1980
aagaatagct	ctcagcaacc	tgttgggttt	tcagcttaac	agtgacttta	ataaatgaag	2040
aaatgtttata	actcgtaaaa	tttcaaaccac	catatttggg	aatttctatc	caagtttcca	2100
tattagacca	gctccttaac	ttgtgatcct	cctgcctcag	cctccaagtg	ctaggatata	2160
ggtgtacatc	atcacaccca	gccttgattc	atatttaata	cctcacgggc	tcacaagtcct	2220
ttagagccaa	aagtttttctc	ttttaaacat	ttaatatgag	taaacatttt	aacattttca	2280
aattctcaca	tgtgtcccat	tccttgaaaa	tctacctttg	gtggggggggg	ggggggggact	2340

atatatatat	atgtccctat	agaactctgc	tctctacact	gcattctctca	tctgtgctct	2400
atgatctatt	cacacactaa	tgctctgacc	agcttgagag	tggtataaga	gcctgtgaca	2460
ctcccgcctc	ttgtgctgag	gacttggtgt	gttaacctgg	aagtcagggt	ttcggatcat	2520
caaaggcttt	acagcctagt	gaaagcattt	caagataaag	gggtgttagt	gagaactgtg	2580
gagagcctcc	agctaaaata	acacaacagg	accaagaacc	ctgtctgtgg	gtgggagtga	2640
ctaggctcta	gccaaatgct	ctgcgctaca	gtagcttctc	gctcgtgtgc	tctgcagaac	2700
cctgagacgc	tgctccagc					2719

<210> 10

<211> 2255

<212> DNA

<213> Avian

<400> 10

gtaagtggca	ctgaaccaat	agtgggattt	atagttttct	ggatgacttt	aattaagtaa	60
tgtcacatgg	aagctattca	ggaggatgta	ctgctatgct	gcagtttgct	taggcattac	120
ttactagaac	tgaattggta	aaatactttc	aatgtctaca	ctgagttgta	tttgttttaa	180
agcacttttg	aatgggaaat	acgtctgatg	attttgccga	ttccaccaac	actccaacgg	240
taatataaag	acacagactg	tttaattggca	cagctggaat	ttaagagaac	ctgtgtgccc	300
ctgtggagtt	agctttggac	agaacagagt	tcttgaatgg	gtgaatttgc	acactgtgta	360
gtggttttctc	agcagctttg	cttcagtgtc	ctcaaaatca	gcttaaattg	acgtaagtgt	420
tttggagtgt	gactgcaaga	agagctggaa	gatgcaaaat	agcagtatct	aatcagatgc	480
aatgaggatg	catgtgtatt	cattgctgtc	tcgatagata	tgaaagctgt	ggtctgcaaa	540
acgcccataa	ttttattaaa	gatcacatta	tacacagagt	tccttgtgag	gctggagtgt	600
ttctcctgat	agcatgctgt	agaggctggg	gaagtgtattg	gttgtctttc	agtgtaaagc	660
aggtagaagt	aagaggctaa	atactgtatt	aattgctggg	gtgaatatgt	cctttattct	720
gcagtgtgag	tgacttttgc	tgctggagga	tgttactact	gcagtccttg	gcagtccttg	780
agctgtaaat	cactccttgg	aagagagtgt	cctgcctgaa	tgatttagct	ttgattttta	840
gctttttgtg	ctctattact	aaatatgggt	ttcattagag	tcctccaagc	tagaaatgca	900
gcctttttcca	gctccctcct	ctccccctcc	ccaagtgtatt	tttggcattg	cattctctgc	960
attggtttga	gcaaaccctcc	tgacctcgaa	ctctgttcca	aaaacagacg	gttggaaagc	1020
atatttctca	attaggaaat	ggtttctcta	aaccactctg	ttcattcatg	ttagataaca	1080
attgtactcc	atagactaaa	tgcttaaata	taaagagcct	gttttcccaa	aagtttaaga	1140
aagtgcgaaa	aattgcaacc	tactttcctt	ttctggtaat	aatgacttaa	tatctggagt	1200
acatcaacgt	gggattttccc	tctccatgcc	ttctcctggc	agctactgta	tcctatcgaga	1260
actgcagcct	gagaagcagt	ccacagctgc	gtgctcgtgg	ctgtgaaggg	tctgcagtga	1320
gagggcgtttg	ggggaggctg	tccctcctag	gtccatctat	gggtggaggct	gaagcggttg	1380
ctcatgctcc	catgctcaat	cagccatggc	tctcactgac	gcgcactgcc	gcttcgacgt	1440
gcacgccagc	aggcccatgg	cagcagggtt	tgatcggtcg	cgaggagcca	gctgggctgc	1500
tggtatgacag	cctgtctcgc	tttggctggt	aacacattgc	aatttgttga	cctctgcatg	1560
gaagtccagg	ctcccagcta	gtcagtgatg	tccctaaccac	actataaatt	gtgggcaaat	1620
agttctcctc	gagtgctggg	attcggggct	tgtttccgta	attgacttta	atacaaacc	1680
tttaaagcat	ttttattacc	cttgttatct	tcctgttgcc	tgaggagaaa	aacaatttct	1740
gttttagtga	agcagggagc	cagcataaat	tactttgtca	ttctacaaat	gcagcttatt	1800
agctgggttg	aaatgatgat	ggagcacaca	ctatggacag	tttcaaaaca	catgctgtcc	1860
ttgattgcat	tttaaagtca	ggatatcacc	tttctactgt	caccagtctt	gtcaggatga	1920
tagaggcagg	ggacatcata	ctgaatctga	tgcaaagaga	cctttgtttt	tgcagctgtc	1980
agtccagcag	tcttctttat	ctcccaccta	cgctcagtg	gtggatttcc	gtggccgaat	2040
ttagataaac	attcgtgtgc	tcaaagctgt	aatgatctgt	ctttccatgc	agcaggactg	2100
gaatagttcc	atggagtact	ttgaattatg	tctggtgcat	acagccttcc	tgccatcag	2160
ttccttttat	accgcattct	ctgtcttaca	gggtggttct	ggtacctcac	tttgttgttt	2220
ttttttcaat	tattcttttc	ttgctgtttc	catag			2255

<210> 11

<211> 10

<212> DNA

<213> Artificial Sequence

<220>

<223> Oligonucleotide

<400> 11

aattgtttaa

10

<210> 12
<211> 10
<212> DNA
<213> Artificial Sequence

<220>
<223> Oligonucleotide

<400> 12
ccctatatca 10

<210> 13
<211> 10
<212> DNA
<213> Artificial Sequence

<220>
<223> Oligonucleotide

<400> 13
aataattaaa 10

<210> 14
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Oligonucleotide

<400> 14
ttgctccttg tttgggaagc 20

<210> 15
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Oligonucleotide

<400> 15
gaggtcccta tatggttggtg 20

<210> 16
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Oligonucleotide

<400> 16
ttttacctaa ttaggaaatg 20

<210> 17
<211> 30
<212> DNA
<213> Artificial Sequence

<220>
<223> Oligonucleotides

<400> 17
gcatcgagct gggaataag cgttggcaat

30

<210> 18
<211> 30
<212> DNA
<213> Artificial Sequence

<220>
<223> Oligonucleotides

<400> 18
gacaccagac caactggtaa tggtagcgac

30

CLAIM FOR BENEFIT OF PRIOR U.S. PROVISIONAL APPLICATION(S)
(35 U.S.C. Section 119(e))

I hereby claim the benefit under Title 35, United States Code, Section 119(e) of any United States provisional application(s) listed below:

PROVISIONAL APPLICATION NUMBER

FILING DATE

60/105,330

October 23, 1998

**ALL FOREIGN APPLICATION(S), IF ANY, FILED MORE THAN 12 MONTHS
(6 MONTHS FOR DESIGN) PRIOR TO THIS U.S. APPLICATION**

PCT/US99/24972

October 22, 1999

POWER OF ATTORNEY

I hereby appoint the following practitioner(s) to prosecute this application and transact all business in the Patent and Trademark Office connected therewith.

APPOINTED PRACTITIONER(S)

REGISTRATION NUMBER(S)

John P. Breen

38,833

Robert J. Decker

44,056

Rober S. MacWright

32,425

(3)

SEND CORRESPONDENCE TO

DIRECT TELEPHONE CALLS TO:

John P. Breen
1224 West Main Street, Suite 1-110
Charlottesville, VA 22903
US _____

John P. Breen
804-243-6103

DECLARATION

I hereby declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code, and that such willful false statements may jeopardize the validity of the application or any patent issued thereon.

SIGNATURE(S)

Gary K. Owens

Inventor's signature

Gary K. Owens

Date 4/13/01

Country of Citizenship US

Residence

Earlsville, VA US

Post Office Address

P. O. Box 472, Earlsville, VA 22936

Christopher Mack

Inventor's signature

Christopher Mack

Date 4/16/01

Country of Citizenship US

Residence

~~Charlottesville, VA US~~ Chapel Hill, NC US NC

Post Office Address

~~2037 Colonial Drive, Charlottesville, VA 22911 US~~
101 BURLWOOD PLACE, CHAPEL HILL, NC 27516 US

Randall Blank

Inventor's signature

Date _____

Country of Citizenship US

Residence

Charlottesville, VA US

Post Office Address

3385 Martin Kings Road, Charlottesville, VA 22902 US

DECLARATION

I hereby declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code, and that such willful false statements may jeopardize the validity of the application or any patent issued thereon.

SIGNATURE(S)

1-00
Gary K. Owens

Inventor's signature

Date 4/13/01

Country of Citizenship US

Residence Earlysville, VA US

Post Office Address P. O. Box 472, Earlysville, VA 22936 ✓ A

Christopher Mack

Inventor's signature

Date

Country of Citizenship US

Residence Charlottesville, VA US

Post Office Address 3037 Colonial Drive, Charlottesville, VA 22911 US

3-00
Randall Blank

Inventor's signature

Date 4/16/01

Country of Citizenship US

Residence Charlottesville, VA US ✓ A

Post Office Address 3385 Martin Kings Road, Charlottesville, VA 22902 US

COMBINED DECLARATION AND POWER OF ATTORNEY
(ORIGINAL, DESIGN, NATIONAL STAGE OF PCT, SUPPLEMENTAL,
DIVISIONAL, CONTINUATION, OR C-I-P)

As a below named inventor, I hereby declare that:

TYPE OF DECLARATION

This declaration is for a national stage of PCT application.

INVENTORSHIP IDENTIFICATION

My residence, post office address and citizenship are as stated below, next to my name. I believe that I am an original, first and joint inventor of the subject matter that is claimed, and for which a patent is sought on the invention entitled:

TITLE OF INVENTION

COMPOSITIONS AND METHODS FOR MODULATING EXPRESSION WITHIN SMOOTH MUSCLE CELLS

SPECIFICATION IDENTIFICATION

The specification was described and claimed in PCT International Application No. PCT/US99/24972 filed on October 22, 1999.

ACKNOWLEDGMENT OF REVIEW OF PAPERS AND DUTY OF CANDOR

I hereby state that I have reviewed and understand the contents of the above-identified specification, including the claims, as amended by any amendment referred to above.

I acknowledge the duty to disclose information, which is material to patentability as defined in 37, Code of Federal Regulations, Section 1.56.

Practitioner's Docket No. 00148-03

PATENT

COMBINED DECLARATION AND POWER OF ATTORNEY
(ORIGINAL, DESIGN, NATIONAL STAGE OF PCT, SUPPLEMENTAL,
DIVISIONAL, CONTINUATION, OR C-I-P)

As a below named inventor, I hereby declare that:

TYPE OF DECLARATION

This declaration is for a national stage of PCT application.

INVENTORSHIP IDENTIFICATION

My residence, post office address and citizenship are as stated below, next to my name. I believe that I am an original, first and joint inventor of the subject matter that is claimed, and for which a patent is sought on the invention entitled:

TITLE OF INVENTION

COMPOSITIONS AND METHODS FOR MODULATING EXPRESSION WITHIN SMOOTH MUSCLE CELLS

SPECIFICATION IDENTIFICATION

The specification was described and claimed in PCT International Application No. PCT/US99/24972 filed on October 22, 1999.

ACKNOWLEDGMENT OF REVIEW OF PAPERS AND DUTY OF CANDOR

I hereby state that I have reviewed and understand the contents of the above-identified specification, including the claims, as amended by any amendment referred to above.

I acknowledge the duty to disclose information, which is material to patentability as defined in 37, Code of Federal Regulations, Section 1.56.

CLAIM FOR BENEFIT OF PRIOR U.S. PROVISIONAL APPLICATION(S)
(35 U.S.C. Section 119(e))

I hereby claim the benefit under Title 35, United States Code, Section 119(e) of any United States provisional application(s) listed below:

PROVISIONAL APPLICATION NUMBER

FILING DATE

60/105,330

October 23, 1998

**ALL FOREIGN APPLICATION(S), IF ANY, FILED MORE THAN 12 MONTHS
(6 MONTHS FOR DESIGN) PRIOR TO THIS U.S. APPLICATION**

PCT/US99/24972

October 22, 1999

POWER OF ATTORNEY

I hereby appoint the following practitioner(s) to prosecute this application and transact all business in the Patent and Trademark Office connected therewith.

APPOINTED PRACTITIONER(S)

REGISTRATION NUMBER(S)

John P. Breen

38,833

Robert J. Decker

44,056

Roder S. MacWright

32,425

SEND CORRESPONDENCE TO

DIRECT TELEPHONE CALLS TO:

John P. Breen
1224 West Main Street, Suite 1-110
Charlottesville, VA 22903
US

John P. Breen
804-243-6103